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ABSTRACT 
Inês Patrícia Félix OLIVEIRA 
Synthesis of inhibitors of polysialyltransferases PST and STX 
 
Keywords: carbohydrate, cancer, polysialyltransferase, polysialic acid, 
glycosylation 
 
PolySialic acid (polySia) is a linear carbohydrate homopolymer of α-
2,8-linked sialic acids and a posttranslational modification of NCAM (neural 
cell adhesion molecule), biosynthesized by combined action of two 
polysialyltransferase enzymes, ST8SiaIV(PST) and ST8SiaII(STX). 
PolySia alters NCAM-dependent cell adhesion that is crucial for the 
CNS development. In adulthood, polySia expression is largely absent 
persisting only in areas of the brain associated with neuronal plasticity. 
Significantly, a number of malignant tumours re-express polySia and there is 
considerable evidence that its presence is related to higher malignancy, 
invasion and metastasis. 
 The hypothesis underpinning this project is that inhibition of polySia 
biosynthesis will prevent (or reduce) tumour cell migration and invasion, 
thereby reducing the incidence of metastasis, which will lead to higher patient 
survival.  
The work reported in this thesis describes efforts towards the 
synthesis polysialyltransferase inhibitors that are structural analogues of 
CMP-Neu5Ac, the natural substrate. Specifically, development of 
 ii 
 
methodology to synthesise building blocks suitable for conjugation as 
inhibitors is described.  
Quinic acid-based substrate analogues were explored, with a focus on 
development of chemistry to achieve substitution of C1-OH. Several 
protected quinic acid-based compounds were synthesized, and 
deoxygenation of the C1-OH through the use of a Barton-McCombie reaction 
was accomplished successfully, allowing an attempt to introduce different 
aliphatic groups at C1 position using the Mukayiama reaction. Synthesis of a 
cytidine building block, suitable for conjugation to either quinic acid or sialic 
acid is also reported. In parallel, studies towards the development of 
sialoside disulfide analogues are described, with novel conditions identified 
for their synthesis.  
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1. INTRODUCTION 
 
1.1. TUMOURIGENESIS – BIOLOGY, GENETICS AND EMERGING 
HALLMARKS OF CANCER 
 
Cell multiplication is a process that requires complex regulatory 
mechanisms that ensure its response to specific body needs at the different 
times during tissue and organ development.1,2 Cancer is a disease that 
results from the breakdown of fundamental regulatory mechanisms of normal 
cell behaviour which include proliferation,  
Fig. 1. 1 – Stages of tumour development.
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differentiation and survival and are essential for maintaining normal function 
in a multicellular organism.1 Loss of regulation triggers uncontrolled growth 
and division which can ultimately result in formation of a mass, tumour, and 
spreading of the cancer cells throughout the body, with establishment of 
secondary areas of growth, a process called metastasis, that can interfere 
with the function of normal tissues and organs. 1,2 
 Tumourigenesis is an accumulation of abnormalities, a multistep 
process, and reflects the progressive genetic alterations/mutations that drive 
the gradual transformation of normal somatic cells into highly malignant 
derivatives. Because of that it’s a disease that develops late in life and is 
associated with the elderly population (Figure 1.1).1,2,3  
Cells need to be in division state so that the mutations pass to 
progeny cells and lead eventually to cancer, that’s why cancers originating 
from non dividing cells, such as muscle and nerve cells, are not common in 
adulthood.2 Studies in experimental human and animal models revealed that 
specific genes, called oncogenes, are capable of inducing cell transformation 
and tumour formation. They originated from the activation of proto-
oncogenes in normal cells as a result of mutation or suffered DNA 
rearrangements. Most of the oncogene proteins (e.g. bcl-2, a cell death 
suppressor that prevents apoptosis) function as signalling molecules 
including polypeptide growth factors, growth receptors and transcription 
factors. Simultaneously tumour suppressor genes are lost or inactivated in 
cancer cells, removing the negative control upon proliferation since it’s 
activation after DNA damage leads to cell cycle arrest allowing DNA repair to 
occur or apoptosis if the damage is excessive (e.g. p53 gene which is 
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inactivated and/or mutated in several human cancers such as liver, breast, 
colon and skin).1,2,3,4 Although cancer is caused by gene mutations, it cannot 
be considered a genetic disease by itself, but there are some cases where 
some individuals have inherited genetic mutations that predispose them to 
develop some types of cancer.2 
 
Figure 1.2 – Acquired capabilities of cancer cells. 
3
 
 
Recent research revealed some shared acquired capabilities in most 
types of human cancer as a result of enabling characteristics as genome 
instability and increased mutability, described previously, and heterotypic 
interactions in the tumour microenvironment between cancer cells and its 
normal neighbours (Figure 1.2 and 1.3). 1,2,3 
These cancer enhancing interactions between cells include an 
inflammatory state, that although occurring primarily as an attempt to 
eradicate altered cells, has tumour promoting effects, through the supply of 
growth factors, enzymes (that facilitate angiogenesis, invasion and 
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metastasis) and release of reactive oxygen species that are oxidants 
mutagenic and carcinogenic. 1,2,3 
 
Tumour cell characteristics include the features described below 
(Figure 1.2):  
 They are not sensitive to antigrowth signals, density-dependent and 
contact inhibition of cell growth, so they do not become quiescent (G0 
stage) in the cell cycle and fail to differentiate normally and enter a 
postmitotic stage; 1,2,3 
 They are not dependent on extracellular growth factors because most 
of them produce their own (e.g. VEGF, vascular endothelial growth 
factor associated with angiogenesis process and TGFα, tumour growth 
factor alpha) which leads to an autocrine growth stimulation (continuous 
autostimulation of cell division) or elicit neighbour cells in their 
microenvironment to synthesize them, leading to deregulation of cell 
growth signaling pathways; 1,2,3 
 Most cancer cells are less adhesive, which reflects alterations in cell-
cell and cell-matrix interactions and loss of adhesion molecules 
expression (e.g. NCAM, which is going to be further discussed ahead 
due to its involvement in this project, E-cadherin and integrins), that 
relates to morphological and cytoskeletal alterations, involving secretion 
of extracellular protease enzymes that degrade extracellular matrix 
components and facilitate invasion of stroma cells, blood vessels and 
normal epithelial cells, contributing to invasiveness of adjacent tissues 
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and metastasis in distant sites where nutrients and space are more 
available; 1,2,3 
 They evade programmed cell death, apoptosis, after DNA damage, 
hypoxia or oncogene hyperexpression, mainly by loss of proapoptotic 
regulators (e.g. mutation in tumour suppressor gene p53); 1,2,3 
 They have unlimited replication as a result of uncoupling of the cell 
growth from cell-cell signalling and its environment, defects in DNA-
repair machinery and chromosomal abnormalities, such as upregulation 
of telomerase expression in 85-90% of cancer cells (enzyme required to 
maintain the ends of eukaryotic chromosomes), because in normal cells 
these enzymes are progressively less expressed in each cell cycle and 
eventually there as complete loss of telomeres and consequently cell 
death; 1,2,3 
 Ability for angiogenesis, through the secretion of growth factors (e.g. 
VEGF and FGF1/2, fibroblast growth factor) and downregulation of 
endogenous inhibitors (thrombospondin-1 and β-interferon), allowing 
the formation of new blood vessels that are going to supply oxygen and 
nutrients allowing the continuous growth, proliferation and metastasis of 
cancer cells. The important role of angiogenesis is demonstrated by 
clear evidence of the use of anti-angiogenic agents to impair tumour 
growth, with agents already in use in the clinic. 1,2,3 
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Nowadays there are two more emerging targets that are currently 
under study in an attempt to try to evaluate their usefulness as cancer 
therapy targets (Figure 1.3): 5,6 
 
 Alteration of the cellular metabolism essential to respond to increasing 
energetic needs due to increased growth and proliferation of cancer 
cells. This characteristic also enables cancer cells to produce energy 
even in hypoxic conditions because glycolysis is the main energetic 
process.5,6 
 Evasion from destruction by the immune system, showing that the 
body’s immune response can have tumour promoting effects, through 
the inflammation process described previously as an enhancing feature 
in tumour development, but also tumour growth and progression 
Fig.1.3 Emerging Hallmarks of cancer and Enabling characteristics. 
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inhibition through the possible recognition and elimination of damaged 
cells. This is supported by the fact that there is an increase of some 
types of cancers in immunocompromised patients (e.g. AIDS).5,6 
 
The physiological changes described previously are therefore 
considered hallmarks of cancer and are all related and dependent on one 
another in a complex circuitry and progressively acquired during tumour 
development. These are also key targets for new mechanism-based 
anticancer drug development (Figure 1.4). 3,6 
 
 
 
 
Fig. 1.4 Therapeutic targeting of the hallmarks of cancer. 
5
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1.2. CANCER STATISTICS AND THE IMPORTANCE OF NEW 
THERAPEUTIC STRATEGIES 
 
There are more than a hundred types of cancer, according to the cells 
from which they originate in the body they can be classified into 3 main 
groups:  
 Carcinomas are the most common type, originating from 
epithelial cells and account for 90% of all human cancers;1 
 Sarcomas are the more common solid tumours in animals and 
originate from connective tissues, such as muscle, bone and 
cartilage;1 
 Leukaemias or lymphomas originate from blood-forming cells 
and cells from the immune system respectively, and their behaviour 
and response to treatment can vary substantially.1  
 
Only malignant tumours are referred to as cancer, because they are 
capable of invading surrounding normal tissues and spread via the circulatory 
and lymphatic systems, a process that is named metastasis and is 
responsible for most (90%) of cancer related deaths due to increased 
resistance to treatment. Benign tumours are localised to a specific area and 
can be removed surgically. 1,3  
According to the World Health Organization, 12.66 million people 
worldwide were diagnosed with cancer in 2008 and 7.56 million died from this 
disease. 7  
The most common types of cancer, that account for 40% of the world’s 
total are: lung, female breast, colorectal and stomach (Figure 1.5) and their 
 9 
 
incidence and also geographic distribution depends on factors that include 
age, sex, race, genetic predisposition and exposure to environmental 
carcinogens among others.4,7  
 
 
Carcinogens, like radiation and chemicals can damage the DNA and 
induce mutations, tobacco smoke being the most talked about in the media 
because of clear evidence relating it to 80 to 90% of lung cancers. But there 
are other known causes of cancer such as tumour promoters, like hormones, 
that stimulate growth of some human cancers (e.g. Oestrogen and breast 
cancer) and viruses (e.g. Human Papilloma Virus and cervical cancer).1,2,4 
As the world’s population is progressively ageing due to increased life 
expectancy in developed countries which is a result of improved health 
Fig. 1.5 The 20 most commonly diagnosed cancers worldwide, 2008 estimates. 
7
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assistance, and because cancer is predominantly a disease of the elderly, an 
increase in the number of cancer cases is expected in coming years.7  
Ideally, prevention of cancer would be the main approach to this 
disease or early detection of premalignant stages where the disease is still 
localised and can be removed surgically or treated with radiation with higher 
success cure rates and less side effects and systemic toxicity. Once the 
cancer has spread and micrometastasis are detected there is the need for a 
systemic approach with the use of chemotherapy drugs, but unfortunately 
there are problems to overcome with their use because most of them are still 
not selective to cancer cells (most targets are common to normal cells). They 
are also often very toxic to the patients, which limits success. The other 
problem is chemoresistance, because usually when the disease has already 
spread it is difficult to reach the tumour localization in cytotoxic 
concentrations (e.g. nervous system and testes) and eventually acquired 
resistance develops, although there are also some cases of inherent 
resistance related to the genomic instability of cancer cells that can trigger, 
for example, the overexpression of transporter molecules that pump out the 
drugs from the cells. Besides that there can be an adaptation of the cancer 
microenvironmental cells due to the survival of some cancer cells after the 
first treatment which allows tumour renewal and clinical relapse, because 
acting upon one key pathway of tumourigenesis may not disable it completely 
or may cause a shift to another supporting hallmark characteristic. 5,6  
To overcome these issues, combination chemotherapy is nowadays 
the main approach, with simultaneous use of drugs with different but 
complementary mechanisms of action and no overlapping toxicities. 1,4 
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The need for better cancer therapeutics demands an improved 
knowledge of molecular characteristics for the design of more efficient and 
selective protocols. Here is where molecular diagnostics plays a key role, 
since it allows the discovery of new therapeutic targets and new genes 
involved in the origin of the disease. The design of personalised therapeutics 
could in fact increase the survival rate of patients, and maybe even cure 
them. 8 
 
1.3. NEURAL CREST-DERIVED CANCERS AND POLYSIA AS AN 
EMERGING THERAPEUTIC TARGET 
 
Prevention of tumour dissemination - localized invasion and 
metastasis - is crucial to patient outcome, since once tumour cells spread 
from the primary location, morbidity and mortality of cancer increases 
exponentially. 9 
Localized invasion, which can be seen in cancers such as 
glioblastoma and bladder cancer requires: partial separation from the primary 
mass; reorganization of extracellular matrix through actin polymerization and 
up-regulation of proteolytic enzymes, and consequently migration through it; 
and survival in adjacent tissues in a syncytial manner. Metastasis, 
characteristic of lung and breast carcinomas, is similar but individual cells 
manage to enter the vasculature and reach other organs in distant locations. 
Motility, of a mass of cells or individual cells, is therefore a rate-limiting 
process in tumour dissemination. Some cancers such as melanoma are even 
able to use both mechanisms of tumour dissemination and for that reason it 
is essential that new cancer therapies target both invasion and metastasis. 9 
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Epithelial-to-mesenchymal transition (EMT) and growth-factor induced 
motility are common characteristics of both processes. EMT allows loosening 
up of the primary tumour cell mass, but it’s difficult to target due to its 
transient nature, since during metastasis this phenotype is converted to a 
more mesenchymal state which allows the seeding/survival at the secondary 
location. Nonetheless there are cells that can move through the ECM by 
acquiring rounded/amoeboid-like morphology that allows movement of cells 
without the need for matrix proteolysis, due to the matrix natural porosity. 
Growth-factor induced motility could be used in the future to make cancer a 
chronic condition, reducing initial and secondary dissemination, since solid 
tumours produce both autocrine and paracrine factors that trigger motility 
signalling cascades, and there are already clinical results using inhibitors for 
the EGF receptor (epithelial growth factor) although with limited success. 9  
Targeting metastasis per se is challenging, since commonly when the 
disease is diagnosed, metastasis or invasion already happened. Design of 
clinical trials to determine the efficacy of these new drugs is also a challenge 
since these drugs are unlikely to be used as single agents (they will be add-
on therapies) and monitoring of tumour nodule size it’s not appl icable, it 
would be necessary to design a trial that would measure progression-free 
time and overall survival, which is possibly more expensive and requires 
follow-up of a larger number of patients. Measurement of a metastatic 
biomarker may be a possible solution in some cases. Nonetheless agents 
targeting tumour dissemination would be able to stop cancer spread, 
enabling effective limiting of tumour progression. Agents may also enhance 
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the efficacy of anti-proliferative agents, by limiting transitions to metastatic or 
resistant cell phenotypes. 9 
 
Neural crest cancers, such as small cell lung cancer, neuroblastomas 
and gliomas, are some of the most difficult cancers to treat. Neuroblastoma is 
one of the more common cancers during childhood, with the tumour 
development process mirroring neuronal development. 4,10 Only leukaemias 
cause more deaths in children. 4,10 Brain tumours (e.g. glioma, astrocytoma) 
do not metastasise, but invade the surrounding brain tissue, a feature related 
to the existence of an anatomic structure, the Blood-Brain Barrier which 
controls the input and output of substances to and from the brain. It is also 
related to the difficulty of delivering chemotherapy drugs to that area and due 
to their limited efficacy and few therapeutic options (lipophilic drugs like 
nitrosoureas that can easily cross the barrier are more likely to be used). 
8,11,12,13  
Due to the enunciated problems and because surgical removal cannot 
be applied to all cases, the identification of new therapeutic targets taking in 
consideration the specific characteristics of individual cancers is of 
paramount importance. Starting from there, researchers revealed that the key 
hallmark, invasiveness, was related to defects in cell interactions due to a 
specific posttranslational modification of NCAM (neural-cell adhesion 
molecule) through the addition of a carbohydrate polySia (polysialic acid). 
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1.3.1. CELL ADHESION DEREGULATION - POLYSIA 
EXPRESSION ON NCAM AS A BIOMARKER FOR A SERIES OF 
CANCERS 
 
Polysialic acid (polySia) has been demonstrated to be a biomarker for 
a series of cancers and presence of polySia in serum is considered to be a 
disease marker.14,15,16 It is expressed in cancers derived from the neural 
crest cells, multipotent vertebrate cells that give rise to several cell lineages, 
such as melanocytes, peripheral and enteric neurons, glia cells, smooth 
muscle, craniofacial cartilage and bone during embryogenesis.8,11,12,13 These 
tumours include glioblastoma 11,12, rhadomyosarcoma 11,17,18, neuroblastoma 
11,13,19,20
, medulloblastoma, pancreatic cancer 11,21, pituitary adenoma (where 
NCAM-polySia is also related to higher growth rate of the tumour)  22, small-
cell lung cancer 23 and Wilm’s tumour 24. However, studies also 
demonstrated that polySia can be found in non-neural crest tumours such as 
multiple myeloma 11, non-small cell lung cancer, 17 thyroid cancer 14 and 
colorectal tumours (with nodal invasion) 25 and be responsible for the 
enhanced migration of cells due to the loss of focal adhesion, cell-to-
extracellular matrix adhesion and metastasis. 15,21,26 
To determine the role of polySia in tumour growth and development 
there are several studies of note in the literature. A selection of these will now 
be explored. 
PolySia is known to promote in vitro migration of neuroblastoma cells, 
and to influence tumour cell growth and differentiation through affecting the 
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NCAM signalling cascade. This involves the triggering of tyrosine kynase 
molecules responsible for the adhesion process. It is due to the expression of 
polySia in neuroblastoma that the scientific community first started to take 
interest in this interesting phenomenon in cancer. As a result most of the 
early information available focused on this type of cancer. More recently, a 
number of studies have emerged referring to the role of polySia in other 
tumours – its expression is widespread in cell lines for the tumour types 
previously outlined. 13,15,16,19 
In vivo studies using polySia-expressing xenografts, implanted into 
nude mice, demonstrated the linkage between polySia expression and the 
appearance of disseminated lung metastases. These in vivo models using 
polySia-expressing and polySia-negative xenografts clearly demonstrate a 
clear relationship between polySia-NCAM and tumour invasion and 
metastasis: the number and extent of metastatic tumour deposits in lung 
cancer 15, neuroblastoma 13,15,16,19, pituitary cancer (topic explored ahead) 22 
and glioma.12 
Studies have demonstrated that polySia controls NCAM signals at cell-
cell contacts to regulate focal adhesion processes in rhabdomyosarcoma and 
neuroblastoma cell lines – TE671, Kelly and SH-SY5Y (polySia+/NCAM+). 
Studies in these cells revealed, using scratch assays in the presence of 
endo-N enzyme, that removal of polySia from NCAM from cell-cell contact 
sites, reduced focal adhesions in a NCAM-dependent manner through 
alteration of NCAM signalling pathways. PolySia enhanced cell migration, 
which is a feature of malignancy in these types of neural crest tumours. 25 
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Studies of human pituitary adenomas, a type of cancer that although is 
mainly benign, can behave aggressively and invade the surrounding tissues, 
revealed that NCAM and polySia can be found in both normal and tumoural 
pituitary gland. The question to be answered was if the situation was similar 
to that observed in other neural crest tumours, polySia-NCAM could be 
tumour marker for malignant pituitary tumours and be related to growth rate 
and malignancy. For that purpose an in vivo model for spontaneous tumours 
using SMtTW – Wistar/Furth WF/Ico female rats was used successfully by 
Daniel et al and high polySia-NCAM levels were observed in tumours with 
malignant features, such as subcutaneous growth, invasion and metastasis. 
14 
It is key to note that through the use of EndoN in several of the studies 
already mentioned (enzyme that is able to remove polySia from NCAM in a 
specific and selective manner), and together with the data from studies using 
in vitro siRNA knock-down of the polysialyltransferase enzymes, PST and 
STX (enzymes that are responsible for the biosynthesis of polySia and that 
are going to be explored ahead in section 1.3.2.), came to substantiate that 
by removing polySia from NCAM, via an enzymatic manner or by removal of 
polysialyltransferase enzyme expression, both had the same result: the 
abolition of cell migration.21 
NCAM-180 the membrane linked isoform of NCAM loses its 
expression in aggressive forms of colon tumours and correlates with poor 
prognosis, so it was speculated that polySia-NCAM could also be an 
oncodevelopmental antigen for colorectal cancer, since it was only observed 
in tumour tissues and not in control/healthy tissues. There are today studies 
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using colorectal patients to determine the prevalence of polySia+/NCAM+ 
and how that affects prognosis. It was observed by Briera et al that lymph 
node metastasis at surgery was correlated with polySia-NCAM coexpression, 
which reflected in a poor patient prognosis. 25 
PolySia-NCAM exerts its effects over cell adhesion processes in a 
very complex manner. For that reason and to help to expand upon some of 
the information mentioned previously, deregulation of cell adhesion 
processes and its relation to CAMs (cell adhesion molecules, where NCAM is 
included) and its relation to polySia will now be considered in more detail. 
The deregulation of cell adhesion is therefore a key step in tumour 
invasion and metastasis, as stable cell-cell interactions are essential for the 
organization of cells into tissues. The process of cell-cell adhesion is 
selective, because cells only adhere to specific neighbour cells, a process 
that is mediated by specific Cell Adhesion Molecules (CAMs) in which NCAM 
is included. 1,6,20 CAMs are integral membrane proteins responsible for cell-
cell and cell-matrix homophilic (same cell type) and heterophilic (different cell 
type) adhesion and interaction. They are divided into 4 groups – selectins, 
integrins, immunoglobulin superfamily and cadherins, and they communicate 
directly with the intercellular signalling pathways (Figure 1.6). 2,3 
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 NCAM belongs to the immunoglobulin family and plays an important 
role during development and differentiation of nervous tissue (glia and nerve 
cells). This cell surface glycoprotein was identified in the 1970s and is 
encoded by one single gene with 20 major exons and its isoforms are 
generated by mRNA alternative splicing (Figure 1.7). 2,27The three isoforms 
of NCAM, differ in length (180, 140 and 120 KDa), protein backbone, mode of 
attachment to the cell membrane and content of sialic acid residues. 2,3 
NCAM 180 is a single pass transmembrane protein and the difference to 
NCAM 140 is that in the last one the cytoplasmic domain is considerably 
shorter. NCAM 120 is a GPI-anchored protein without cytoplasmic domain. 
There is also a secreted form of NCAM that can be formed by enzymatic 
excision of NCAM 120 GPI-anchor and is related to the formation of 
truncated NCAM.  18,27,28,29 
Fig. 1.6 Types of molecules that bind cells to each other and to the extracellular matrix. 
2
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Human NCAM extracellular motifs responsible for cell interactions are: 
five immunoglobulin-like domains (IgI to IgV) with six N-glycosylation sites, 
followed by two fibronectin type III-like domains (F3I, which appear to act as 
the initial recognition site and docking for the polysialyltransferase enzymes 
that are going to be described later in this section, and F3II) (Figure 1.7 and 
1.9). 18,27,28,30 
The adhesive properties of NCAM are modulated by addition of α(2→8) 
chains of sialic acid molecules to the N-glycosylation sites to form polySia. 
(Figure 1.8) 
Fig. 1.7 A) NCAM structure; B) NCAM isoforms; C) NCAM cis and trans-interactions.
27
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PolySia is a negatively charged sugar, switching NCAM from an 
adhesive form, in its absence, to a poorly adhesive form in its presence, 
which enables the modulation of cell interactions and adhesion.  NCAM-
polySia also triggers cellular signalling cascades. 2,3,18,27,28 
There are an increasing number of studies focussing on the crucial 
role of glycans (assemblies of oligo and polysaccharide sugars) in 
tumourigenesis, since glycosylation is a common modification to cell 
membranes and secreted proteins. This has a major impact in protein folding, 
stability and function of native proteins, regulating through intracellular and 
intercellular signalling cascades. This in turn affects the stages of tumour 
development: proliferation, invasion, metastasis and angiogenesis, and has 
emerged in the last decades as an important new therapeutic targets for 
cancer therapy. 27,31 
These sugars can exist in free form, such as hyaluronan, or in the form 
of glycoconjugates, with lipids, such as glycophingolipids (oligossacharides 
linked to ceramide) or proteins, as in the case of proteoglycans (heparin 
Fig. 1.8 Chemical structure of polysialic acid. 
50 
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sulphate and chondroitin sulphate) and glycosylphosphatidinylinositol (GPI)-
linked proteins. Glycoproteins are very abundant on the cell surface and the 
linkage can be made through an asparagine amino acid (N-linked glycoside) 
or through serine or threonine amino acids (O-linked glycoside). 31 
N-glycosylation of glycoproteins is the prevalent form, being related 
with protein folding, cell recognition and cell adhesion, and because it is so 
prevalent it was hard in the beginning for researchers to correlate altered N-
glycans to the development of some types of tumours. 31 
The majority of glycans exist as membrane-bound glycoconjugates, in 
the glycocalyx (extracellular structure that coats the plasma membrane of 
cells and it’s formed by glycans and glycoconjugates), and this localisation in 
the cell membrane is what allows them to be such a crucial part of the cell 
adhesion (cell-cell and cell-matrix), communication and motility process, 
since even small changes in glycosylation can affect cell signalling cascade 
of tyrosine kinase phosphorilations. In fact some of the first-identified tumour-
specific antibodies where directed against carbohydrate antigens on tumour 
glycoproteins. 31,32,33 
One of the main alterations in some types of tumours that were 
noticed by researchers was the overexpression of glycoconjugates with 
polysialic acid on cell membrane-located NCAM. (Figure 1.9) 31 
Sialic acid (Neu5Ac) is the terminal monosaccharide on 
glycoconjugates that is most abundant in eukaryotic cells, and besides being 
involved in cell interactions, as already stated, is also present in the capsule 
of some bacteria - that cause meningitis facilitating their escape to the 
immune system response. Sialic acid is also involved in viral infections, since 
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viruses such as influenza have on their surface a glycoprotein enzyme 
designated neuraminidase (acetyl-neuraminyl hydrolase) responsible for 
release of the newly formed virus through removal of sialic acid sugars that 
exist in the membrane of host cells, therefore increasing the spread of the 
infection. 34,35  
In fact, studies regarding the role of sialic acid in viral infections and its 
emerging role as being implicated in therapeutic targets, led to the 
development of anti-viral therapies that are commercially available nowadays 
and that became famous at the time of the first outbreak of bird flu, such as 
zanamivir and oseltamivir, which are neuraminidase inhibitors. 34,36  
The work developed with these inhibitors was also crucial to our own 
project since they are built from carbacycles derived from quinic acid, and our 
main objective in this thesis project was to synthesise quinic acid-based 
analogues to couple to CMP and determine their inhibitory effect towards 
polysialyltransferases and the biosynthesis of polysialic acid. 37 
The presence of polySia on NCAM in mammalian brains was 
described for the first time in the 1980’s and this glycosylation is the most 
important of all the post-translational modifications that NCAM can sustain. 
38,39,40 It is a linear homopolymer carbohydrate of α(2→8)-linked sialic acid 
residues that can correspond up to 30% of the NCAM molecular mass and its 
normal length varies usually up to 100 residues of sialic acid, and is usually 
attached to N-glycosylation sites 5 and 6 on the 5th Ig domain of NCAM. 
(Figure 1.9) 41,42,43,44 
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Fig. 1.9  PolySia structure and localization on NCAM.
44 
 
Polysialylation of NCAM is highly developmentally regulated: 
expression is very high during embryonic development when neuronal cells 
need to move to different parts of the body and reaches its peak at the 
perinatal phase, but soon after birth levels decrease rapidly such that the 
majority of adult tissues lack this glycan. 45 PolySia is nonetheless still 
present (albeit in dramatically lower concentrations) in plastic areas of adult 
brain where there is still neurite outgrowth and regeneration of neuronal cells, 
such as the olfactory bulb. 45 However, as stated before, polySia expression 
has been identified in some malignant/aggressive tumours, where it is an 
oncodevelopmental antigen, related to poor prognosis. 11,18,40,46 
As previously discussed, polySia is able to attenuate NCAM-
dependent interactions, and subsequently cell adhesion, since it allows 
changes in cell position or shape, due to its own structural characteristics. 
PolySia can mediate cell-cell and cell-matrix adhesiveness, by conditioning 
 24 
 
homophilic (NCAM to NCAM, cis-interactions if in the same membrane, and 
involving the IgI-IgI dimer formation, or trans-interactions if in opposing 
membranes, involving the formation of a IgI-IgII cis dimer and IgII-IgIII trans 
dimer – “flat-zipper” or IgI-IgIII and IgII-IgII – “compact zipper”,  Figure 1.7) 
27,28,47 and heterophilic (NCAM can bind to other members of the Ig family, 
such as L1 and TAG-1, for example in small-cell lung cancer, where NCAM 
it’s not expressed, and to members of the extracellular matrix, such as 
glycosaminglycan heparin, chondroitin and heparin sulphate proteoglycans)  
11,15  interactions due to its stereochemical properties. These are the large 
size/bulkiness, which physically impairs attachment of cells, and 
polyanionic/negatively charged nature due to the presence of the carboxylic 
functionality that allows it to sustain water molecules and ion species ( 
Figure 1.10).28,48,49,50 
The polyanionic characteristics and large size of the polySia molecule 
cause the hydrodynamic radius of NCAM extracellular part to double, 
increasing the inter-membrane space and disrupting the adhesive properties 
of NCAM and other cell adhesion molecules (as shown in Figure 1.10). 
21,48,49 
There is now evidence that NCAM polysialylation increases inter-
membrane repulsion and abrogates NCAM homophilic adhesion, through 
disrupting inter-membrane adhesion mediated by C- and E-cadherin. 30,48,49 
PolySia effects are also regulated by triggering NCAM-dependent cell 
signalling through a cascade of phosphorylations that alter cell adhesion, 
such as the non-tyrosine kinase receptor Fyn (from the Src family) and the 
 25 
 
focal adhesion kinase (FAK) that then activate the downstream ERK/MAP 
kinase pathways. 15,18  
 
The use of endoneuraminidase (endo-N) enzyme to remove polySia 
from where it is attached on the cell surface, both in vivo and in vitro was a 
determinant for the discovery of its key role in adhesion, migration and 
synapse formation, as stated previously. 27,28,43,50,51 
  Fig. 1.10 Homophilic and Heterophilic interactions mediated by PolySia.
50
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One example where polySia is involved in other cell-cell interactions 
that do not require the presence of NCAM, is in the case of 
migration/chemotaxis of mature dendritic cells (mDC cells), where the 
absence of polySia in neuropilin-2 membrane glycoprotein, also from the 
immunoglobulin family, is responsible for the decrease in chemotaxis of mDC 
to the lymph nodes were they are responsible for presenting antigens to the 
lymphocites, and triggering of an immune response.52 PolySia can be 
therefore also a suitable target for modulation of the immune system 
response and be used as a therapy also in this case. 52 
In relation to its immunogenic/antigen characteristics, there are 
already available some studies regarding the possible use of polySia in a 
carbohydrate vaccine towards some types of cancer (namely small-cell lung 
cancer), in an attempt to trigger an immunological response to cellular 
polySia in the hope of reducing the occurrence of micro-metastases which is 
nowadays thought to be the main factor leading to chemoresistance in these 
tumours. 53,54,55,56 However, there is a natural human immune tolerance to 
polySia that develops in embryogenesis where its expression is increased 
and due to its presence in some areas of the brain, which increases the 
difficulty in constructing a vaccine, which has led to the need of some 
structural modifications. 53,55,56  
This demonstrates why, as mentioned before, polySia is a good 
therapeutic target and why the synthesis of inhibitors for the enzymes that 
biosynthesise polySia is worthwhile and required. This is a topic of increasing 
interest and as such forms the central core of the project described in this 
thesis. 
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Increased polySia expression is related to increased migration and 
invasion of tumour cells. However, to consider the opposite, a decrease of 
polysialic expression has also been reported to be involved in some 
diseases, such as schizophrenia (possibly due to mutations in the 
polysialyltransferase enzymes). Alterations in its expression appear to be 
related to neurodegenerative diseases including Alzheimer’s and Parkinson’s 
diseases, where there is an increase in NCAM-polySia in the hippocampus 
region due to disorganization of polySia-immunoreactive fibres. Still 
regarding the neurodegenerative diseases there is now evidence that 
oligodendrocytes, cells responsible for myelination, down-regulate polySia 
synthesis during differentiation as a prerequisite to the normal myelinization 
process and myelin maintenance which is essential for normal neuronal 
conductivity. 27,28,57,58, 59 
NCAM-polySia has been considered for promoting neuronal plasticity 
and repair of brain damage caused by lesions or infections, with beneficial 
effects in cognitive function, due to the possibility of synaptogenesis and 
axonal growth.  Since it can be found in plastic areas of the brain it’s related 
to the recovery after lesions, learning and memory formation. This happens 
because polySia by decreasing cell adhesion facilitates neuronal cell 
plasticity and also because it triggers cell signalling involving BDNF and FGF 
receptors, promoting long term potentiation, but still numerous questions 
remain to be answered. Nonetheless there is evidence that a polySia mimetic 
administrated to mice immediately following spinal cord injury caused neurite 
outgrowth and lesion recovery. 27,54,60,61  
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Ultimately, careful consideration for exclusion of molecules from the 
brain, by prevention of crossing the blood brain barrier may be important. 
In summary, polysialic acid behaves like a molecular switch for cellular 
behaviour. NCAM facilitates cell adhesion. Once polysialic acid is 
synthesised on the tumour cell surface, a number of changes are initiated, 
which results in a cell with enhanced migratory, invasive and metastatic 
potential. PolySia increases the physical size of NCAM, leading to repulsive 
forces between adjacent cells. PolySia also binds to other adhesion 
molecules and causes changes in intracellular signalling, which alters cell 
behaviour. In short, polySia has excellent potential as a target against tumour 
dissemination. 
 
1.3.2. BIOSYNTHESIS OF POLYSIA – PST AND STX ENZYMES 
 
In eukaryotic cells there are two closely related enzymes responsible for 
the synthesis of polySia: two α(2→8) polysialyltransferases named PST 
(ST8SiaIV) and STX (ST8SiaII). 28,30,37,45 These enzymes catalyse the 
transfer of sialic acid to an acceptor and are fairly homologous at amino acid 
level with 59% identity. 62,63, 64, 65 
The α(2→8) polysialyltransferases belong to a gene family of vertebrate 
sialyltransferases that also includes α(2→3) and α(2→6) sialyltransferases. 
These enzymes are far more common in normal cells, and therefore much 
more studied. They are also commercially available for studies. On the other 
hand, it is more difficult to find α(2→8) enzyme structural information. Among 
the α(2→8) polysialyltransferases, besides PST (ST8SiaIV) and STX 
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(ST8SiaII), four others have already been cloned: ST8SiaI, ST8SiaIII, 
ST8SiaV and ST8SiaVI. Their distribution in tissues also differs and their 
genes are found in different chromosomes. 28,63,64,65 
ST8SiaII and ST8SiaIV are also characterised by their ability to carry 
out autopolysialylation, and cells producing polySia often express both 
enzymes. These enzymes act synergistically for the synthesis of polySia in 
tumour cells, which means that in most cases even if only one of the 
enzymes is present, polysialylation of NCAM can still occur in vitro and in 
vivo. 62, 63,64,65  
The expression of two similar enzymes has triggered speculation 
among the researchers as to why there are two, both utilising one single 
acceptor, CMP-Neu5Ac, and this important question has not yet been 
answered. Some studies have started to address this question and I will here 
refer to some key points relating to this issue: 
 Their expression profiles are very different, since STX is the 
predominant enzyme in the embryo and PST persists postnatally, 
playing the predominant role in adulthood in those limited areas with 
polySia is still expressed. Studies using Northern blot analysis 
revealed that in mice, expression of the enzymes was tissue-specific: 
PST is expressed in lung and heart, and only moderately in skeletal 
muscle and brain and STX was more expressed in the lung and testes 
and moderately in the brain. In human tissues PST transcript was 
found in the spleen, small intestine and leukocytes and almost no STX 
could be detected. Crucially, it is STX that is the dominant enzyme in 
tumours; 64,66,67  
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 The distribution of chain length of polySia: studies have 
demonstrated that when PST or STX are expressed alone the chains 
are shorter than 30 residues and that the presence of longer chains 
requires their combined presence and combinatory action. The degree 
of polysialylation is lower with ST8SiaII (about 40 residues) and higher 
with ST8SiaIV (around 60);  45,65, 68 
 The attachment to the carrier oligossacharide is also slightly 
different: they both preferably attach to N-glycosylation site 6, but STX 
uses also the N-glycosylation site 5; 45,63, 68 
 The enzymes have the capability to accept modified CMP-sialic 
acid structures to produce modified polySia. Studies involving feeding 
of cells with modified N-acyl mannosamines (which is the precursor 
from which N-acetylneuraminc acid is synthesized, Figure 1.10) 
demonstrated that these synthetic mannosamines (ManLev, 
Man5Prop, Man5But, Man5Pent), were taken up by the cells and 
processed by their machinery. Man5Prop, Man5But and Man5Pent 
(Figure 1.15) could inhibit the synthesis of polySia, mainly through 
selective inhibition of STX (ST8SiaII) in vitro. This is also sustained by 
the fact that in adults a decreased in vivo efficiency of PST 
polysialylation and a higher efficiency of STX have been reported. 
38,44,69,70 
 
Some initial studies described that STX was not able to polysialylate 
all forms of NCAM: only NCAM 180 and NCAM 140, but not the GPI-
anchored form. However, recent studies came to show that was not the case, 
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and that STX and PST have in fact no preference in using different isoforms 
of NCAM as acceptors. 71 
 
 
 
 
Sialic acids are synthesised first in the cytosol of cells. UDP-N-
acetylglucosamine (originating from glycolysis or intake from diet, e.g. egg 
white is rich in sialic acid) is converted by GNE, a bi-functional enzyme, to 
the mannosamine precursor (ManNAc), which then is converted in three 
steps to neuraminic acid (Neu5Ac = sialic acid). 39 
Sialic acid is then transported to the nucleus of the cell where it is 
activated by coupling to a cytidine nucleoside and converted to CMP-
Neu5Ac, which is the common glycosyl donor to all sialyltransferase 
enzymes. The donor substrate is then transported to the Golgi apparatus 
where by combined the action of polysialyltransferases, PST and STX, allows 
Fig. 1.11 Biosynthesis of PolySia. 
39
 
GNE 
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the continuous addition of sialic acid to the 5th immunoglobulin domain of 
NCAM (Figure 1.9 and 1.11) and the biosynthesis of polySia. 39,44 
There are now a number of cell lines available for the study of the 
effect of the presence (polySia+ cells) or absence (polySia- cells) polysialic 
acid in tumour cells, for the study of polysialyltransferase enzymes (PST-
/STX-, PST+/STX+, PST+/STX- and PST-/STX+) – the ICT has a panel of 
such lines, fully characterised for enzyme and polySia expression. Also, with 
the development of molecular biology methods, it is now possible to transfect 
cells (using vectors and plasmids) to express the 
molecules/proteins/enzymes (PCR method to increase the amount of protein) 
of interest, and to quantify accurately the amount of proteins present in the 
cells (through the use of immune assays - Western blot, ELISA), as well as 
identify the tissue location of a certain protein (immunostainning, 25) and to 
determine/identify the proportion of distribution of certain protein biomarker 
(flow cytometry with the use of specific antibodies for polySia and NCAM, 9). 
To study effects of agents on tumour cell migration, the most common 
in vitro assay is perhaps the scratch assay, to determine if a compound in 
contact with polySia positive cells is able to inhibit the polysialyltransferase 
enzymes which can be easily determined visually by the degree of by which 
the scratch made artificially closes or not. 44 Regarding the in vivo models for 
study of polySia there are several described in the literature involving 
xenografts in nude mice 11, the use of SMtTW (in vivo model of spontaneous 
tumours malignant and benign in Wistar rats) 22 and the use of NCAM 
deficient mice. 28 Simultaneously the use of endo-N enzyme to remove 
polySia from where it is attached, i.e. NCAM, has been used both in vitro and 
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in vivo, and it has allowed for the establishment of the relationship between 
polySia absence from NCAM and a decrease in tumour cell migration. 28,71 
A surprising fact is that knockout mice for NCAM or 
polysialyltransferases enzymes do not show phenotype developmental 
defects. Instead, studies demonstrated that NCAM-polySia or polySia itself 
have a more important role in maintaining normal CNS function. 30, 72,73,74 
For this project the knowledge that there are only a limited number of 
proteins that are polysialylated is also important. Besides NCAM only 7 other 
proteins have been identified: synaptic cell adhesion molecule 1, integrin α-5 
subunit, neuropilin-2, α subunit of the voltage-dependent sodium channel, a 
form of CD36 scavenger receptor found in milk, and the 
polysialyltransferases themselves, that as mentioned before have the ability 
of autopolysialylation, but STX is involved to a lesser degree than PST. 
Studies have shown that polysialylated enzymes tend to add more polySia to 
NCAM and it is speculated that it improves enzyme-substrate linkage. 
However this has been disputed, since when this process is abolished, the 
enzymes are still active even if not polysialylated. There is lot to unravel 
regarding the mechanism of polysialylation. 30, 72,73,74 
 
1.4. DRUG DISCOVERY AND POLYSIA – RATIONAL DRUG 
DESIGN AND MOLECULAR MODELLING  
 
Drug discovery, besides the development of new drugs, aims for the 
improvement of safety and efficiency of new therapies, allowing not only a 
cure but also an overall improvement in the quality of life, even if that means 
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the minimising of suffering through palliative cares, which often happens 
when dealing with cancer. 75 
As mentioned previously one of the main problems in cancer therapy 
is still the occurrence of disastrous side effects due to a lack of specificity for 
tumour cells. That makes the drug discovery and design of new medicines 
time consuming, since it needs a multi-disciplinary team, including medicinal 
chemists, molecular biologists, organic chemists, pharmaceutical scientists 
and geneticists, among others, and it needs above all to be increasingly 
innovative, with the identification of new therapeutic targets, to respond to the 
increasing demands of the patients. For that, drug design tends to be 
progressively more expensive, and from all of the new drugs synthesised 
every year, only a few are going to be commercialised, and even then that 
will take several years, drug development is still expensive and time 
consuming – a single drug can cost up to 1 billion Euros and take at least 10 
years to be developed. 75 
As a result, new techniques are arising to try and expedite theses 
processes, without compromising the safety of the new drugs.75 When a 
suitable therapeutic target is identified and validated, drug candidates are 
chemically synthesised. 76 A target can be classified broadly as usually a 
protein or biomolecule (e.g. enzyme or receptor) for a drug in vivo. 
Target validation is the first step of new drug discovery methods and 
involves physiological, pathological and pharmacological evaluation of the 
target biomolecule, evaluation that can be made at a molecular, cellular or 
whole animal level. The next steps include designing a bioassay to measure 
biological activity, constructing a high-throughput screen to find hit 
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compounds and evaluation of those hits in terms of stability, pharmacological 
effects and in vivo and in vitro toxicity. 76 
In cancer there is an increasing role and importance of personalised 
therapeutics, as previously mentioned, that accounts for intra and inter-
patient tumour heterogeneity, since now there is a better understanding of 
the biology features of tumours as described in the Hallmarks of cancer 
(Figures 1.2, 1.3 and 1.4). The use of personalised therapeutics has 
potential advantages over conventional chemotherapies by increasing patient 
survival and also through the reduction of toxic side effects, taking into 
account patient’s age, overall health, tumour type, stage and grade, among 
other features, but are more expensive, since they have a limited/specific use 
and for that their economical return is slower. It was also discovered that 
targeted therapies have the disadvantage of acquired resistance, since they 
are taken in long periods of time, which also can lead to less compliance of 
the patients. Personalized therapies are already available for some types of 
cancers, such as breast, non-small cell lung cancer and colorectal cancer. 
For example: in breast cancer, the identification of genes such as BRCA1, 
BRCA2, CDH1, CHEK2, P53 has recently been under the media spotlight. 
These findings allow prior warning, possibly decades before any cancer 
develops, to patients with these genetic predisposing characteristics. This 
gives the individuals (and their clinicians) the power to make early decisions 
to prevent/detect the cancer, and gives the oncologist the means to predict 
the efficacy of a given chemotherapy, which is more tailored to the individual 
patient. Also, in breast cancer, there has recently been much interest in the 
specific target HER-2 (epidermal growth factor receptor oncogene). This 
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tyrosine kinase receptor was proved to be overexpressed in 10-34% of 
breast cancers and to be related to malignancy – proliferation, migration and 
metastasis - and to poor prognosis. New therapeutics were developed, anti-
HER-2 (inhibitors), such as trastuzumab and lapatinib. Lapatinib is in phase II 
trials for use in cases of trastuzumab resistance and CNS metastasis), and is 
showing promising results. 3,5,75,76 
In contrast, previously the discovery of new drugs relied on trial-and-
error testing of compounds and also in the use of known natural products 
which by experience were known to have a specific use. More recently, 
rational drug design is the core process for drug development. It is based on 
a substrate of a specific and well described therapeutic target, a molecule 
involved in a specific molecular or signalling pathway that is specific for a 
disease, for which a three dimensional structure is known through methods of 
X-ray crystallography and spectroscopy. Computational chemistry is 
frequently used, employing molecular modelling which allows identification of 
a series of compounds that can bind/fit into a specific protein target, predict 
their action and determine which is the better molecule for that specific target 
with high affinity and selectivity. This makes the process of drug development 
less time consuming, since it allows to the discovery of several possible hit 
compounds for a specific known target, and less dependent of in vivo testing, 
since the behaviour of similar hit compounds are already known. 
Nonetheless, full understanding of the complex molecular pathways involved 
in tumour progression is still to be gained. Chemoresistance, acquired or 
secondary, continues to be a major problem, as is the appearance of 
unexpected side effects and bioavaibility problems. 75,76 
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Rational drug design requires a series of key components, as 
described in Figure 1.12:  
 Suitable target with biological rationale that substantiates it (e.g. 
there is in vitro and in vivo evidence that polySia-NCAM correlates to 
increased migration and metastasis in malignant tumours); 75,76 
 Druggable target, which means that the drug molecule will be 
able to reach it and cause an effect (e.g. with polySia there are already 
evidence that when unnatural mannosamine precursors of CMP-Neu5Ac are 
fed to cells they can alter the function of the enzymes responsible for the 
biosynthesis of polySia causing an inhibitory effect); 75,76 
 Selective target (e.g. polySia is only overexpressed in some 
types of tumours in adulthood, and because of that side effects resulting from 
the alteration of polySia in healthy cells should be minor); 75,76 
 Administrable drug (oral, iv or other) in a way that allows for an 
effective concentration to reach the tumour cells without harming 
normal/healthy cells (without any major side effects); 75,76 
  Right biomarker which proves reproducibility and validation of 
the target and drug – studies have demonstrated that polySia is by itself a 
biomarker of disease and can be easily detected/measured. 75,76 
 38 
 
 
 
 
 
 
 
1.4.1. GLYCOSYLTRANSFERASE INHIBITORS 
 
The development of glycosyltransferase inhibitors is an expanding 
area and has advanced immensely over the past decade.  Several enzymes 
have been reported in the literature due to the increasing understanding of 
their importance in modulation of cell interactions and signalling pathways. 
The synthesis of specific inhibitors is therefore essential to the understanding 
of their influence in biological systems. 77,78  
As previously mentioned, glycosyltransferases catalyse the transfer of 
a sugar moiety (e.g. Neu5Ac) from an activated nucleotide sugar (e.g.CMP-
Neu5Ac) to the hydroxyl group of an acceptor, which can be a growing 
Fig. 1.12 Key components of oncology drug development. 
75
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oligossacharide (e.g. polySia in NCAM), a lipid or a protein. (Figure 1.11) 
77,79 
At the present time there are already a number of sialyltransferases 
available for study and for in vitro testing of compounds; these are mainly 
animal α(2→6) sialyltransferases, but there are some key problems that 
make rational drug design difficult. Little is known about the 3-D structure of 
the enzymes and their catalytic mechanism.77,78,79 
In order to identify potential glycosyltransferase inhibitors, generally 
three different approaches are used:  
 
 Design of acceptor analogues – there are strict specificities 
regarding the terminal glycan portion of the acceptor structure and 
some inhibitors have been synthesised, but show lower inhibitory 
activity when compared to donor analogues and transition state 
mimetics; 78,79, 80 ,81 
 Design of donor analogues – CMP-NeuAc, is the donor 
substrate of all sialyltransferase enzymes and as such analogues of 
that molecule as inhibitors are of great importance; 77,78, 79 ,80 
 Design of transition state mimetics – e.g. CMP-NeuAc≠ using 
carbomimetic molecules. Horenstein proposed in the 1990’s that the 
sialylation transfer reaction proceeded through a SN1-like mechanism, 
forming an oxacarbenium ion-like intermediate (Figure 1.13), with a 
positive charge in C2 delocalized with the ring oxygen atom. Kinetic 
studies have shown that the affinity towards an enzyme active site is 
107 to 1015 times higher when in transition state, emphasising the 
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potential importance of these types of analogues. 77,78, 79 ,80 This 
approach is often the most challenging chemically. 
 
 
 
 
There are different types of glycosyltransferase inhibitors, but most of 
those already synthesised against sialyltransferases lack significant activity. 
The first approaches focused on modifications to the Neu5Ac core (Figure 
1.14) of CMP-sialic acid, constructing substituted analogues with: C5 amino 
group acetylated or glycosylated; acetylated hydroxyl groups, specifically C9; 
C9 phosphorylation and C8 methylation or sulfatation. Besides the fact that 
saccharide chemical synthesis is very difficult, sugars often (but not always) 
possess undesirable physicochemical properties that makes them very 
difficult to handle and purify (they frequently require preparative HPLC). 
79,80,81 
             
              Fig. 1.14 Structure of Neu5Ac.  79 
Fig. 1.13 Transition state Neu5Ac
≠
 proposed mechanism. 
79
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For that reason, one approach was to start to replace the sugar (in this 
case sialic acid) core for a carbohydrate mimetic, where the glycosidic 
oxygen atom of the sugar moiety is substituted by a heteroatom or carbon 
atom. This often resulted in iminosugars and carbasugars, in the hope of 
maintaining the shape and function of the natural substrates, maintaining 
their biological function and ground/transition state, but increasing their 
affinity and stability towards the enzymes. 77  
In iminosugar analogues, the oxygen atom is substituted by a nitrogen 
atom and they are potentially important compounds since biological activity 
tends to be high, making them good candidate drugs for diabetes, cancer 
and viral infections as glycosyltransferase transition state mimetics inhibitors. 
Several inhibitors were already synthesized including pyrrolidinols and 
piperidinols. 77 
 
1.4.1.1. CARBASUGAR ANALOGUES OF CMP-Neu5Ac 
 
Carbasugars and analogues are a group also designated as 
carbomimetics or pseudo-sugars. This is the group that has received the 
most interest for this project since it includes analogues of 
furanoses/pyranoses where the oxygen atom is substituted by a carbon 
atom. Besides maintaining affinity towards enzyme, there have been many 
examples in the literature of promising compounds. 77 
Syntheses of carbasugar-based nucleotide analogues of CMP-
Neu5Ac have been reported in the literature. Sialyltransferase enzyme 
inhibitors of this type were the focus of this project. Our goal was to inhibit 
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α(2→8) polysialyltransferases PST and STX leading to a decrease in polySia 
biosynthesis and its expression on NCAM. Such effects were hypothesised to 
have antimetastatic activity. 77 Schmidt et al. reported the synthesis of 
structural CMP-Neu5Ac donor analogues and transition state (CMP-
Neu5Ac≠) analogues, using phosphorous derivatives, with potent 
sialyltranferase inhibitory activity (rat liver α(2→6) sialyltransferases are the 
most commonly used for these kinetic studies) described in Figure 1.15.  
Here, donor analogues were quinic acid-based analogues and when 
compared to the Km of the natural substrate (Km = 46 µM) unmodified quinic 
acid showed a Ki = 44 µM. These similar values indicate that the Neu5Ac 
core is not necessary for inhibitory activity but the nucleotide is. This 
suggested that the quinic acid core could be a good substitute for the sialic 
acid core, which has a difficult synthetic chemistry, without loss of activity 
towards the sialyltransferase enzymes. Compounds that were transition state 
mimetics, with delocalized positive charge in the core ring as it happens in 
CMP-Neu5Ac (Figure 1.13), showed the highest inhibitory activity in this 
studies (Ki = 40 nM, as can be seen in Figure 1.15). 78,79,83,84 These types of 
compounds are often the most challenging synthetically. These compounds 
were not considered in this work (but were subject of future plans: see 
Conclusions and Future work). 
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Fig. 1.15  Biological evaluation of sialyltransferase inhibitors. 
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In order to block the full transferase potential of these enzymes, there 
are certain aspects of the donor substrate binding area that potentially need 
to be fulfilled such as: inclusion of a CMP moiety or a monophosphate 
residue, tolerates variations in the phosphate linkage and at C4, C5 and C9 
positions of Neu5Ac, but stability of the glycosidic bond is crucial. Quinic acid 
and its derivatives, attached to CMP via the tertiary hydroxyl fulfils these 
demands, and although the protection of the other hydroxyl groups of quinic 
acid at C3, C4 and C5 is required, methodologies for that purpose are 
already available and are simple to perform. This includes the attachment of 
the CMP aglycone to the modified sialic acid core, via a classical phosphite 
amide methodology (the formation of the glycosidic linkage is usually the last 
step of the synthesis process inhibitors of sialyltransferases) (see Scheme 
5.1.1). 78,81,83,84,85 
Quinic acid is a chiral natural product that has the advantages of being 
commercially available, having a carboxylic group that facilitates 
functionalization, as well as the required axial-equatorial triol pattern that can 
mimic the sugar moiety of Neu5Ac. It is also important to mention that there 
is also a study were a macrolide antibiotic with a quinic acid scaffold led to in 
vitro inhibition of tumour cell migration, which came to emphasize its role as 
the starting material for the synthesis of sialyltransferase inhibitors 
carbasugars. 86,87,88 
As referred to previously, natural products account for the majority of 
drugs and drug leads available today in several therapeutic areas (cancer 
and mainly infection). These natural products include ribosomal peptides, 
alkaloids and polyketides also referred to as macrolides. 88 
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During the study of macrolide antimycobacterials with a quinic acid-
scaffold (designed to create pseudo-disaccharides to mimic mycothiol 
already known for its antimicrobial and antifungals effects), it was discovered 
by Metaferia et al. that some of the synthesized compounds had tumour 
migration inhibitory effects, superior to migrastin.  
Migrastin is a streptomycite-derivative macrolide that has an IC50 of 29 
µM in breast cancer cells, which led to the interest in developing analogues 
with higher potenty and selectivity  (Figure 1.16).  88 
 
 
 
 
Metaferia et al., when using a quantitative chamber assay and 
qualitative wound healing assay (also referred to as scratch assay) obtained 
tumour migration inhibition values (Ki) in the nanomolar range. Further 
studies made by this group determined that this high tumour migration 
inhibition effect was a result of blockage of rac-mediated lamellipodia 
formation (actin fibres formation involved in cell migration), similar to the one 
in migrastin and its analogues. 88 
Fig. 1.16  Chemical structure of quinic acid and migrastin antibiotic. 
88 
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CMP-analogues derived from a natural sialyltransferase inhibitor CDP 
(cytidine diphosphate), also possessed good kinetic characteristics and the 
synthesis of transition state analogues by introduction of a double bond 
between C2 and C3 of quinic acid, similar to what happens in the transition 
state of CMP-Neu5Ac (which can be seen in Figure 1.13), increased activity 
three-fold (Ki = 15 and 10 µM) the binding to α(2→6) rat liver 
sialyltransferase over CMP-Neu5Ac. 78,83,84  
The cytidine nucleotides proved to have a greater inhibitory ability than 
other nucleotides such as UTP, UDP, UMP, ATP and AMP, and the number 
of phosphates and electronegative potential (presence of a negative charge) 
appear to be related with increasing inhibitory potential. CTP was the 
nucleotide with the higher inhibitory activity and AMP the one with the least. 
However, how the phosphate group contribute to the formation of the 
glycosidic linkage is still not understood. 79 
The available studies regarding the synthesis of the previously 
described structural analogues of CMP-Neu5Ac, whether it was transition 
state mimetic or not and carbasugar or not, enable researchers access to 
some important information about what is required for inhibitors to display 
high affinity to sialyltransferases:  
 The more potent inhibitors were transition-state analogues, 
polar and charged (at least two negative charges close to the 
glycosylation site); 
 Had planarity at the anomeric center, increased distance 
between CMP and anomeric carbon for bond cleavage; 
 Cytidine was the nucleoside.   
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Nonetheless it still has to be determined whether these compounds 
have in vitro and in vivo efficacy, since the above characteristics usually 
decrease membrane permeability, and so these compounds may not be able 
to enter the cell and cause any biological inhibitory effect. One of the 
approaches to overcome this issue could be the use of sialyltransferase 
prodrug molecules. 79 
 
1.4.1.2 UNNATURAL MANNOSAMINE PRECURSORS 
 
It is important to highlight once again the fact that a study where after 
feeding unnatural mannosamine precursors (Figure 1.17, Man5But, 
Man5Prop and Man5Pent, which contain alterations at the C5 amine acetyl 
group of mannosamine natutal precursor of sialic acid) to cells for the 
synthesis of polySia, they were incorporated into the corresponding CMP-
Neu5Ac molecule, through the action of normal cell machinery. Reports 
described selective inhibition of STX α(2→8) polysialyltransferase and a 
resultant decrease in polySia expression on NCAM. 44 Besides CMP, these 
compounds remain the only reported polySTX inhibitors in the literature. 
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The quantification of their activity, determination of Km and Ki values, 
can be now determined through radioactive assays. These assays possess 
safety risks and are relatively expensive.  
Other methods that can be used for this purpose include: 
 Fluorescence-labelled CMP-Neu5Ac; 77,78,89 
 NADH oxidation; (77,78,89) 
 UV-labelled acceptor structures, that afterwards are  converted 
to an UV-labelled product; 77,78,89 
 More recently: a non-radioactive glycosyltransferase assay that 
uses specific phosphatases. The release of inorganic 
phosphate from this enzymatic reaction is directly proportional 
to the sugar molecule transferred, and can be detected by 
colorimetric reagents. This assay is also of interest to our 
group because of the possibility of being amenable to a 
Fig. 1.17 Unnatural mannosamines. 
44
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multiwell plate format, allowing the simultaneous screening of 
several compounds. 77,78,89 
It can be stated that at the present time there are several examples of 
inhibitors for sialyltransferases, using both sialic acid analogues and 
carbasugar compounds, but these still require biological testing to investigate 
whether they can enter the cell and produce therapeutic effects.  
On the other hand there are not reported the affinity kinetic studies of 
these compounds using α(2→8) human polysialyltransferases.  
Sialyltransferases are emerging, and will be of use in the design of 
compounds affecting polySia biosynthesis and its inhibition, which will allow 
further progress regarding the knowledge of this important new therapeutic 
target. 
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2. HYPOTHESIS 
 
Malignant tumours re-express polySia and there is now substantial in 
vitro and in vivo evidence that the polysialic acid presence in many tumours 
is related to higher malignancy, invasion and metastasis. 
My hypothesis is that if the expression of polySia could be inhibited in 
those cancer cells that express it, through the inhibition of 
polysialyltransferase enzymes, PST and STX, enzymes which are 
responsible for polySia biosynthesis, then reduced polySia levels in those 
cancer cells would also reduce tumour cell migration, invasion of surrounding 
tissues and metastasis in distant locations/organs.  
These combined effects would lead ultimately to an improvement of 
patient outcomes, mainly due to the reduction of cancer malignancy and 
higher survival of cancer patients.  
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3. AIMS AND OBJECTIVES 
 
The overall aim of the broader research project, of which the work 
described in this thesis is a part, was the development of inhibitors of the 
polysialylation process in tumours.  
The aim of this project was to develop chemical methodology towards 
the synthesis of a series of polysialyltransferase inhibitors which mimic the 
natural substrate (CMP-Neu5Ac) and that could be used to probe activity in 
cellular systems. A summary of the overall strategy with regards to 
modification to the CMP-Neu5Ac substrate is outlined in Scheme 3.1. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.1. - Structural modifications for the construction of CMP-Neu5Ac analogues for 
inhibition of polySia biosynthesis. 
 
Specifically, the aim of the work described in this thesis was the 
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suitable chemical functionality for conjugation as potential 
polysialyltransferase inhibitors. This aim was achieved through the following 
objectives: 
 
1. Synthesis of building blocks in which the core Neu5Ac sugar structure 
in CMP-Neu5Ac is replaced by a carbocycle.  
1.1. Synthesis of quinic acid-based analogues, with the aim of C1-
OH substitution, to enable conjugation to CMP and/or other 
moieties.  
1.2. Evaluation of the use of the Barton-McCombie deoxygenation 
reaction and the Mukaiyama aldol addition, to synthesize C1 
substituted quinic acid-based compounds. 
 Evaluation of reaction conditions for optimisation of the 
Barton-McCombie reaction, to remove the C1 hydroxyl 
group and insert a hydrogen atom. 
 Investigation of the feasibility of the use of the Mukaiyama 
reaction and testing of the reaction conditions, for the 
introduction of aliphatic groups at the C1 position. 
2. Synthesis of a suitably protected cytidine building block suitable for 
coupling to the core structure of sialic acid or carbacycle (e.g. quinic 
acid analogues) via a phosphate or otherwise. 
3. Investigation into methodology for the synthesis of disulfide sialic acid 
building blocks, and investigation into broader utility of the approach to 
non-sialic acid-based glycosyltransferase inhibitors. 
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4. MATERIALS AND GENERAL METHODS 
 
Commercially available reagents were used as received without 
further purification, all were of reagent grade. Anhydrous solvents were used 
throughout, unless otherwise stated in the description of the method. 
Petroleum ether refers to the fraction of petroleum spirit boiling in the range 
of 60 to 80 °C (Fisher).  
Quinic acid (D(-)-quinic acid 98%), potassium thioacetate (KSAc batch 
1), TTMSS ( batch 2), TMSCl, phenylacetaldehyde, TiCl4, TBDMSCl, 
TBDPSCl, hydrazine acetate, iodoethane, iodine and LDA solution (1.8 M in 
THF) batches were purchased from Sigma-Aldrich; N-acetylneuraminic 
(sialic) acid was purchased from Dextra laboratories; cytidine, potassium 
thioacetate (KSAc batch 2) and benzyl bromide were purchased from Alfa 
Aesar; imidazole and thiocarbonyldiimidazole were purchased from Fluka; 
TTMSS was purchased from FluoroChem (batch 1).  
Flash column chromatography using 9385 silica gel 60 (40-63 μm) 
from Merck was used for purification of products and analytical thin layer 
chromatography (TLC) was performed on plates precoated with silica gel 60 
F254 (Merck), for monitoring of the reactions. Visualization of the TLC plates 
was carried out using ultraviolet light (254 nm) and/or a basic solution of 
potassium permanganate (KMnO4) followed by heating. For the sugar 
compounds sulphuric acid (H2SO4) char staining was used. When stated, 
regarding flash column chromatography and TLC, mixtures of solvents are 
referred to as percentage volume to volume (v/v) ratios. 
For full characterization of the obtained products, optical rotations 
were measured using a PerkinElmer 341 polarimeter. The concentration (c) 
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is given in grams per 100 mL and solvents are stated for each compound. 
Proton Nuclear Magnetic Resonance (1H NMR) spectra were recorded using 
a Bruker AMX400 (400 MHz) instrument. Chemical shifts are reported in 
parts per million (ppm) and coupling constants (J) are expressed in Hertz 
(Hz). Carbon Nuclear Magnetic Resonance (13C NMR) was performed on the 
same instrument operating at 101 MHz. NMR solvents used were as stated 
for each compound. Routine low resolution mass spectra (LRMS) were 
generated using a Micromass Quattro Ultima spectrometer in the 
electrospray ionisation (ESI) or atmospheric solid admission probe (ASAP) 
modes, and high resolution mass spectrometry (HRMS) was performed at 
the National Mass Spectrometry Centre (Swansea, UK) using a MAT95 or 
MAT900 instrument in electrospray ionisation (ESI) mode. 
For the majority of compounds reported, the assignment of the carbon 
numbers does not follow IUPAC rules; the numbering of atoms is assigned in 
the structure. 
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5. RESULTS AND DISCUSSION 
 
5.1. QUINIC ACID-BASED ANALOGUES OF CMP-Neu5Ac 
 
Regarding the synthesis of the structural analogues of CMP-Neu5Ac 
(see Scheme 3.1), by replacement of the core sugar structure by a 
carbacycle, quinic acid, scheme 5.1.1 describes a summary of the tested 
reactions and the successfully synthesised compounds (which are 
numbered). 91 
 
 
Scheme 5.1.1. – Quinic acid-based compounds: a summary tested reactions and 
synthesized compounds. 
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5.1.1. Protection of C3, C4 and C5 hydroxyl groups 
 
The first objective was to protect the C3, C4 and C5 carbons of quinic 
acid, with the final aim to substitute the C1 tertiary hydroxyl group. 
Substitution at this position, e.g. by an aliphatic group, was key to being able 
to manipulate quinic acid in the manner we required, to produce potential 
inhibitors. Due to the similarities between quinic acid and the sialic acid part 
of CMP-sialic acid, a suitable linkage/functional group at that position would 
enable the synthesis of several compounds to be coupled, via a phosphate 
linkage or otherwise, to a cytidine molecule or other suitable nucleoside. The 
quinic acid-based analogues would then be evaluated biologically to 
demonstrate their inhibitory activity towards polysialyltransferases, PST and 
STX. 92,93,94 
 
5.1.1.1. Lactone and isopropylidene ring formation 
 
 
Starting from quinic acid, 3,4-O-isopropylidene-1,5-quinic lactone (1) 
was synthesised successfully using acetone and sulphuric acid as the 
catalytic donor, to promote the formation of the isopropylidene ring between 
C3 and C4 and the lactone ring between the carboxyl function and the C5 
carbon (see Scheme 5.1.2). These protecting groups ensure that only the 
free hydroxyl group is at the C1 position, which could be substituted 
afterwards. Different conditions were already reported in the literature, with 
conflicting reports of success. An investigation was initiated to obtain the best 
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synthetic method (see Table 5.1.1 for reaction conditions tested - use of 
desiccating agent, temperature and reaction time, and results obtained). 92 
 
 
 
Scheme 5.1.2. – Synthesis of 3, 4-O-isopropylidene-1, 5-quinic lactone (1) starting from 
commercially available D-(-)-quinic acid 98%. 
 
 
 Method 1, reported by Barco et al.,95 proved to be the least successful 
due to long reaction times and the need for purification, which proved to be 
difficult due to solubility issues with the crude reaction mixture (see Table 
5.1.1, entry 1). Methods 2 96 and 3 97 were very similar. Using reflux (see 
Table 5.1.1, entry 2 and 3), but the use of longer reaction times gave a higher 
quantitative yield of compound (1), without the need for purification via 
chromatography. This was since the work-up employed (neutralization to pH 
6-7 with solid NaHCO3, filtration, solvent evaporation and extraction using 
water and DCM) completely removed the main impurity, as confirmed by TLC 
and NMR. 
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Met. Solv. Cat. 
Desic. 
agent 
Conditions 
Results 
Temp. Time 
1a) 
Acetone H2SO4 
- RT 185 hrs 
 
Impure, difficult 
purification 
2b) 
Na2SO4 
(7 eq) 
Reflux 
80 ºC 
4.15 
hrs 
 
No purification  
 
η qt. = 66% 
3c) 
Na2SO4 
(6 eq) 
Reflux 
75 ºC 
24 hrs 
 
No purification  
 
η qt. = 85-96% 
 
η qt. = quantitative yield 
a) Adapted from Barco et al. (1997). 
95
 
b) Adapted from Baptistella (2004). 
96 
c) Adapted from Abella (2006) better and more simple synthetic method. 
97
 
 
 
Table 5.1.1. – Testing conditions and results, for the synthesis of 3, 4-O-isopropylidene-1, 5-
quinic lactone (1) starting from commercially available D-(-)-quinic acid 98%. 
  
5.1.1.2. Esterification of the acidic function 
 
Simultaneously, starting from quinic acid a second of my main 
objectives was the esterification of the acid function, to yield compound (2) 
methyl quinate (see Scheme 5.1.3).  
Esters are useful in drug compounds since they can improve 
lipophilicity. A lipophilic drug penetrates cellular membranes much easier 
than a more hydrophilic compound, due to being more readily transported 
and reaching the desired target area, namely the highly 
selective/impermeable blood-brain barrier which needs to be surpassed by 
drugs that are intended to act in the CNS. 92 
Using methanol as a polar protic solvent, different conditions were 
investigated to obtain the best synthetic method (see Table 5.1.2 for reaction 
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conditions tested – catalyst used, temperature and reaction time, and results 
obtained). 36,92,98 
 
 
Scheme 5.1.3. – Synthesis of methyl quinate (2) starting from commercially available D-(-)-
quinic acid 98%. 
 
  
η qt. = quantitative yield 
a) Adapted from Bianco (2001). 
36
 
b) Adapted from Frank (1998) better and more simple synthetic method. 
98
 
 
 
Table 5.1.2. – Testing conditions and results, for the synthesis of methyl quinate (2) starting 
from commercially available D-(-)-quinic acid 98%. 
 
Method 1, which was previously reported by Bianco et al., 36 proved to 
be the least successful due to longer reaction times and the need for 
neutralization work-up. This was due to the use of sulphuric acid as catalyst 
(see Table 5.1.2, entry 1). Method 2, adapted from Frank et al., 98 proved to 
be the better synthetic method. Amberlite exchange resin IR-120H+ was used 
as a catalytic proton donor and reflux, which gave a higher quantitative yield 
of compound (2), with shorter reaction times and without the need of complex 
Met. Solv. Catalyst 
Conditions 
Results 
Temp. Time 
1a) 
MeOH 
 
H2SO4 
 
RT ovn. + 96 hrs 
No purification 
step 
η qt. = 69% 
2b) 
Amberlite 
resin IR- 120 
H+ 
Reflux 
75 ºC 
24 hrs 
No work-up 
No purification 
step 
η qt. = 99% 
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work-up (it was only necessary to filter the resin and evaporate solvent) and 
purification through a chromatography column, (see Table 5.1.2, entry 2). 
 
5.1.1.3. Trisubstitution of C3, C4 and C5: acetylation and 
sialylation 
 
Once compound (2) methyl quinate (see Scheme 5.1.3) had been 
synthesized was fine-tuned, the objective was then to devise strategies to 
protect the hydroxyl groups of C3, C4 and C5. (see Scheme 5.1.4) 92,94,99 
 
 
Scheme 5.1.4. – Synthesis of methyl 3, 4, 5-tri-O-acetylquinate (3) starting from the 
previously synthesised methyl quinate (2). 
 
5.1.1.3.1. Trisubstitution of C3, C4 and C5: Acetylation  
 
The first strategy employed consisted of the acetylation of those 
positions and synthesis of 3, 4, 5-tri-O-acetylquinate, compound (3) (see 
Scheme 5.1.4).  Different conditions have been reported, commonly using 
pyridine, and an acetyl donor such as acetic anhydride or acetyl chloride.  
Those conditions were investigated and modified (see Table 5.1.3 for 
reaction conditions tested – reagents used, temperature and reaction time, 
and results obtained). 
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
Pyr. 
 
Ac2O (4 eq) 
RT 1 hr 
No s.m.  
Difficult purification 
2 RT ovn.  
Tetra-acetylated 
compound 
 (C1, C3, C4 and C5) 
3 
 
0 ºC to RT 1.30 hrs 
No s.m. 
Difficult purification 
 
4b) 
 
DCM solv. 
Pyr. (1.5 eq) 
Acetyl chloride  
(2 eq) 
 
-20 ºC to RT 1 hr 
5 
 
Pyr.  
Ac2O (3 eq) 
-40 ºC to RT 2 hrs 
6 
0 ºC to RT 
(Ac2O added 
dropwise  for 
30 min) 
2.15 hrs 
Still s.m. 
η ac. = 8% 
7 
 
DCM solv. 
Et3N 
Ac2O (3.1 eq) 
 
0 ºC to RT 
(Ac2O added 
dropwise  
for 30 min) 
3.15 hrs 
Still s.m. 
η ac. = 14% 
8* 
 
Pyr.  
Ac2O (4.5 eq) 
 
3 hrs 
No s.m.  
η ac. = 28% 
9*# 
 
Pyr.  
Ac2O (3.5 eq) 
 
3.45 hrs 
No s.m.  
η ac. = 49% 
η ac. = after column  yield 
a) Adapted from Bianco (2001).
36
 
b) Adapted from Kondo (2005). 
100
 
* starting material (s.m.) methyl quinate was previously purified through a flash column before setting up the 
reactions;  
# showed to be the better synthetic method. 
 
Table 5.1.3. – Testing conditions for the synthesis of methyl 3, 4, 5-tri-O-acetylquinate (3) 
starting from previously synthesized methyl quinate (2). 
 
Method 136 involving use of pyridine and acetic anhydride as acetyl 
donor, proved to be unsuccessful, because the reaction time recommended 
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was too short (1 hour) and the resulting TLC of the crude reaction mixture 
indicated several products (more than 5), probably resulting from the 
presence of mono, di, tri and tetra-acetylated compounds plus impurities (see 
Table 5.1.3, entry 1). This also indicated that fewer equivalents of acetic 
anhydride should be used to minimize the formation of the undesired tetra-
acetylated compound. For that reason and to begin to identify which spot in 
the TLC corresponded to which acetylated compound, method2 (see Table 
5.1.3, entry 2) using the same conditions but overnight, was set up. That 
enabled the exclusive formation of tetra-acetylated compound, which could 
now be identified in future analyses. Method3 (see Table 5.1.3, entry 3), 
demonstrates the first attempt to optimise the reaction time, by decreasing 
the temperature to 0ºC (ice bath) during the addition of acetic anhydride. 
Nonetheless, the reaction was still fast, with a similar result as obtained while 
using method 1. 
Method4 (see Table 5.1.3, entry 4), adapted from Kondo et al, 100 uses 
acetyl chloride as acetyl donor and lower temperatures through the use of ice 
and salt bath, during the addition of the reagents. These conditions did not 
alter the reaction time, since starting material couldn’t be detected by TLC 
after 1 hour and none of the spots were prevalent over the others, when 
comparing to the previously described methods, and still gave a complex 
mixture difficult to purify. 
With the previous results in mind, it was thought that the reaction 
temperature could be further decreased, and in method 5 (see Table 5.1.3, 
entry 5) an acetonitrile and dry ice bath was used to reach -40ºC, and the 
equivalents of acetic anhydride were also decreased. As a result it was 
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possible to reduce the reaction velocity, but still none of the spots shown in 
the TLC were prevalent over the others and purification was not successful. 
Since decreasing the temperature was not the answer to solve this 
problem of fast consumption of the starting material, the strategy was turned 
to how the actual addition of the reagents was made. So in method 6 (see 
Table 5.1.3, entry 6), the acetic anhydride was added to the cooled (at 0 ºC) 
solution of compound (2) and pyridine, very slowly, dropwise over a period of 
30 minutes. In addition, this time the reaction was quenched before the total 
consumption of starting material to try to minimize the formation of by-
products and to determine which spot corresponded to the desired 
compound, to enable a more accurate control of the reaction in the 
subsequent attempts. As a result it was possible to isolate and determine for 
the first time the Rf of compound (3), although with very low yield. 
Due to the low yield obtained, it was felt that method 6 still needed 
further optimisation, and so it was thought that the use of a different base 
could help to improve the reaction outcome, and in method 7 triethylamine 
was used (see Table 5.1.3, entry 7) to decrease the presence of impurities, 
nonetheless the yield obtained for compound (3) was still low. 
Since changing the base did not improve the resolution of the mixture 
obtained in method 8 and 9 (see Table 5.1.3, entry 8 and 9) compound (2), 
the starting material was purified by column chromatography in the hope of 
decreasing the impurities that were making it difficult to purify the reaction 
products. This did not initially appear to be necessary, given an apparently 
clean reaction. As a result, method 9 represented an improvement. It was 
determined that for this type of acetylation reaction, the following was 
 64 
 
required: careful purification of the starting material, use of more than 3 but 
less than 4 equivalents of acetic anhydride in the reaction, dropwise addition 
of acetic anhydride at 0 ºC, and constant TLC monitoring of the reaction, to 
try to minimize the by-product formation. 
 
5.1.1.3.2. Trisubstitution of C3, C4 and C5: Silylation  
 
Starting from methyl quinate (2) (see Scheme 5.1.3), the second 
strategy for protection consisted of silylation of the three hydroxyl groups, 
through the formation of silyl ethers. For that purpose, the following 
protecting groups were considered TBDMS (tert-butyldimethylsilyl- 
introduced using tert-butyldimethylsilylchloride, see Scheme 5.1.5, compound 
4) and TBDPS (tert-butyldiphenylsilyl- introduced using tert-butyldiphenylsilyl 
chloride, see Scheme 5.1.6), mainly because their stability in a basic medium 
was more suitable. The synthetic method commonly uses: DMF as solvent 
and imidazole as a catalyst, especially if the silyl compound is bulkier, since 
there is a need for formation of a more reactive intermediate. The conditions 
were reproduced and modified to obtain the best synthetic method (see 
Table 5.1.4 and 5.1.5 for reaction conditions tested – reagents used, 
temperature and reaction time, and results obtained). 
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Scheme 5.1.5. – Synthesis of methyl 3,4,5-tri-(tert-butyldimethylsilyloxy)-1-hydroxy-
cyclohexane-1-carboxylate (4) starting from previously synthesized methyl quinate (2).  
 
Regarding the synthesis of 3,4,5-tri-(tert-butyldimethylsilyloxy)-1-
hydroxy-cyclohexane-1-carboxylate (4), method 1, which was previously 
reported by Abella et al. 101 (see Table 5.1.4, entry 1) the use of a 
considerable number of equivalents of the TBMDS-Cl reagent (10 eq.) and 
imidazole (15 eq.), at a temperature of 65 ºC for 22 hrs was reported, but it 
was concluded that this reaction time was insufficient. As a result, unreacted 
starting material (2) was recovered.  
With that in mind, in method 2 (see Table 5.1.4, entry 2) using the 
same ratios of reagents and a previously purified starting material (2), the 
reaction temperature was increased to 80 ºC and the time to 72 hrs, which 
proved to be the best conditions to arrive at the desired compound, with an 
excellent yield of 93% after purification. 
Method 3 (see Table 5.1.4, entry 2) also using purified starting 
material, reflects the attempt to use a smaller amount of equivalents of 
TBMDS-Cl (6 eq.) and imidazole (9 eq.) and a shorter reaction time, which 
led to an average yield of 43% after purification.  
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
 
DMF solv. 
 
Imidazole  
(15 eq) 
 
TBDMSCl  
(10 eq) 
 
Δ 65 ºC 22 hrs 
Only s.m.  
and reagents 
2*# 
Δ 80 ºC 
72 hrs η ac. = 93% 
3* 
 
DMF solv. 
 
Imidazole  
(9 eq) 
 
TBDMSCl  
(6 eq) 
 
24 hrs η ac. = 43% 
a) Adapted from Abella (2009). 
101
 
 Δ = heating. η ac. = after column  yield 
* starting material (s.m.) methyl quinate was previously purified through a flash column before setting up the 
reactions. 
# showed to be the better synthetic method. 
 
Table 5.1.4. – Testing conditions for the synthesis of methyl 3,4,5-tri-(tert-
butyldimethylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate (4) starting from previously 
synthesized methyl quinate (2). 
  
Regarding the attempt to synthesise methyl 3,4,5-tri-(tert-
butyldiphenylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate (see Scheme 
5.1.6) starting from methyl quinate (2), in method 1 (see Table 5.1.5, entry 1) 
adapted from Abella et al., 101 firstly it was reacted with TBDPSCl (6 eq.) and 
imidazole (10 eq.) at 70 ºC for 24 hrs., but after that time TLC indicated no 
progression of the reaction. Due to this, 2.6 eq. of TBDPSCl were added and 
the reaction temperature increased to 80 ºC and the reaction stirred for 24 
hrs more. As a result only unreacted starting material 2 and reagents were 
recovered. 
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Scheme 5.1.6. – Attempt at the synthesis of methyl 3,4,5-tri-(tert-butyldiphenylsilyloxy)-1-
hydroxy-cyclohexane-1-carboxylate starting from previously synthesized methyl quinate (2). 
 
In method 2 (see Table 5.1.5, entry 2) the method that had proved to 
be the most successful for the synthesis of compound (4) was adopted (see 
Table 5.1.4, entry 2), and as such the same amounts of reagents and 
conditions were used. Nonetheless, the attempt at the synthesis of the tri-
substituted compound with TBDPS was unsuccessful because only di-
substituted C3 and C5 compound was isolated after purification. This 
indicates that the three hydroxyl groups are possibly too hindered for the 
bulkier TBDPS group to be able to protect the C4 hydroxyl group in the 
presence of the other two. 
After the successful synthesis of compound (4), there was an attempt 
at the synthesis of 3,4,5-tri-O-tert-(butyldimethylsilyloxy)-shikimate (see 
Scheme 5.1.7). The existence of the double bond between C1 and C2, was 
already reported in the literature for the tri-acetylated compound (3) by 
Bianco et al., 36 and presented a compound of interest due to the elimination 
of the C1 hydroxyl group and possibility of reduction of the alkene formed to 
an alkane, with the use of an hydrogen source and an appropriate catalyst 
(e.g. Pd, Pt or Ni). 
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
 
DMF solv. 
 
Imidazole  
(10 eq) 
 
TBDPSCl  
(8.6 eq) 
 
Δ 70 ºC 
+ 
Δ 80 ºC 
24 hrs 
+ 
24 hrs 
Only s.m.  
and reagents 
2 
 
DMF solv. 
 
Imidazole  
(15 eq) 
 
TBDPSCl  
(10 eq) 
 
Δ 80 ºC 72 hrs Di-substituted compound 
a) Adapted from Abella (2009). 
101
 
 Δ = heating. S.m. = starting material. 
 
Table 5.1.5. – Testing conditions for the attempt at the synthesis of methyl 3,4,5-tri--(tert-
butyldiphenylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate starting from previously 
synthesized methyl quinate (2). 
 
 
 
Scheme 5.1.7. – Attempt at the synthesis of methyl 3,4,5-tri-O-tert-(butyldimethylsilyloxy)-
shikimate starting from previously synthesised 3,4,5-tri-(tert-butyldimethylsilyloxy)-1-hidroxy-
cyclohexane-1-carboxylate (4). 
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
 
Thionylchloride 
 
Pyridine  
 
0 ºC to RT 
(SOCl2 added 
dropwise) 
7 hrs -  
a) Adapted from Bianco (2001). 
36
 
  
Table 5.1.6. – Attempt at the synthesis of methyl 3,4,5-tri-O-tert-(butyldimethylsilyloxy)-
shikimate starting from previously synthesized 3,4,5-tri-(tert-butyldimethylsilyloxy)-1-hydroxy-
cyclohexane-1-carboxylate (4). 
 
In Table 5.1.6 the reaction conditions used are described.. The 
method adapted from Bianco et al. 36 used thionyl chloride and pyridine, in a 
based-induced E2 elimination reaction, but although no starting material (4) 
could be isolated after 7 hrs, no desired product was detected: the NMR 
spectrum indicated the absence of any double bond. Further possibilities 
include the use of POCl3 (phosphorous oxychloride) or Martin sulfurane 
dehydrating reagent, reported by Shing et al. 102; this would be the subject of 
future work. 
5.1.1.4. Selective opening of the C1-C5 lactone ring 
 
 
Scheme 5.1.8. – Synthesis of methyl 3, 4-O-isopropylidene quinate (5) starting from 
previously synthesized 3,4-O-isopropylidene-1,5-quinic lactone (1). 
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One of the most challenging reactions for the quinic acid-based 
analogues proved to be that described in Scheme 5.1.8. The reaction aimed 
for the synthesis of methyl 3, 4-O-isopropylidene quinate (5) starting from the 
already successfully synthesised quinide acetal (1), through the use of an 
apparently very common method, described several times in the literature, 
using methanol as solvent and a sodium methoxide on methanol solution for 
the opening of the C1-C5 lactone ring, resulting in simultaneous esterification 
of the carboxyl function of quinic acid. 
 
The first method attempted was (see Table 5.1.7, entry 1 and 2) 
adapted from Abella et al, 97 using 1.3 eq of 0.5 M NaOMe in MeOH,  added 
slowly drop-wise over 30 min at 0 ºC, and then stirring for 1-2 hrs. (see Table 
5.1.7, entry 1) or 20 hrs. (see Table 5.1.7, entry 2).  
After that time, TLC didn’t indicate any unreacted starting material and 
so work-up consisted of neutralization of the basic medium using 1 eq. of 
acetic acid, followed by extraction using NaHCO3/DCM. However, no 
compound was recovered. 
Since this outcome was a surprise, given that this type of reaction is 
common, I started by modifying the work-up procedure, in an attempt to 
minimise potential compound losses through that route.  
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Met. Solv. Reag. 
Conditions 
W.up Results 
Temp. Time 
1a) 
MeOH 
NaOMe 
0.5 M in 
MeOH 
(1.3 eq) 
0 ºC to RT 
(NaOMe 
added 
dropwise  
for 30 
min) 
1-2 
hrs 
acetic acid 
(1 eq) (neut.) 
NaHCO3/DCM 
(extrac.) 
No s.m. 
Nothing 
recovered 
2 
20 
hrs 
3(b) 
6.30 
hrs 
acetic acid 
(1 eq) (neut.) 
EtOAc/silica   
gel pad 
4(c) 7 hrs 
acetic acid  
(1 eq) (neut.) 
No W.up 
5(d) 
NaOMe 
freshly 
made(1.3 
eq) 
5.30 
hrs 
Amberlite IR-
120 H+ 
Methyl 
quinate 
(2) 
6 
NaOMe 
0.5 M in 
MeOH 
(1.3 eq) 
3.45 
hrs 
Dowex 
50wx2-200 
(neut.) No s.m. 
Nothing 
recovered 
7 
acetic acid  
(1 eq) (neut.) 
EtOAc/NH4Cl 
(extrac.) 
8(e) 
MeOH 
NaOMe 
0.5 M in 
MeOH 
(1.3 eq) 
0 ºC to 
RT 
(NaOMe 
added 
dropwise  
for 30 
min) 
3.45 
hrs 
acetic acid  
(1 eq) (neut.) 
DCM/water 
(extrac.) 
No s.m. 
Nothing 
recovered 
9 ovn. 
acetic acid  
(1 eq) (neut.) 
No W.up 
Acidic 
form (A) 
10 
24 
hrs 
Amberlite IR-
120 H+ 
Methyl 
quinate 
(2) 
11 
5.30 
hrs 
Amberlite IR-
120 H+  
(pH 7) 
η qt.  
= 40-49% 
12# 
MeOH 
+ 
sieves 
22 
hrs 
η qt. 
= 62% 
13 
MeOH 
+ 
Na2SO4  
(5 eq) 
48 
hrs 
η qt.  
= 8% 
                 η qt. = quantitative  yield. S.m. =starting material. 
(a) Adapted from Abella (2006). 
97
 (b) Adapted from Wang (1999). 
103
  
(c) Adapted from Mohan (2010). 
38
 (d) Adapted from Schimdt (1998). 
86
 
 (e) Adapted from Shing (2001). 
102
 # showed to be the better synthetic method 
Table 5.1.7. – Testing conditions for the synthesis of 3,4-O-isopropylidene quinate starting 
from 3,4-O-isopropylidene-1,5-quinic lactone (1). 
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Entry 3 from Table 5.1.7 uses the same method but a different work-
up after neutralization referred in the literature by Wang et al.134, in which the 
crude solution was evaporated, dissolved in EtOAc and then filtered through 
a silica gel pad. However, the result was the same as previously reported for 
entry 1 and 2.  
In entry 4 from Table 5.1.7 the conditions described by Mohan et al. 38 
can be found. In this case, column chromatography is performed after 
neutralization with acetic acid. However, once again, NMR did not show 
evidence of the desired compound, since although some of the characteristic 
signals were present, the methyl COOCH3 signal was not. 
 
After this result, the characteristics of the NaOMe solution were 
examined, because sometimes it is better to prepare this from fresh due to its 
progressive degradation over time, which can affect the outcome of the 
reaction. Alternative types of neutralization were also sought, less aggressive 
but that allowed the esterification. 
After consulting the literature, method 5 (see Table 5.1.7, entry 5) 
adapted from Schimdt et al.86 was identified, this method used a freshly made 
NaOMe solution and Amberlite exchange resin IR-120H+ for neutralization 
and ester formation. The resin, as stated previously for the synthesis of 
methyl quinate (2), had the advantage of a simple work-up. Nonetheless only 
compound (2) was recovered, which results from the opening of both 
isopropylidene ring and the lactone ring, from which we can assume that the 
resin was too acidic. With that in mind a weaker acid resin was used, as 
outlined in entry 6, which proved unsuccessful and different extraction pairs 
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in entry 7 and 8, the last one adapted from Shing et al. 102 , also proving to be 
unsuccessful. 
Reaction times were subsequently increased, as was attempting the 
reaction without work-up but still with acetic acid as neutralisation agent 
(entry 9 Table 5.1.7). Finally it was confirmed, as stated in entries 4 and 9, 
the compound synthesised was in fact the acid form A (see Scheme 5.1.9), 
which indicated that opening of the lactone was occurring, but not 
esterification. 
With that in mind neutralization with Amberlite resin was once again 
attempted, but with longer reaction times (entry 10 Table 5.1.7). Once again 
the compound synthesised was methyl quinate (2), this time however it was 
possible to notice that before neutralization, TLC showed a spot with higher 
Rf than after neutralization. At this point it was concluded that the amount of 
Amberlite resin was crucial to the success of the reaction, so I attempted to 
use the smallest amount possible, monitoring progress of the reaction 
carefully, contrary to literature methods (entry 11, Table 5.1.7). For the first 
time the desired compound was obtained (5) in good yield. 
Now that the reaction was finally optimised, my goal was now to try to 
minimize the difficulties in the work up due to the formation of water 
molecules in the reaction media, so entry 12 reflects that, with the use of 
molecular sieves and entry 13, the use of Na2SO4. Of the two strategies, the 
one using molecular sieves proved to be the better synthetic method, 
improving the yield further to 62%. 
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5.1.1.5. Selective C3-C4 isopropylidene ring formation  
 
 
Scheme 5.1.9. – Attempt at the synthesis 3, 4-O-isopropylidene quinic acid (A) of starting 
from commercially available D-(-)-quinic acid 98%. 
 
Since some of the attempted strategies proved unsatisfactory, 
specifically the exclusive opening of the C1-C5 lactone ring in the quinide 
acetal (see Scheme 5.1.8 stated previously), a different method, based in the 
literature method of Wang et al.103, was attempted to arrive at a suitably 
protected quinic acid derivative. The method involved the exclusive 
isopropylidene protection of C3 and C4 (see Scheme 5.1.8), leaving C1 and 
C5 hydroxyl groups free, and the carboxyl function. The objective was to 
subsequently protect C5 and convert the carboxyl function to an ester. 
 
 
Reagents Catalyst 
Conditions 
Results 
Temp. Time 
1a) 
 
Toluene 
 
DMP (4 eq) 
 
Na2SO4 (2.2 eq) 
 
p-TSOH  
(0.1 eq) 
Reflux 84 ºC ovn. - 
a) Adapted from Wang (1999). 
103
 
  
Table 5.1.8. – Attempt at the synthesis of 3, 4-O-isopropylidene quinic acid (A) of starting 
from D (-)-quinic acid 98%. 
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The method (see Table 5.1.8) used toluene as solvent, p-
toluenesulfonic acid (p-TSOH) as acidic catalyst, DMP (2,2-
dimethylaminopropane) to form the isopropylidene ring and Na2SO4 as a 
drying agent. 103 Results were inconclusive, because although NMR of the 
material recrystalized from the crude reaction mixture, presented as white 
needle crystals, seemed to correspond to the one from the desired 
compound (A), the mass spectrum did not correspond. The mass spectrum 
showed a main species with a mass of 246, which corresponds to the 
esterified compound. This can be a result of an artefact in the NMR that 
didn’t allow the signal of the CH3, compound (5), from the ester to be seen in 
the first place or in other hand the process of mass spectrometry could reflect 
the presence of a mixture of both compound (A) and compound (5).  
Since the method for the synthesis of methyl 3,4-O-isopropylidene 
quinate (5) starting from the quinide acetal (1) previously reported (Scheme 
5.1.8, Table 5.1.7) was so difficult to reproduce, due to high sensitivity to the 
neutralization process, different approaches were tried, starting from 
previously synthesised methyl quinate (2). 
 
 
Scheme 5.1.10 – Attempt at another synthetic approach for methyl 3,4-O-isopropylidene 
quinate (5) starting from previously synthesized methyl quinate (2). 
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 The first method, entry 1 Table 5.1.9, consists of an adaptation from a 
method used for the synthesis of quinide acetal (1) (see entry 3, Table 5.1.1) 
using acetone as solvent, sulphuric acid as catalyst, but at lower temperature 
and shorter reaction time, to promote isopropylidene ring formation between 
C3 and C4, without affecting the ester functionality. However, it was 
concluded that despite using milder conditions the favoured product for this 
reaction was still quinide acetal (1), which meant that the conditions trigger 
the formation of lactone between the ester group and the C5 free hydroxyl. 
 With the last result in mind, a weaker acid was considered, and one 
that is known to maintain the ester functionality, the Amberlite resin IR-
120H+. As can be seen in entry 2 Table 5.1.9, the solution mixture completely 
degraded, which could be noticed fairly on due to the black colour of the resin 
and at the same time we noticed the formation of water molecules in the 
medium.  
Facing up the last results, sodium sulphate was additionally employed 
as a desiccating agent, in addition to carrying out the reaction at room 
temperature to try to prevent degradation and to try to reduce the formation 
of by-products (see entry 3 and 4, Table 5.1.9). As a result the reactions 
were retarded, but the one using Amberlite resin promoted the formation of 
compound (A) (see Tcheme 5.1.9), in which unfortunately the ester was 
hydrolysed, and in the one using sulphuric acid, once again the product 
formed was the quinide acetal (1). 
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Met. Reagents Catalyst 
Conditions 
Results 
Temp. Time 
1 Acetone  
 
H2SO4 
 
Reflux 
65 ºC 
1.15 hrs 
Quinide acetal 
(1) 
2 Acetone 
Amberlite 
IR-120 H+ 
29 hrs Degradation  
3 
Acetone 
+  
Na2SO4 (6 
eq) 
Amberlite 
IR-120 H+ 
RT 46 hrs Acidic form (A) 
4 
Acetone 
+  
Na2SO4 (6 
eq) 
H2SO4 RT 30 hrs 
Quinide acetal 
(1) 
5a) 
Toluene 
DMP  
(4 eq) 
 Na2SO4  
(4 eq) 
p-TSOH 
(0.1 eq) 
Reflux 
84 ºC 
ovn. 
Acidic form (A) 
after recryst. 
a) Adapted from Wang (1999). 
103
 
Table 5.1.9. – Testing conditions for the attempt at the synthesis of 3,4-O-isopropylidene 
quinate (5) starting from previously synthesized methyl quinate (2). 
  
Although the method for the synthesis of compound (A) (Scheme 5.1.9 
and Table 5.1.8) proved unsuccessful, a similar method was attempted for 
the synthesis of compound (5). Entry 5 103 , Table 5.1.9 reflects that the 
attempt, using toluene, DMP and p-TSOH overnight at reflux, but after 
recrystalization, the product obtained was compound (A), without the ester 
function. There was insufficient time to repeat this method using shorter 
reaction times, but this will be the subject of future work, to determine 
whether compound (5) is not an intermediary product of this reaction. 
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5.1.1.6. C5 protection with TBDMS after C3-C4 isopropylidene ring 
formation 
 
 
Scheme 5.1.11 – Synthesis of methyl 5-(tert-butyldimethylsilyloxy)-3,4-O-isopropylidene 
quinate (6) starting from previously synthesized methyl 3,4-O-isopropylidene quinate (5). 
 
 Although it was not possible to fine-tune the synthesis of compound 
(5), the yields obtained enabled us to nevertheless continue the protection 
steps, now concentrating on the free C5 hydroxyl group. Our strategy was to 
protect it with the TBDMS group (see Scheme 5.1.11), due to the already 
discussed favourable characteristics and easy introduction method, using 
TBDMS-Cl, and imidazole in DMF. Table 5.1.10 describes the reactions 
conditions used for the synthesis of methyl 5-(tert-butyldimethylsilyloxy)-3, 4-
O-isopropylidene quinate (6).92 
 Entry 1, Table 5.1.10 describes what proved to be the best synthetic 
method, using 2 eq. of TBDMSCl, 60 ºC and a reaction time of 3.30 hrs. This 
gave an average yield of 44%.  
Entry 2, Table 5.1.10 describes the attempt to improve on the previous 
yield by using higher amounts of TBDMS-Cl and Imidazole and increased 
reaction temperature. However, this proved unsuccessful. It is possible that 
the compound was sensitive to the 10 ºC increase of the temperature and for 
that reason degraded. In the future it would be desirable to repeat the 
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reaction, increasing the equivalents and the reaction time but maintaining the 
60 ºC temperature or even decreasing it slightly. 
 
Met. Reagents 
Conditions 
Results 
Temp. Time 
1# 
DMF solv. 
Imidazole  
(3 eq) 
TBDMSCl  
(2 eq) 
Δ 60 ºC 3.30 hrs η ac. = 44% 
2 
DMF solv. 
Imidazole  
(4.5 eq) 
TBDMSCl  
(3 eq) 
Δ 70 ºC 28 hrs - 
Δ = heating. η ac. = after column yield 
# showed to be the better synthetic method. 
Table 5.1.10. – Testing conditions for the synthesis of 5-(tert-butyldimethylsilyloxy)-3,4-O-
isopropylidene quinate (6) starting from previously synthesized methyl 3,4-O-isopropylidene 
quinate (5). 
 
5.1.1.7. C3 protection with benzyl and C1-C5 protection with 
lactone 
   
 
Scheme 5.1.12. – Attempt at the synthesis of 3-benzyloxy-1, 4-dihydroxy-1, 5-quinic lactone 
starting from commercially available D-(-)-quinic acid 98%. 
 
 With persistent difficulties in achieving the protection of the free 
adjacent hydroxyl groups in quinic acid that were experienced, alternative 
more robust and reliable procedures were constantly sought after.  
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A further alternative method considered was as follows: the synthesis 
of 3-benzyloxy-1, 4-dihydroxy-1, 5-quinic lactone (Scheme 5.1.12). This 
compound, if successfully synthesised, could be subsequently protected at 
C4 position, for example using the TBDMS protection method utilised for the 
synthesis of compound (6). 
Table 5.1.11 reflects that attempt. Toluene, DMF and p-TSOH were 
stirred initially with quinic acid, to enable in a first step: formation of the 
lactone and acetonide rings. Once the dibutyltin oxide is added an 
intermediate compound is formed with the tin between C3 and C4, which will 
be determinant for the regioselectivity of nucleophilic substitution reaction 
after addition of benzyl bromide at C3 position. Despite using a Dean-Stark 
reflux apparatus, unfortunately the reaction proved difficult to replicate and 
degradation was the only result obtained. 104,105  
 
Met. Reagents Cat. 
Conditions 
Results 
Temp. Time 
1a) 
Toluene+D
MF 
+ 
Dibutyltin 
oxide 
(1.2 eq) 
+ 
BnBr 
(1.6 eq) 
p-TSOH  
(0.2 eq) 
Dean-Stark 
reflux 110 ºC 
17 hrs 
+ 
4.3 hrs 
+ 
18 hrs 
Degradation  
a) Adapted from Hanessian (1997) 
104
 and Zeng (2009) 
105
 
 
Table 5.1.11. – Testing conditions for the attempt at the synthesis of 3-benzyloxy-1,4-
dihydroxy-1,5-quinic lactone starting from commercially available D (-)-quinic acid 98%. 
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5.1.2. Optimisation of the Barton-McCombie reaction, to remove the 
C1 hydroxyl group and insert a hydrogen atom. 
 
Another of my objectives involved an investigation into the possibility 
of the use of the Barton McCombie deoxygenation reaction to manipulate C1. 
This reaction has not previously been applied to quinic acid, and as such 
would represent a novel means by which to synthesise novel quinic acid-
based structures (see reaction mechanism Scheme 5.1.13). 106,107,108,109 
 
  
Scheme 5.1.13. - Barton-McCombie radical deoxygenation reaction 
mechanism schematics. 106,107,108,109 
 
This reaction allows for the deoxygenation of secondary and tertiary 
alcohols, through the replacement of a hydroxyl functional group by a 
hydride, via a radical reaction mechanism. Traditionally tributyltin hydride 
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(Bu3SnH) was used due to it being a good source of hydrogen atoms and its 
radical stability (the bond between S-Sn is very stable). 109,110,111,112,113 
However, Bu3SnH is highly toxic, relatively expensive and often 
presents difficulties in terms of removal from the reaction mixtures. Efforts 
have been made to find feasible alternatives, such as the corresponding tin 
oxide, trialkylborane-water complexes and TTMSS (tris(trimethylsilyl)silane). 
114,115, 116 
In the first step, the alcohol (in this specific case a tertiary alcohol) is 
converted to a thiocarbonyl derivative using DMAP as a catalyst. 
107,108,110,112,117  
In the second step of the reaction, TTMSS radical formation is initiated 
by AIBN. The TTMSS radical then abstracts the thioester forming a very 
stable S-Si bond and the TTMSS-thioester and the alkyl radical. The alkyl 
radical is capable of abstracting the hydrogen from the newly formed TTMSS 
molecule, resulting in the formation of the desired deoxygenated product 
(Scheme 5.1.13). 
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5.1.2.1. Thiocarbonyl derivative formation – Barton McCombie 1st 
step optimization 
 
 
 
Scheme 5.1.14. – Synthesis of 1-O-(thiocarbonyldiimidazolyl)-3, 4-O-isopropylidene-1,5-
quinic lactone (7) starting from 3,4-O-isopropylidene-1,5-quinic lactone (1) – 1
st
 step of 
Barton McCombie Radical Deoxygenation.  
 
Initial tests to apply this reaction starting from quinide lactone 1 (see 
Scheme 5.1.14) to synthesize 1-O-(thiocarbonyldiimidazolyl)-3, 4-O-
isopropylidene-1,5-quinic lactone (7) proved promising, so the reaction 
conditions were studied and optimized, work that is described in Table 
5.1.12. 
The first method (see entry 1, Table 5.1.12) used DCE as solvent, 1.5 
eq of the thiocarbonyldiimidazole, 0.2 eq DMAP and at RT. However the 
reaction was very slow (160 h) and the yield low. So, in method 2 (see entry 
2, Table 5.1.12) the equivalents of thiocarbonylimidazole reagent were 
increased slightly. As a result a higher yield was obtained, but the reaction at 
RT was still very slow. 
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Met. Reagents Cat. 
Conditions 
Results 
Temp. Time 
1 
DCE solv. 
Thiocarbonyldiimidazole 
(1.5 eq) 
DMAP 
(0.2 
eq) 
RT 
160 
hrs 
η ac. = 18% 
2 
DCE solv. 
Thiocarbonyldiimidazole 
(1.7 eq) 
96 
hrs 
η ac. = 66% 
3 
DCE solv. 
Thiocarbonyldiimidazole 
(1.5 eq) 
Δ  
50 ºC 
90 
hrs 
η ac. = 28% 
4 
Acetonitrile solv. 
Thiocarbonyldiimidazole 
(2 eq) 
Reflux 
83 ºC 
24 
hrs 
η ac. = 63% 
5 
DCE solv. 
Thiocarbonyldiimidazole 
(2 eq) Reflux 
85ºC 
η ac. 
 = 74-76% 
6# 
DCE solv. 
Thiocarbonyldiimidazole 
(2 eq) 
DMAP 
(0.4 
eq) 
η ac. = 86% 
 
Original conditions adapted from Barton and McCombie (1975). 
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# shown to be the better synthetic method. η ac. = after column yield 
Table 5.1.12. – Testing conditions for the synthesis 1-O-(thiocarbonyldiimidazolyl)-3,4-O-
isopropylidene-1,5-quinic lactone (7) starting from 3,4-O-isopropylidene-1,5-quinic lactone 
(1). 
 
To improve reaction velocity the temperature of the reaction was 
increased (see entry 3, Table 5.1.12) to 50ºC, but at that temperature the 
reaction was still slow and there was not any significant improvement in the 
yield. 
An increase in the amount of thiocarbonyldiimidazole equivalents (2 
eq) followed, and further increases in the temperature to reflux conditions. 
Two reflux reactions were simultaneously tested using different solvents, 
acetonitrile (see entry 4, Table 12) and DCE (see entry 5, Table 5.1.12). As a 
result the reaction time could be reduced to 24 h. Higher yields were 
obtained when using DCE. 
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 Although major improvements had already been made, we additionally 
investigated whether the quantity of DMAP had any significant effect on the 
reaction performance. To this end, the same conditions were employed as in 
entry 5, but with double the amount of DMAP. We observed that there was a 
further increase in the yield to 86%. These were the optimised conditions: 
step one was successfully achieved and optimised. 
 
 
Scheme 5.1.15. – Synthesis of 1-O-(thiocarbonyldiimidazolyl)-3, 4, 5-tri-O-acetylquinate (8) 
starting from 3, 4, 5-tri-O-acetylquinate (3) - 1
st
 step of Barton McCombie Radical 
Deoxygenation. 
 
 After optimization of the first step of the Barton McCombie reaction 
attention was focused on applying these conditions to other compounds that 
were synthesised previously, i.e. compounds that were protected differently 
to quinide lactone (1), but still had the tertiary hydroxyl group at C1 position.  
Scheme 5.1.15 shows the synthesis of 1-O-(thiocarbonyldiimidazolyl)-
3, 4, 5-tri-O-acetylquinate (8) starting from 3, 4, 5-tri-O-acetylquinate (3) and 
Scheme 5.1.16 the synthesis of 1-O-(thiocarbonyldiimidazolyl)-3,4,5-tri-O-
(tert-butyldimethylsilyloxy) cyclohexane-1-carboxylate (9) starting from 3,4,5-
tri-(tert-butyldimethylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate (4). 
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1# 
DCE solv. 
DMAP (1.5 eq) 
Thiocarbonyldiimidazole 
(3 eq) Reflux 
85 ºC 
48 hrs η ac. = 14% 
2 
DCE solv. 
DMAP (1 eq) 
Thiocarbonyldiimidazole 
(3 eq) 
120 hrs η ac. = 2% 
 
# showed to be the better synthetic method. η ac. = after column yield 
 
  
Table 5.1.13. – Testing conditions for the synthesis of 1-O-(thiocarbonyldiimidazolyl)-3, 4, 5-
tri-O-acetylquinate (8) starting from 3, 4, 5-tri-O-acetylquinate (3). 
 
 In entry 1 Table 5.1.13 DCE was used as solvent in a reaction at reflux 
as for the synthesis of compound (7). The amount of DMAP catalyst was 
increased to 1.5 eq and thiocarbonyldiimidazole to 3 eq. As a result the 
desired compound (8) was obtained after 48 hrs., but only in low yield. The 
reaction time was increased in an attempt to increase the yield (see entry 2 
Table 5.1.13). However, this reaction proved less successful. 
 
 
 
Scheme 5.1.16. – Synthesis of 1-O-(thiocarbonyldiimidazolyl)-3,4,5-tri-O-(tert-
butyldimethylsilyloxy) cyclohexane-1-carboxylate (9) starting from 3,4,5-tri-(tert-
butyldimethylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate (4) - 1
st
 step of Barton 
McCombie Radical Deoxygenation. 
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In entry 1 table 5.1.14, the alternative TBDMS-protected derivative 
was utilised. DCE was used as solvent under reflux once again. The amount 
of DMAP catalyst was increased to 0.8 eq and thiocarbonyldiimidazole to (4) 
eq. As a result we obtained the desired compound (9) after 48 hrs in a higher 
yield than in compound (8). It is possible that compounds (3) and (4) result in 
a ring conformation which is less favourable for this type of reaction than is 
the case for compound (1), where this reaction proved very successful. 
  It was thought that perhaps changing the reaction conditions could 
improve the outcome (entry 2, Table 5.1.14). Firstly, DMF was used as 
solvent, with sodium hydride as a catalyst. However no progression of the 
reaction could be detected by TLC. In the end only starting material was 
recovered and a mixture of compounds which were not separable. 
Nevertheless the reaction worked very successfully when starting from 
compound (4), and compound (9) was synthesized with higher yield than 
compound (8). 
 In parallel, alternatives to thiocarbonyldiimidazole were explored for 
the first step of the Barton-McCombie reaction. It was possible that these 
may have been more favourable for the acetate and TBDMS-protected 
derivatives. Phenyl isothiocyanate was available in our laboratory, a 
compound that can be used in this kind of reactions, and so the synthesis of 
1-O-(phenylthioxocarbamoyl)-3,4-O-isopropylidene-1,5-quinic lactone starting 
from 3,4-O-isopropylidene-1,5-quinic lactone (1) was attempted (see Scheme 
5.1.17) using THF as solvent and sodium hydride as catalyst to promote 
removal of the hydrogen of the tertiary hydroxyl group at C1 position.  
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1# 
DCE solv. 
DMAP  
(0.8 eq) 
Thiocarbonyldiimidazole 
(4 eq) 
Reflux 
85 ºC 
48 hrs 
η ac. = 31% 
 
( 36% s.m. 
recovered) 
2 
DMF solv. 
NaH (1.3 eq) 
Thiocarbonyldiimidazole  
(3 eq) 
 
0 ºC 
+ 
RT 
+ 
Δ 45 ºC 
+ 
Δ 70 ºC 
  
30 min 
+ 
ovn. 
+ 
24 hrs 
+ 
24 hrs 
52% s.m. 
recovered 
 
Mixture of 
compound with 
s.m. not separable 
 
Δ = heating. η ac. = after column yield. S.m. = starting material. # showed to be the better synthetic method. 
 
Table 5.1.14. – Testing conditions for the synthesis of 1-O-(thiocarbonyldiimidazolyl)-3,4,5-
tri-O-(tert-butyldimethylsilyloxy)cyclohexane-1-carboxylate (9) starting from 3,4,5-tri-(tert-
butyldimethylsilyloxy)-1-hydroxy-cyclohexane-1-carboxylate (4). 
 
 
Scheme 5.1.17. – Attempt at the synthesis of 1-O-(phenylthioxocarbamoyl)-3,4-O-
isopropylidene-1,5-quinic lactone starting from 3,4-O-isopropylidene-1,5-quinic lactone (1) - 
1
st
 step of Barton McCombie Radical Deoxygenation with different thio compound. 
  
Entry 1 Table 5.1.15 describes the first attempt using 2 equivalents of 
phenylisothiocyanate and NaH, first at 0 ºC to add the NaH and then at RT, 
but after considerable time (144 hrs) there was no progression and ultimately 
only degradation products evident. For this reason, the numbers of 
equivalents of phenylisothiocyanate were increased (see entry 2 Table 
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5.1.15) and after addition of NaH at 0 ºC and equilibration of the temperature 
at RT, the reaction was stirred at 35 ºC. However, once again after 24 hrs the 
reaction had degraded. It is a possibility that the NaH was too basic, and so 
an alternative method that proved to be the best one for the synthesis of 
compound (7), using DCE, DMAP as a catalyst and reflux at 85 ºC for 45 hrs 
was used. However, the poor result was the same. This confirmed that 
thiocarbonyldiimidazole is the better reagent for this kind of reaction applied 
to quinic acid chemistry. Other alternatives were not pursued. 
 
Met. Reagents Cat. 
Conditions 
Results 
Temp. Time 
1 
THF solv. 
Phenylisothiocyanate 
(2 eq) NaH  
(2 eq) 
 
0 ºC to 
RT 
144 
hrs 
 
No 
progression 
Degradation 
 
2 
THF solv. 
Phenylisothiocyanate 
(3 eq) 
0 ºC to 
RT 
+ 
Δ 35 ºC 
24 hrs 
3 
DCE solv. 
Phenylisothiocyanate 
(3 eq) 
 
DMAP  
(0.2 eq) 
 
Reflux 
85 ºC 
45 hrs 
Δ = heating. 
 
  
Table 5.1.15. – Testing conditions for the attempt at the synthesis of 1-O-
(phenylthioxocarbamoyl)-3,4-O-isopropylidene-1,5-quinic lactone starting from 3,4-O-
isopropylidene-1,5-quinic lactone (1). 
 
 
5.1.2.2. Deoxygenation – Barton McCombie 2nd step optimization 
 
The next objective was to attempt the second step of the Barton-
McCombie reaction and to synthesise 3,4-O-isopropylidene-1,5-lactone 
cyclohexane (12) starting from 1-O-(thiocarbonyldiimidazolyl)-3,4-O-
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isopropylidene-1,5-quinic lactone (7) (see Scheme 5.1.18). The reaction was 
an adaptation from the literature, method originally described by Barton and 
McCombie, but as described earlier, using TTMSS in place of the more 
traditionally used and more toxic tin compound (see Scheme 5.1.13, reaction 
mechanism). 
 
 
 
Scheme 5.1.18. – Synthesis of 3,4-O-isopropylidene-1,5-lactone cyclohexane (12) starting 
from 1-O-(thiocarbonyldiimidazolyl)-3,4-O-isopropylidene-1,5-quinic lactone (7) – 2
nd
 step of 
Barton McCombie Radical Deoxigenation reaction. 
 
 Entry 1 Table 5.1.16 describes the method first employed, as an 
adaptation of the published procedure: it used toluene as solvent, TTMSS (2 
eq) and AIBN as a catalyst (0.2 eq) for the formation of the radical species by 
heating the reaction medium at 90 ºC for 20 hrs. This method was tried 
several times but gave very mixed, inconsistent yields. 
 For that reason the reaction conditions were first changed by 
increasing the number of equivalents of AIBN to 0.4 eq (see entry 2 Table 
5.1.19). Nonetheless no major improvement in the reaction outcome was 
accomplished. For that reason method 1 was adopted as standard for future 
reactions for the synthesis of hydrogenated compound (12). 
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Met. Reagents Cat. 
Conditions 
Results 
Temp. Time 
1a)# 
Toluene 
solv. 
TTMSS* 
(2 eq) 
AIBN 
(0.2 eq) 
Δ 90 ºC  20 hrs 
η ac. = 56-96% 
(inconsistent) 
2 
Toluene 
solv. 
TTMSS* 
(2 eq) 
AIBN 
(0.4 eq) 
Δ 90 ºC 24 hrs η ac. = 59% 
a) Adapted from original methodology by Barton and McCombie (1975). 
106
 
Δ = heating. η ac. = after column yield 
# showed to be the better synthetic method. 
* TTMSS is only added to the reaction mixture (s.m.+solvent+cat.) after the system is purged for 5 min with N2. 
 
  
Table 5.1.16. – Conditions for synthesis of 3,4-O-isopropylidene-1,5-lactone cyclohexane 
(12) starting from 1-O-(thiocarbonyldiimidazolyl)-3,4-O-isopropylidene-1,5-quinic lactone (7). 
 
 Since compound (12) was successfully synthesised, removing the 
tertiary hydroxyl group and substituting it by a hydrogen atom, one of the key 
goals of the project was accomplished. It would be possible to attempt to 
react different substituents to position C1 while maintaining the ester 
functionality. This represents the first example of a Barton-McCombie type 
reaction with quinic acid.  
 
5.1.3. Nucleophilic substitution reactions at C1 hydroxyl group 
 
Simultaneously to the work described so far, some simple nucleophilic 
substitution reactions at the C1 hydroxyl group were attempted, starting from 
compound (1). We used for those reactions benzyl bromide (see Scheme 
5.1.19), TBDMSCl (see Scheme 5.1.20) and TBDPhSCl (see Scheme 
5.1.21), as potentially useful protecting groups to allow manipulation of the 
remainder of the ring. 
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Scheme 5.1.19. – Synthesis of 1-O-benzyl-3,4-O-isopropylidene-1,5-quinic lactone (10) 
starting from 3,4-O-isopropylidene-1,5-quinic lactone (1). 
 
Met. Reagents Cat. 
Conditions 
Results 
Temp. Time 
1a) 
DMF solv. 
BnBr 
(1.2 eq) 
 
NaH  
(2 eq) 
 
 
 
0ºC to RT 
(NaH 
added 
dropwise  
for 30 
min) 
 
19 hrs η ac. = 51% 
a ) Adapted from Schawrdt (2010) 
118
 . η ac. = after column yield.  
 
  
Table 5.1.17. – Testing conditions for the synthesis of 1-O-benzyl-3,4-O-isopropylidene-1,5-
quinic lactone (10) starting from 3,4-O-isopropylidene-1,5-quinic lactone (1). 
 
 For the synthesis of 1-O-benzyl-3,4-O-isopropylidene-1,5-quinic 
lactone (10), starting from 3,4-O-isopropylidene-1,5-quinic lactone (1) we 
used a previously described method from Schawrdt et al. 118 using DMF as 
solvent, BnBr as nucleophile, and NaH as a catalyst to remove the hydrogen 
atom from the C1 hydroxyl. After 19 hrs, a moderate yield of 51% after 
column was successfully obtained for compound (10) (see Table 5.1.17). The 
synthesis of 1-(tert-butyldimethylsilyloxy)-3,4-O-isopropylidene-1,5-quinic 
lactone (11) starting from 3,4-O-isopropylidene-1,5-quinic lactone (1) was 
then attempted.  
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Scheme 5.1.20. – Synthesis of 1-(tert-butyldimethylsilyloxy)-3,4-O-isopropylidene-1,5-quinic 
lactone (11) starting from 3,4-O-isopropylidene-1,5-quinic lactone (1). 
 
Also, an adaptation from the method described by Prazeres et al. 119 
using DCM as solvent, pyridine as a catalyst and TBDMSCl as a nucleophile 
was utilised (see entry 1 Table 5.1.18). After 20 hrs. compound (11) was 
successfully prepared in a good yield of 57%.  
 
Met. Reagents 
Conditions 
Results 
Temp. Time 
1a)# 
DCM solv. 
Pyridine 
(2 eq) 
TBDMSCl 
(3 eq) 
 
0 ºC to RT 
 
20 hrs η qt. = 57% 
2 
DMF solv. 
Imidazole 
(8 eq) 
TBDMSCl 
(3 eq) 
RT 48 hrs η ac. = 11% 
a)Adapted from Prazeres(2008). 
119
  η ac. = after column yield. η qt. = quantitative yield.  
# showed to be the better synthetic method. 
 
  
Table 5.1.18. – Testing conditions for the synthesis of 1-(tert-butyldimethylsilyloxy)-3,4-O-
isopropylidene-1,5-quinic lactone (11) starting from 3,4-O-isopropylidene-1,5-quinic lactone 
(1). 
 
In the hope of improving the reaction yield further, the reaction 
conditions were changed (see entry 2, Table 5.1.18) to DMF solvent, to using 
imidazole and TBDMSCl at RT for 48 hrs. However, the obtained yield was 
lower (11% after column) than obtained previously. 
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The same method was then applied to synthesise 1-(tert-
butyldiphenylsilyloxy)-3,4-O-isopropylidene-1,5-quinic lactone starting from 
3,4-O-isopropylidene-1,5-quinic lactone (1) (see Table 5.1.19), but there was 
no progression of the reaction and only starting material was recovered. This 
led to the conclusion that position C1 is insufficiently accessible when using 
bigger substitution groups such as TBDPS. 
 
 
Scheme 5.1.21. – Attempt at the synthesis of 1-(tert-butyldiphenylsilyloxy)-3,4-O-
isopropylidene-1,5-quinic lactone starting from 3,4-O-isopropylidene-1,5-quinic lactone (1). 
 
 
Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
DCM solv. 
Pyridine 
(1.7 eq) 
TBDPSCl 
(3 eq) 
 
0 ºC to RT 
 
20 hrs - 
a) Adapted from Prazeres(2008). 
119
 
 
  
Table 5.1.19. – Conditions for the attempt at the synthesis of 1-(tert-butyldiphenylsilyloxy)-
3,4-O-isopropylidene-1,5-quinic lactone starting from 3,4-O-isopropylidene-1,5-quinic lactone 
(1). 
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5.1.4. Selective opening of the lactone C1-C5 after deoxygenation of 
C1 
  
Starting from compound (12), 3,4-O-isopropylidene-1,5-lactone 
cyclohexane, synthesis of 3,4-O-isopropylidene-cyclohexane-1-carboxylate 
(13) was attempted (see Scheme 5.1.22). The method used was reported 
previously for the synthesis of compound (15) and is commonly used for the 
opening of lactone rings and regeneration of the ester group, through the use 
of a methanolic solution of NaOMe solution. 
 Entry 1 Table 5.1.20 describes the method used where the reaction 
mixture was stirred for 5 hrs with NaOMe and then neutralized with the 
smallest amount possible the Amberlite IR-120 H+ resin. As described in 
previous reactions of this type (already described in this thesis for the 
synthesis of compound (5)) both rings, i.e. the lactone and also the 
isopropylidene, opened giving compound (14) (see Scheme 5.1.23). 
 
 
Scheme 5.1.22. – Synthesis of 3,4-O-isopropylidene-cyclohexane-1-carboxylate (13) 
starting from 3,4-O-isopropylidene-1,5-lactone cyclohexane (12). 
  
Owing to the result of the previous reaction, the reaction time was 
reduced (see entry 2 Table 5.1.20) and the smallest possible amount of resin 
was calculated. As a result, the desired compound was successfully obtained 
(13), but as expected, due to the inconsistency of the reaction the yield after 
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purification was very low (only 17%), and the reaction was, once again, 
difficult to reproduce. However, this was a promising starting point for future 
reaction optimisation. 
 
Met. Solv. Reag. 
Conditions 
w.up Results 
Temp. Time 
 
1 
 
MeOH 
 
NaOMe 
0.5 M in 
MeOH 
(1.3 eq) 
 
 
0 ºC to 
RT 
(NaOMe 
added 
dropwise  
for 30 
min) 
5 hrs 
Amberlite 
IR-120 H+  
(pH 7) 
 
(14) 
Opening of the 
isopropylidene 
ring 
 
2# 
 
 
3 hrs η ac. = 17% 
# showed to be the better synthetic method. η ac. = after column yield.  
  
Table 5.1.20. – Conditions for synthesis of 3,4-O-isopropylidene-cyclohexane-1-carboxylate 
(13) starting from 3,4-O-isopropylidene-1,5-lactone cyclohexane (12). 
 
5.1.5. Non-selective opening of both lactone C1-C5 and C3-C4 
isopropylidene rings after deoxygenation of C1 
  
With the previous results in mind, the synthesis of compound (14), formed 
during the process of attempting the synthesis of compound (13), was 
considered. It was concluded that the opening of both rings during the 
reaction with NaOMe in MeOH could actually be an advantage, since then it 
could be possible to protect the three hydroxyls (we previously successfully 
synthesise compound (4), tri-substituted with TBDMS at C3, C4 and C5) for 
further derivation. 
 
 97 
 
 
Scheme 5.1.23. – Synthesis of 3,4,5-O-tri-hydroxy-cyclohexane-1-carboxylate (14) starting 
from 3,4-O-isopropylidene-1,5-lactone cyclohexane (12). 
 
For that reason my purpose was now to synthesise 3,4,5-O-tri-
hydroxy-cyclohexane-1-carboxylate (14) starting from 3,4-O-isopropylidene-
1,5-lactone cyclohexane (12) without any concerns about the amount of 
Amberlite IR-120 H+ resin used in the process (see Scheme 5.1.23). 
Table 5.1.21 describes the method used, it closely resembles the one 
described for compound (13) in Table 5.1.20, the only difference being the 
excess of resin used and the final pH (acidic).  
The method was successful and after column chromatography, a yield 
of compound (14) of around 70% was obtained. In addition, the reaction 
proved very reproducible, which is in contrast to the reaction for the exclusive 
opening of the C1-C5 lactone ring. 
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Met. Solv. Reag. 
Conditions 
w.up Results 
Temp. Time 
 
1 
 
MeOH 
 
NaOMe 
0.5 M in 
MeOH 
(1.3 eq) 
 
 
0 ºC to RT 
(NaOMe 
added 
dropwise  
for 30 min) 
3-4 
hrs 
Amberlite 
IR-120 H+  
(pH 3-4) 
excess 
η ac. =  
65-70% 
η ac. = after column yield.  
 
Table 5.1.21. – Conditions for synthesis of 3,4,5-O-tri-hydroxy-cyclohexane-1-carboxylate 
(14) starting from 3,4-O-isopropylidene-1,5-lactone cyclohexane (12). 
 
5.1.5.1. Tri-silylation of C3, C4 and C5 
  
The next step, as previously mentioned, was to protect the three hydroxyl 
groups and synthesise 3,4,5-tri-O-(tert-butyldimethylsilyloxy)-cyclohexane-1-
carboxylate (15) starting from 3,4,5-O-tri-hydroxy-cyclohexane-1-carboxylate 
(14) (see Scheme 5.1.24). 92,99 
 
 
Scheme 5.1.24. – Synthesis of 3,4,5-tri-O-(tert-butyldimethylsilyloxy)-cyclohexane-1-
carboxylate (15) starting from 3,4,5-O-tri-hydroxy-cyclohexane-1-carboxylate (14). 
 
 Entry 1 Table 5.1.22 describes the first method used and was an 
adaptation from the one used for the synthesis of compound (4). DMF was 
used as solvent, with imidazole and TBDMSCl, heating at 80 ºC for 24 hrs. 
Unfortunately only the di-substituted compound at C3 and C5 positions was 
recovered. It was reasoned that a longer reaction time was required, but 
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instead the solvent for the reaction was exchanged for pyridine (see entry 2 
Table 5.1.22).  
 
Met. Reagents 
Conditions 
Results 
Temp. Time 
 
1 
 
DMF solv. 
Imidazole 
(9 eq) 
TBDMSCl 
(6 eq) 
Δ 80 ºC 24 hrs 
Di-substituted 
compound C3 and C5 
2# 
Pyridine solv. 
Imidazole 
(9 eq) 
TBDMSCl 
(6 eq) 
η ac. = 78% 
# showed to be the better synthetic method. η ac. = after column yield.  
 
  
Table 5.1.22. – Conditions for synthesis of 3,4,5-tri-O-(tert-butyldimethylsilyloxy)-
cyclohexane-1-carboxylate (15) starting from 3,4,5-O-tri-hydroxy-cyclohexane-1-carboxylate 
(14). 
 
As a result, and in keeping with the other reaction conditions, it was 
possible to obtain, with the same 24 hrs. reaction time, and after column 
chromatography, a yield of compound (15) of 78%. 
 
5.1.6. Mukaiyama reaction - testing of the reaction conditions, for 
the introduction of aliphatic groups at the C1 position  
 
Having now successfully synthesized compound (15), we were closer 
to one of our major goals, because at this stage we had now successfully 
synthesised the starting material required to attempt the Mukaiyama Aldol 
Addition Reaction (see Scheme 5.1.25 and 5.1.27). 120,121,122,123,124,125, 126 
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              Scheme 5.1.25. – Mukaiyama aldol addition reaction mechanism. 
119,126
 
 
This reaction is a powerful tool for carbon-carbon bond formation and 
as such is widely used in asymmetric and total synthesis. It has the 
advantage of using mild conditions and a directed donor and acceptor, but it 
is an indirect process and many factors play a key role in the stereochemistry 
of the product (synclinical or antiperiplanar 1:1 or 3:1), although today there 
are enantioselective methods. 120,121,122,123,124,125, 126 
Nonetheless a successful outcome to using this reaction in the quinic 
acid compounds with tertiary hydrogen at C1 position, would lead to being 
able to introduce at that position, while maintaining the ester functionality, a 
series of aliphatic substituents (see Scheme 5.1.26 for some examples of 
quinic acid C1 substituted compounds that we aim to synthesise).  
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This would represent novel methodology, not previously applied to 
compounds of this type. 
 
 
 
                            Scheme 5.1.26. - Quinic acid C1 substituted compounds. 
 
There are two synthetic routes, the Lewis acid-mediated and the Lewis 
base-mediated methods. The traditional route uses a stoichiometric or 
catalytic amount of a Lewis acid (LA) such as titanium chloride, boron 
trifluoride diethyl etherate (BF3.Et2O) and tin chloride (SnCl4).  
The first step consists of the synthesis of an intermediate silyl enol 
ether, through the use of LDA (to abstract the tertiary proton) and TMSCl. 
The second step consists of the formation of the new carbon-carbon bond, 
with the activation of the aldehyde or ketone electrophile by the Lewis acid, 
through an open transition state (see scheme 5.1.25 for the reaction 
mechanism schematics). 
The synthesis of 1-(benzyl-2-trimethylsilyloxy)-3,4,5-tri-O-(tert-
butyldimethylsilyloxy)-cyclohexane-1-carboxylate starting from 3,4,5-tri-O-
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(tert-butyldimethylsilyloxy)-cyclohexane-1-carboxylate (15) was attempted 
(see Scheme 5.1.27). The method used is an adaptation from that originally 
used by Mukaiyama et al. 119,126 
 
 
Scheme 5.1.27. – Attempt at the synthesis of 1-(benzyl-2-trimethylsilyloxy)-3,4,5-tri-O-(tert-
butyldimethylsilyloxy)-cyclohexane-1-carboxylate starting from 3,4,5-tri-O-(tert-
butyldimethylsilyloxy)-cyclohexane-1-carboxylate (15) – Mukaiyama Aldol Addition Reaction. 
 
 Entry 1 Table 5.1.23 describes the reaction conditions used in the first 
attempt. The reaction has 2 steps, as stated before. In the first step, 
compound (15) was dissolved in THF and LDA is added. After 15 min, 
TMSCl was added and the reaction was stirred for 15 min, everything at 0 ºC. 
In the second step, a solution of DCM, TiCl4 and phenylacetaldehyde was 
first prepared (phenylacetaldehyde was the aldehyde chosen as a model to 
test the reaction) at -78 ºC. This solution was then added to the mixture 
prepared in the first step and stirred for 1 hr. unfortunately only unreacted 
starting material was recovered.  
Following this result, the reaction times of all steps were increased 
(see entry 2 Table 5.1.23), but unfortunately this did not affect the reaction 
outcome and once again only unreacted starting material was recovered. 
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Met. Reagents 
Conditions 
Results 
Temp. Time 
1a) 
THFsolv. 
+ 
LDA 1.8 M in THF(1.1 eq) 
+ 
TMSCl (1 eq) 
0 ºC 
15 min 
(s.m.+THF+LDA) 
+ 
15 min 
(+TMSCl) 
Only 
unreacted 
s.m. 
DCM solv. 
+ 
TiCl4 1 M in DCM (1 eq) 
+ 
Phenylacetaldehyde  
(1 eq) 
-78 ºC 
1 hr 
(+previous 
mixture) 
2a) 
THFsolv. 
+ 
LDA 1.8 M in THF(1.1 eq) 
+ 
TMSCl (1 eq) 
0 ºC 
30 min 
(s.m.+THF+LDA) 
+ 
1 hr 
(+TMSCl) 
DCM solv. 
+ 
TiCl4 1 M in DCM (1 eq) 
+ 
Phenylacetaldehyde    
(1 eq) 
-78ºC 
1.30 hrs 
(+previous 
mixture) 
a) Adapted from Mukaiyama (1973). 
119,126
 
 
Table 5.1.23. – Testing conditions for the attempt at the synthesis of 1-(benzyl-2-
trimethylsilyloxy)-3,4,5-tri-O-(tert-butyldimethylsilyloxy)-cyclohexane-1-carboxylate starting 
from 3,4,5-tri-O-(tert-butyldimethylsilyloxy)-cyclohexane-1-carboxylate (15). 
 
 As future work, the plan would be to alter the equivalents of the 
reagents used and closely monitor the reaction at the end of the first step, to 
confirm that the intermediate is formed. A detailed investigation would need 
to be instigated to ascertain if the problem is in the first step, in the second 
step or both, and act accordingly. 
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5.2. CYTIDINE MODIFICATIONS SUITABLE FOR COUPLING TO 
QUINIC ACID AND SIALIC ACID-BASED ANALOGUES OF 
CMP-Neu5Ac VIA PHOSPHATE OR OTHER SUITABLE 
LINKAGES 
 
 
                Scheme 5.2.1. – Cytidine: tested reactions and synthesized compounds.  
 
 In parallel to my efforts towards the synthesis of quinic acid-based 
analogues, it was necessary to be engaged in the preparation of suitably 
protected cytidine derivatives. As referred to previously, one of the aims of 
this project is coupling, through a suitable linkage, of the quinic acid 
compounds, synthesized and described is the previous section, to a cytidine 
nucleotide, so that it resembles the natural substrate of the sialyltransferase 
enzymes, CMP-Neu5Ac. In that way they would have hopefully serve as 
effective polyST inhibitors.  
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The quinic acid analogue compounds, alone or coupled, through 
different linkages, to cytidine or other nucleotide, would be evaluated through 
biological assays to determine their possible use as inhibitors and their 
affinity towards the enzymes.   
Cytidine was chosen as the first molecule to be coupled, since it is part 
of the natural substrate (CMP-sialic acid) for the enzymes responsible for the 
synthesis of polySia, namely PST and STX. Due to a shortage of time, only 
the cytidine chemistry and optimization of the reaction conditions for that 
molecule (synthesized compounds – see Scheme 5.2.1 for the schematics of 
all the reactions and synthesized compounds) is presented here. 
 Preparation of the cytidine molecule involves a series of protection 
steps. 92 
  
 
Scheme 5.2.2. – Synthesis of 2’,3’-O-isopropylidene cytidine (16) starting from commercially 
available cytidine. 
 
 The first step consists of the protection of the diol at positions C2’ and 
C3’ with a isopropylidene ring (similar to what was made before with quinic 
acid to protect adjacent positions C3 and C4).  
Synthesis of 2’,3’-O-isopropylidene cytidine (16) starting from 
commercially available cytidine (see Scheme 5.2.2) was achieved using 
acetone as the solvent and as reagent for the formation of the isopropylidene 
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ring, with the help of p-TSOH as a catalyst that deprotonates the hydroxyl 
groups, refluxing at 80 ºC for 2 hrs.  
These conditions were replicated successfully and always with very 
good yields of compound (16), and therefore the methodology did not require 
further optimization (see Table 5.2.1). 
 
 Met. Solv. Cat. 
Conditions 
Results 
Temp. Time 
1 
 
Acetone 
 
p-TsOH 
(9.3 eq) 
Reflux 80 ºC 2 hrs η ac. = 93-97% 
η ac. = after column yield. 
Table 5.2.1. – Testing conditions for the synthesis of 2’,3’-O-isopropylidene cytidine (16) 
starting from cytidine. 
 
The second protection step of the cytidine molecule, consists of the 
protection of the O5’ hydroxyl group. The common methodology, is to protect 
it using TBDMSCl.  
Synthesis of 2’,3’-O-isopropylidene-5’-tert-butyldimethylsilyloxy 
cytidine (17) starting from 2’,3’-O-isopropylidene cytidine (16) (see Scheme 
5.2.3) was obtained using DMF as the solvent, 2 eq. of imidazole to 1 eq. 
TBDMSCl at RT for 45 min, which was so far the standard procedure (see 
entry 1 Table 5.2.2). However the obtained yield using those conditions was 
very low. 
 
 107 
 
 
Scheme 5.2.3. – Synthesis of 2’,3’-O-isopropylidene-5’-tert-butyldimethylsilyloxy cytidine 
(17) starting from 2’,3’-O-isopropylidene cytidine (16).  
 
 For that reason the amount of imidazole and TBDMSCl used was 
increased (see entry 2, Table 5.2.2) as well as the reaction time to 1.30 hrs. 
As a result the yield improved, albeit slightly. 
 
Met. Solvent Reagents 
Conditions 
Results 
Temp. Time 
1 
 
DMF 
 
Imidazole 
(2 eq) 
TBDMSCl 
(1 eq) 
RT 
45 min η ac. < 5% 
2 
Imidazole 
(2.5 eq) 
TBDMSCl 
(1.1 eq) 
1.30 hrs η ac. =13% 
3# 
Imidazole 
(5 eq) 
TBDMSCl 
(2.2 eq) 
1 hr η ac. = 97% 
# showed to be the better synthetic method. η ac. = after column yield. 
Table 5.2.2. – Testing conditions for the synthesis of 2’,3’-O-isopropylidene-5’-tert-
butyldimethylsilyloxy cytidine (17) starting from 2’,3’-O-isopropylidene cytidine (16). 
 
 With that in mind the amount of reagents were further increased (see 
entry 3 Table 5.2.2) and after stirring for 1 hr. it was possible to obtain 
compound (17) with an excellent yield of 97%, after column chromatography. 
 108 
 
After optimization of the previous step, protection of the amine group 
follows. The method uses Boc2O as the protection agent, THF as the solvent 
and DMAP as the catalyst, at RT overnight. 
 
 
Scheme 5.2.4. – Synthesis of  N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc1, 18a) and N,N-Di-tert-butyldicarbonate 
2´,3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc2, 18b) 
starting from 2’,3’-O-isopropylidene-5’-tert-butyldimethylsilyloxy cytidine (17). 
 
  The method starting from 2’,3’-O-isopropylidene-5’-tert-
butyldimethylsilyloxy cytidine (17) leads to the synthesis of two compounds 
N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy 
cytidine (Cyt-5’TBDMS-Boc1, 18a, substituted with one Boc molecule) and 
N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-butyldimethylsi 
lyloxy cytidine (Cyt-5’TBDMS-Boc2, 18b, substituted with two Boc molecules) 
(see Scheme 5.2.4). The ratio of the two compounds may vary but it is 
preferable to have compound 18b as the major compound, because in 
protection steps ahead, protection with two Boc appeared more stable.  
 Entry 1 Table 5.2.3 describes the reaction to give an overall yield of 
79% and Boc1:Boc2 ratio of 44:56, compound (18b) as the major one, as 
determined by NMR spectroscopy. 
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 In the hope of improving further the overall yield and the yield of 
compound (18b), the amount of Boc2O reagent and DMAP were increased to 
see whether it had any effect on the reaction outcome (see entry 2 Table 
5.2.3). As a result a lower overall yield was obtained, but a higher ratio of 
compound (18b), Boc1:Boc2 ratio of 28:72. 
 For the next step the mixture of both compounds (18a) and (18b) was 
used. Although it was preferable to have compound (18b), it is not essential. 
 
Met. Reagents Catalyst 
Conditions 
Results 
Temp. Time 
1 
 
THF solv. 
Boc2O 
(1.7 eq) 
 
DMAP 
(0.95 eq) 
RT ovn. 
η ac.18a = 35% 
 
η ac.18b = 44% 
 
η ov. = 79% 
2 
 
THF solv. 
Boc2O 
(2 eq) 
 
DMAP 
(1 eq) 
η ac.18a = 19% 
 
η ac.18b = 50% 
 
η ov. = 69% 
η ac. = after column yield.; η ov. = overall yield. 
Table 5.2.3. – Testing conditions for the synthesis of N-tert-butyldicarbonate 2´,3´-O-
isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc1, 18a) and N,N-Di-
tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-
5’TBDMS-Boc2, 18b) starting from 2’,3’-O-isopropylidene-5’-tert-butyldimethylsilyloxy 
cytidine (17). 
 
 The last step to be described in this section regarding the protection 
steps of cytidine is the one that follows and consists of the removal of the 
TBDMS group from the C5’ position and regeneration of the hydroxyl group.  
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Scheme 5.2.5. – Synthesis of  N-tert-butyldicarbonate 2´,3´-O-isopropylidene cytidine (Cyt-
5’OH-Boc1, 19a) and N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene cytidine (Cyt-5’OH-
Boc2, 19b) starting from N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc1, 18a) and N,N-Di-tert-butyldicarbonate 
2´,3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc2, 18b). 
 
 Starting from a mixture of N-tert-butyldicarbonate 2´,3´-O-
isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc1, 
18a) and N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc2, 18b) compounds N-tert-
butyldicarbonate 2´,3´-O-isopropylidene cytidine (Cyt-5’OH-Boc1, 19a) and 
N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene cytidine (Cyt-5’OH-Boc2, 
19b) (see Scheme 5.2.5) were successfully synthesised, using the method 
described in Table 5.2.4, that uses THF as solvent, TBAF as the deprotection 
agent at RT for 2 hrs. As a mixture of compounds was used as starting 
material, as expected we obtained a mixture of compounds, i.e. one 
compound with one Boc and two Boc groups. As can be seen in Table 5.2.4 
compound (19a), with only one Boc, is the major compound, because as 
mentioned previously, the mono Boc is slightly less stable to the remaining 
conditions. In any case, the overall yield was very high and the mixture could 
be used as the starting material for the next step. 
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Met. Solv. Reag. 
Conditions 
Results 
Temp. Time 
1 
 
THF 
 
 
TBAF 1 M in THF 
(1.2 eq) 
Added dropwise 
 
RT 2 hrs 
η ac.19a = 54% 
 
η ac.19b = 43% 
 
η ov. = 97% 
η ac. = after column yield. η ov. = overall yield. 
Table 5.2.4. – Conditions for the synthesis of N-tert-butyldicarbonate 2´,3´-O-isopropylidene 
cytidine (Cyt-5’OH-Boc1, 19a) and N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene 
cytidine (Cyt-5’OH-Boc2, 19b) starting from mixture of N-tert-butyldicarbonate 2´,3´-O-
isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-5’TBDMS-Boc1, 18a) and N,N-Di-
tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (Cyt-
5’TBDMS-Boc2, 18b). 
 
The next step involved, the replacement of an iodine atom at C5’ 
position. This reaction had to be made in a schedule that allows for the 
immediate coupling step as soon as the iodine compound is synthesized. 
Unfortunately due to insufficient time, the reaction scheme could not be 
further explored. The advantage was that the compound was stable and 
could be stored ready for future use. 
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5.3.  SIALIC ACID-BASED ANALOGUES: DEVELOPMENT OF 
METHODOLOGY FOR THE SYNTHESIS OF SIALO-DISULFIDES 
 
 
              Scheme 5.3.1. – Sialic acid: tested reactions and synthesized compounds. 
 
 This section describes one final area of activity in which I was 
engaged: glycosyl disulfides, and in particular sialic acid-based disulfides. 
The wider group already had studied in a very detailed manner the sialic acid 
chemistry for the synthesis of thiosialosides.  
Glycosyl disulfides represent an interesting group of compounds which 
have received attention due to their potential use as glycosyl donors in 
synthetic reactions and their potential as probes to increase understanding of 
biological systems. 127, 128 
 We recognised the possibility of synthesising sialic acid-based 
disulfide compounds from a by-product identified in the synthesis of sialic 
acid sulfides, when using KSAc in EtOAc – namely acetyl disulfide sialoside 
(24) (Scheme 5.3.1) – a very useful potential building block. 127  
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The disulfide by-product was observed when attempting to synthesise 
akyl and aryl thiosialosides. The synthesis of a second by-product, the acetyl 
disulfide form stated previously, was identified. This work was summarised in 
a peer-reviewed publication and appended to this thesis (Appendix, chapter 
9). 
The key step in the synthesis of thiosialosides, the conversion of 2-
chlorosialoside to 2-thioacetate via the use of KSAc, was already known to 
form also an unsaturated by-product Neu5Ac2en. These by-products were 
difficult to separate from the main sulphide compound, and HPLC needed to 
be used, since the disulfide was usually a minor product. 127  
Firstly, a way to encourage synthesis of this particular compound was 
investigated – i.e. to improve the disulfide:sulfide formation ratio, so that this 
was the major product and not the sulfide. It was observed that the addition 
of I2 to the KSAc in EtOAc medium, drove the reaction to the preferential 
formation of disulfide. These represent novel conditions for molecules of this 
type, with considerable potential scope for synthesis of glycosyl disulfide 
derivatives. An attempt to optimise the conditions for this reaction was 
therefore proceeded.  
 
Scheme 5.3.2. – Synthesis of methyl 5-acetamido-3,5-dideoxy-β-D-glycero-D-galacto-2-
nonulopyranosonate (N-Acetylneuraminic methyl ester, 20) starting from commercially 
available sialic acid. 
 
 Scheme 5.3.1 summarises the principle reactions and compounds 
made during these disulfide-related studies. 
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Sialic acid is a sugar that contains an amine (acetate-derivatised, and 
so effectively protected), five hydroxyl groups and a carboxylic acid. It was 
therefore necessary to introduce protecting groups to the molecule before 
being able to derivatise it. 129 
The first protection step led to the synthesis of methyl 5-acetamido-
3,5-dideoxy-β-D-glycero-D-galacto-2-nonulo-pyranosonate (N-Acetyl-
neuraminic methyl ester, 20) using commercially available sialic acid as 
starting material (see Scheme 5.3.2). This method utilises MeOH as the 
solvent, which with the Amberlite resin as catalyst and proton donor, is a 
commonly used method for the conversion of a carboxylic acid to its ester 
form. After 48 hrs at RT an almost quantitative yield of compound (20) was 
obtained. The reaction proved to be highly reproducible, even with multi-gram 
scale-up. 
 The second protection step consisted of the synthesis of the penta-O-
acetylated sialic acid methyl ester, 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-
dideoxy-D-glycero-D-galacto-2-nonulopyranosonate (21) starting from 
previously synthesized methyl 5-acetamido-3,5-dideoxy-β-D-glycero-D-
galacto-2-nonulopyranosonate (N-Acetylneuraminic methyl ester, 20, see 
Scheme 5.3.3).  
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Scheme 5.3.3. – Synthesis of 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-
D-galacto-2-nonulopyranosonate (21) starting from methyl 5-acetamido-3,5-dideoxy-β-D-
glycero-D-galacto-2-nonulopyranosonate (N-acetylneuraminic methyl ester, 20). 
 
 The acetylation process proceeded smoothly. After 24 hrs reaction, 
and flash column chromatography, the yield was approximately 90%. The 
compound obtained was actually a mixture of two anomers (i.e. the α and β 
anomer of compound 21). These isomers proved impossible to separate by a 
chromatography column. The β anomer was the major product due to the 
position of the adjacent ester function. 
 
 
Scheme 5.3.4. – Synthesis of methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-
dideoxy-β-D-glycero-D-galacto-2-nonulopyranosonate (22) starting from 5-acetamido-
2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-galacto-2-nonulopyranosonate (21). 
 
The next step involved chlorination of position C2 to synthesise methyl 
5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-β-D-glycero-D-
galacto-2-nonulopyranosonate (22) starting from, the mixture of anomers at 
C2 position, 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-
galacto-2-nonulopyranosonate (21) (see Scheme 5.3.4). 
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The chlorination method uses acetyl chloride and a stream of HCl gas 
a the source of Cl species, first bubbling for 15 min at 0 ºC and then leaving it 
to stir at RT for a further 48 hrs. The reaction gave successfully compound 
(22) as exclusively β anomer. The reaction was high yielding and 
reproducible.  
 
 
Scheme 5.3.5. – Synthesis of 2-(acetylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-
trideoxy-2-thio-α-D-glycero-D-galacto-2-nonulopyranosonate (Neu5Ac-2SSAc, 24) starting 
from methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-β-D-glycero-D-galacto-
2-nonulopyranosonate (22). 
 
 Once the chlorinated sialic acid had been synthesised, it was now 
possible to start considering the synthesis of disulfide sialic acid compounds 
in some detail. In the first instance, my aim was to synthesise 2-
(acetylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2-thio-α-D-
glycero-D-galacto-2-nonulopyranosonate (Neu5Ac-2SSAc, 24) from the 
chlorinated compound (22) (see Scheme 5.3.5), while minimising the 
formation of any by-products (e.g. unsaturated derivative 25). 127,128 It was 
determined that the source of KSAc was very important to the outcome of the 
reaction. 127 The number of equivalents of KSAc used was preferably 6 eq; 
iodine was initially used at 1.5 eq to allow the formation of the disulfide. At 
this stage, the precise mechanism of the reaction is not known. The reaction 
conditions were stirring at RT overnight. 
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 As two batches of KSAc were available, an old one and a newly 
purchased one (and from different commercial brands), one of the objectives 
was to assess the influence of the reagent quality (Table 5.3.3 entries 1, 2 
and 3 refer to the use of an batch 1 of KSAc reagent which was already 
opened for some time and entries 4, 5 and 6 to the use of a batch 2 a newly 
purchased batch) on the outcome of the reaction.  
A second objective was to see if the use of a different solvent (other 
than the normally-used EtOAc). DMF was selected as an alternative (see 
entry 3 and entry 6 of Table 5.3.4) solvent to be evaluated. The number of 
equivalents used of KSAc and I2, 6 eq. and 1.5 eq. accordingly were not 
changed at this stage. Importance of temperature on the reaction was also 
explored: since EtOAc was employed either at RT (see entry 1 and 4 of 
Table 5.3.4) or at 85 ºC (see entry 2 and 5 of Table 5.3.4).  
As can be seen in Table 5.3.4, when using the old KSAc batch (entries 
1, 2 and 3), the result was the same – synthesis of compound Neu5Ac2en 
(25), independently from the solvent and reaction conditions used. It can 
therefore be concluded that the reagent was already degraded and for that 
the main product obtained was the oxidized compound (25), methyl 5-
acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-D-glycero-D-talo-
non-2-enonate (Neu5Ac2en). 
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Met. 
KSAc 
batch  
Solv. KSAc I2 
Conditions 
Filt. Results 
Temp. Time 
1 
ONE 
(1) 
EtOA
c 
6 eq 
1.5 
eq 
 
RT 
 
ovn. 
yes 
Neu5Ac-2en 
(25) 
2 
 
85ºC 
 
yes 
3 DMF 
 
Δ 80ºC 
 
no 
4# 
TWO 
(2) 
 
EtOA
c 
 6 eq 
1.5 
eq 
RT 
ovn. 
yes 
Mixture 
 
Neu5Ac-2SAc 
(23) 60% 
 
Neu5Ac-
2SSAc (24) 
40% 
5 85ºC yes 
 
Neu5Ac-2en 
(25) 
6 
 
DMF 
 
Δ 80ºC 
 
no Degradation  
1) Batch one, LF005421, 25 g Alfa Aesar. 
2) Batch two, BCBF7702 Sigma-Aldrich 
# showed to be the better synthetic method.Adapted from Morais et al (2009) 
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Table 5.3.4. – Conditions for the synthesis of 2-(acetylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-
acetyl-2,3,5-trideoxy-2-thio-α-D-glycero-D-galacto-2-nonulopyranosonate (Neu5Ac-2SSAc, 
24) starting from methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-β-D-
glycero-D-galacto-2-nonulopyranosonate (22). 
 
 The same result was obtained when using the new batch of KSAc, but 
using EtOAc under reflux conditions (entry 5 Table 5.3.4), which can lead us 
to conclude that increasing the temperature reduces production of the 
disulfide compound, in favour of the unsaturated compound (25).  
 Substitution of EtOAc for DMF (entry 6 Table 5.3.4) for better 
solubilisation of the new batch of KSAc in the reaction medium proved not to 
be useful, because it only led to complete degradation of the starting 
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material. It would be useful to try DMF at RT in the future work to see if the 
problem was the high temperature used, and not the solvent itself. 
 The better method is highlighted in entry 4, Table 5.3.4. Nonetheless it 
was still a mixture of compounds, the sulfide compound (23, Neu5Ac-2SAc) 
and the disulfide compound (24, Neu5Ac-2SSAc) in a ratio of 60% sulfide: 
40% disulfide which meant that the desired compound was not the main 
product. 
 
Met. 
KSAc 
batch  
Solv. KSAc I2 
Conditions 
Filt. Results 
Temp. Time 
1(1) TWO(2) EtOAc 6 eq 
1.5 
eq 
RT ovn. yes 
 
Mixture 
 
Neu5Ac-
2SAc (23) 
30% 
 
Neu5Ac-
2SSAc (24) 
70% 
 
1) S.m. for this reaction was the mixture 4 (see table 5.3.4). 
2) Batch two, BCBF7702 Sigma-Aldrich. 
 
Table 5.3.5. – Conditions for the improvement of mixture 4 (see Table 5.3.4) ratio of 2-
(acetylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2-thio-α-D-glycero-D-
galacto-2-nonulopyranosonate (Neu5Ac-2SSAc, 24). 
 
 To separate this mixture preparative HPLC was required. However, it 
was believed that it would be possible to improve the reaction ratio further by 
reacting the mixture obtained previously (60% sulfide: 40% disulfide) under 
the same conditions with a further 6 eq of KSAc new batch and 1.5 eq of 
iodine (see Table 5.3.5). As a result it was possible to improve the reaction 
ratio, to 30% sulfide: 70% disulfide. 
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Scheme 5.3.6. – Attempt at the alkylation of mixture 4 (see Table 5.3.4): synthesis of methyl 
5-acetamido-4,7,8,9-tetra-O-acetyl-2-S-benzyl-2,3,5-trideoxy-2-thio-β-D-glycero-D-galacto-2-
nonulopyranosonate (Neu5Ac-2SBn, 26) and 2-(benzylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-
acetyl-2,3,5-trideoxy-2-thio-β-D-glycero-D-galacto-2-nonulopyranosonate (Neu5Ac-2SSBn, 
27). 
 
 Having studied the methodology for the synthesis of compound (24) 
and achieving a more satisfactory ratio between sulphide and disulfide, my 
next objective was to study potential methodology for the alkylation of 
disulfide sialic acid compounds (see Scheme 5.3.6), starting from the 
aforementioned acetyl disulfide derivative. Unlike the reaction conditions for 
the simultaneous de-protection and alkylation of sialosides starting from the 
thioacetate using diethylamine,127,130 this reagent was not suitable, resulting 
in breakdown of the starting material. Triethylamine alone had no effect at all. 
It was found that initial dissolution in DMF, followed by addition, in a specific 
order, of triethylamine, alkylating agent and hydrazine acetate, at 50 ºC 
during 20 min (Table 5.3.6) was sufficient to promote de-protection and 
alkylation. The chosen alkykating agents were iodoethane (EtI) and benzyl 
 121 
 
bromide (BnBr), and the starting material used was the mixture of 
compounds (23) and (24) obtained previously (entry 4 Table 5.3.4). A 
preliminary set of small-scale reactions was investigated, before embarking 
on preparative HPLC method development in order to separate the mixture, 
since there was insufficient time to do so before.  
 When using EtI (entry 1 Table 5.3.6) complete degradation of the 
reaction mixture was observed. However, when using BnBr (entry 2 Table 
5.3.6) a mixture of compounds (26) and (27) was observed. These were the 
expected products, given the nature of the starting material. 
 
Met. Reagents 
Alk.  
(R) 
Conditions 
Results 
Temp. Time 
 
1(1) 
 
 
DMF solv. 
Et3N cat. 
(3 eq) 
Hydrazine 
acetate 
(1.1 eq) 
EtI 
(2 eq) 
Δ  
50 ºC 
20 min Degradation  
2(1) 
DMF solv. 
Et3N cat. 
(3 eq) 
Hydrazine 
acetate 
(1.1 eq) 
BnBr 
(2 eq) 
Δ  
50 ºC 
20 min 
Mixture of  
 
Neu5Ac-2SBn (26) 
and 
Neu5Ac-2SSBn (27) 
 
(1) S.m. for this reaction was the mixture 4 (see table 5.3.4) and the reagents were added in a specific 
order: first the Et3N, then the alkylating agent and last the hydrazine acetate. 
          
Table 5.3.6. – Conditions for the attempt at the alkylation of mixture 4 (see table 5.3.4). 
 
 Following purification of compound (24) the method used in entry 2 
Table 5.3.6 was re-assessed (see Scheme 5.3.7 and Table 5.3.7). 
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Scheme 5.3.7. – Attempt at the alkylation of pure 2-(acetylsulfanyl)-5-acetamido-4,7,8,9-
tetra-O-acetyl-2,3,5-trideoxy-2-thio-α-D-glycero-D-galacto-2-nonulopyranosonate (Neu5Ac-
2SSAc, 24). 
 
Met. Reagents 
Alk.  
(R) 
Conditions 
Results 
Temp. Time 
 
1(1) 
 
 
DMF solv. 
Et3N cat. 
(3 eq) 
Hydrazine 
acetate 
(1.1 eq) 
BnBr 
(2 eq) 
Δ  
50 ºC 
20 min Neu5Ac-2SBn (26) 
(1) S.m. for this reaction was purified by HPLC and the reagents were added in a specific order: first the 
Et3N, then the Alkylating agent and last the hydrazine acetate. 
 
 
Table 5.3.7. – Conditions for the attempt at the alkylation of pure 2-(acetylsulfanyl)-5-
acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2-thio-α-D-glycero-D-galacto-2-
nonulopyranosonate (Neu5Ac-2SSAc, 24). 
 
 As can be seen in Table 5.3.7 the result wasn’t the one predicted, 
since compound 26 (Neu5Ac-2SBn, 26) was exclusively obtained. Further 
studies are needed to confirm this result. Should it be proved correct, 
additional investigations are required regarding this methodology to shed 
some light regarding the mechanism involved and the role that each reagent 
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takes in it, so that in the future we could be able to synthesise directly the 
disulfide compounds and their alkylated forms of sialic acids, but also in the 
hopes of applying this quite simple methodology to other sugars and aliphatic 
compounds. 
 
5.4. ACETOBROMO-GLUCOSE METHODOLOGY STUDIES FOR THE 
SYNTHESIS OF SULFIDE AND DISULFIDE COMPOUNDS 
 
 
   Scheme 5.4.1. – Acetobromo-glucose: tested reactions and synthesized compounds. 
 
 As previously mentioned, one of my objectives when developing the 
methodology for the synthesis of sialic acid-based disulfides, was to 
investigate whether it would be possible to apply the approach more broadly. 
To be more specific, whether it would be possible to synthesise disulfides of 
other compounds (other sugars, aliphatic compounds among others of 
interest) was studied. In order to examine wider applicability to sugars, 
glucose was selected as a good starting point, specifically utilising the readily 
commercially available acetobromo-α-D-glucose (see Scheme 5.4.1).   
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Scheme 5.4.2. – Synthesis of 1-(acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-α-D-glucopyranosate 
(28) starting from commercially available acetobromo-α-D-glucose (AcBrGlu). 
 
 The first objective was to apply the methodology previously used for 
sialic acid sulfide chemistry, for the synthesis of the sulfide 1-(acetylsulfanyl)-
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosate (28, see Scheme 5.4.2) starting 
from acetobromo-α-D-glucose (AcBrGlu). The method used acetone as the 
solvent, 6 eq of KSAc, RT overnight. It was predicted that since glucose was 
less reactive than sialic acid, harsher conditions may be required to achieve 
introduction of the thioacetyl function in this case. 
 As before, both the old (entry 1 and 2 Table 5.4.1) and new batches of 
KSAc (entry 3 and 4 Table 5.4.1) were tested to assess any effect on the 
outcome of the reactions. As happened previously with sialosides, 
independently of the reagents and reaction conditions used, the only result 
was complete degradation. Nonetheless these results did help to determine 
some key points: the reaction required heating, and when using acetone as 
solvent the reaction time had to be monitored closely (the optimum conditions 
proved to be 3-4 hrs). 
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Met. 
KSAc 
batch  
Solv. KSAc 
Conditions 
Filt. Results 
Temp. Time 
1 
ONE(1) 
Acetone 
6 eq 
RT 
+ 
Reflux  
70 ºC 
ovn. 
+ 
4.30 
hrs 
yes 
 
Degradation  
2 DMF 
 
Δ 80 ºC 
 
ovn. no 
3 
TWO(2) 
 
DMF 
 
6 eq 
Δ 80 ºC 
1.20 
hrs 
no 
Mixture 
 
AcGluc-1SAc 
(28)  
 
α and β 
anomer 
4# 
 
Acetone 
 
Reflux 
70 ºC 
3 hrs yes 
 
η ac. (28) = 
82% 
 
α anomer 
 
1) Batch one, LF005421, 25 g Alfa Aesar. 
2) Batch two, BCBF7702 Sigma-Aldrich. 
# showed to be the better synthetic method. η ac. = after column yield. 
Adapted from Morais et al (2009) 
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Table 5.4.1. – Conditions for the synthesis of 1-(acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosate (28) starting from commercially available acetobromo-α-D-glucose 
(AcBrGlu). 
 
With these results in hand, the effect of changing the solvent to DMF 
(entry 3 Table 5.4.1) at 80 ºC from acetone (entry 4 Table 5.4.1) reflux at 
70ºC was tested. Using DMF led to more rapid product formation, perhaps 
partly due to increased solubility of KSAc. More significantly, it was 
determined that these conditions led to a non stereoselective reaction, giving 
a mixture of α and β anomers of the desired compound (28). When using 
acetone, after 3 hrs, the α anomer of compound (28) was successfully 
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synthesised exclusively, and with high yield. The methodology using acetone 
was therefore adopted. 
Having successfully synthesised the sulphide (thioacetate) form 
acetobromo-α-D-glucose, the next goal was to investigate synthesis of the 
equivalent acetyl disulfide form of the molecule, specifically: 1-
(acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-1-thio-α-D-glucopyranosate (29, see 
Scheme 5.4.3). The reaction conditions established before for the synthesis 
of compound (24) were initially used. 
 
 
Scheme 5.4.3. – Synthesis of 1-(acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-1-thio-α-D-
glucopyranosate (29) starting from commercially available acetobromo-α-D-glucose 
(AcBrGlu). 
 
 Again both batches of KSAc were used: batch 1 (see entries 1, 2, 4, 5 
and 6 Table 5.4.2) and batch 2 (see entry 3 Table 5.4.2), as previously 
described for the synthesis of compound (24), using 6 eq. of KSAc and 1.5 
eq of iodine. 
 Firstly, batch 2 of KSAc was used, with acetone as solvent (see entry 
1 and 2 Table 5.4.2) since these were the conditions determined to be the 
best for the synthesis of the sulfide compound (28) (see Table 5.4.1). We 
previously noted that for the synthesis of compound (28) that heating at 
raised temperature was required: the reaction did not progress at room 
temperature. Refluxing in acetone at 70 ºC was selected, in one method for 
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only 2 hrs (entry 1 Table 5.4.2) and in the other overnight stirring (entry 2 
Table 5.4.2). When using the first method a mixture of sulfide compound (28) 
and the desired disulfide compound (29) was obtained. TLC analysis 
indicated the presence of only one compound (28), as in the proton and 
carbon NMR. However, mass spectrometry indicated also the presence of 
compound (29). This result needs confirmation since it can be an artefact of 
the mass spectrometry process. When the reaction was left overnight the 
main product was compound (28), with degradation occurring. 
As synthesis of the disulfide proved unsuccessful, use of DMF as 
solvent was next tested, using both bacth 1 (entry 3 Table 5.4.2) and batch 2 
of KSAc (entry 4 Table 5.4.2) at 80 ºC overnight. As expected from previous 
studies, DMF did increase the solubility of KSAc salts, but as happened 
previously (Table 5.4.1 entry 4), the result was a mixture of α and β anomers 
of compound (28). Next, acetonitrile was used, but a similar outcome was 
observed (entry 5 Table 5.4.2).  
On analysing the results obtained, it was possible that it could be that 
in the first 2 hrs the sulfide compound (28) was formed and then afterwards it 
led to the synthesis of compound (29) when iodine was added.  
For that reason in entry 6 a reflux in acetonitrile was first attempted, 
with the acetobromo-glucose starting material and the new batch KSAc for 2 
hrs, to allow the formation of SAc. After cooling to RT, iodine was added and 
the reaction left overnight to allow the formation of disulfide compound (29). 
As result we obtained the same as in entry 1, a mixture sulfide compound 
(28) and the desired disulfide compound (29), with the latter still a small 
minority.  
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Met. 
KSAc 
batch  
Solv. 
KSA
c 
I2 
Conditions 
Filt. Results 
Temp. Time 
1 
TWO 
(1) Acetone 6 eq 
1.5 
eq 
 
Reflux 
70 ºC 
 
 
2 hrs yes 
Mixture 
 
AcGluc-1SAc 
(28)  
AcGluc-
1SSAc (29)  
 
2 
 
ovn. yes 
Mainly 
AcGluc-1SAc 
(28)  
More 
degradation 
3 
 
ONE 
(2) 
 
DMF 6 eq 
1.5 
eq 
Δ  
80 ºC 
ovn. no 
Mixture 
AcGluc-1SAc 
(28)  
 
α and β 
anomer 
4 
 
TWO 
(1) 
 
5 
TWO 
(1) 
MeCN 6 eq 
1.5 
eq 
 
Reflux 
82 ºC 
 
ovn. no 
Mixture 
AcGluc-1SAc 
(28)  
 
α and β 
anomer 
6* 
Reflux 
82 ºC 
+ 
RT 
 
2 hrs 
+ 
ovn. 
no 
Mixture 
 
AcGluc-1SAc 
(28) 
AcGluc-
1SSAc 
(29)   
1) Batch two, BCBF7702 Sigma-Aldrich. 
2) Batch one, LF005421, 25 g Alfa Aesar. 
* reaction 6 was refluxed with KSAc for 2 hrs to form the SAc, and then let to cool to RT to add the iodine and 
stir ovn. Adapted from Morais et al (2009) 
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Table 5.4.2. – Conditions for the synthesis of 1-(acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-1-thio-
α-D-glucopyranosate (29) starting from commercially available acetobromo-α-D-glucose 
(AcBrGlu). 
 
Although it proved possible to synthesise the desired sulfide 
compound using this methodology for the first time, further studies are 
needed to optimise it. 
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6. CONCLUSION AND FUTURE WORK  
 
6.1. Conclusion  
 
In this thesis I have described efforts towards the development of 
chemical methodology to synthesise key building blocks for the synthesis of 
potential polysialyltransferase inhibitors. The overall strategy, outlining 
structural modifications for the construction of CMP-Neu5Ac analogues for 
inhibition of PSA biosynthesis (sialyltransferase inhibitors) that are in the 
work plan are demonstrated in Scheme 3.1.  
The focus of the majority of the work described in this thesis 
concerned the modification of the core structure of Neu5Ac, through 
replacement of the sugar sialic acid ring by a carbacycle with similar 
structure: quinic acid (or quinic acid analogues). This kind of carbomimetic 
has the potential for potent inhibition of the polysialyltransferase enzymes. 
The quinic acid-based chemistry proved to be challenging. Reactions 
were not easily reproducible because they were very sensitive, often to pH 
variations of the reaction medium, and therefore it was difficult to optimize the 
reaction conditions and there is the need for further studies in the near future.  
Key reactions proved successful, thereby achieving methodology not 
previously described for molecules of this type. The Barton-McCombie 
reaction was successfully optimized, which allowed deoxygenation of the C1 
position of quinic acid analogues – a novel approach. 
Functionalization of the C1 position is crucial to any future work, as 
this will be key to conjugation with other moieties (e.g. cytidine). It is also 
attractive since it is not described in the literature. Success will allow the 
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synthesis of aliphatic compounds and others (see Scheme 5.1.27). The 
literature only describes substitution of C3, C4 and C5 hydroxyls; 
deprotonation of C1 hydroxyl and attachment of others groups, but never 
complete removal/substitution of the C1 hydroxyl. 
Besides carbacycles, replacement of the phosphate linkage between 
sialic acid and cytidine in the substrate (CMP-sialic acid) was considered. 
Following identification of a novel acetyl disulfide sialoside derivative, efforts 
were placed into the potential utility of this compound as a building block for 
asymmetrical disulfide synthesis. Novel methodology for the synthesis of this 
acetyl disulfide compound was successfully developed. Reaction conditions 
were optimised for  selectivity and reproducibility.  
Consideration was also given to the wider application of this 
methodology to other compounds: other sugars or even aliphatic compounds. 
Optimization of the synthesis of disulfide sialic acid compound was 
accomplished, but unfortunately when adapting it to a glucose sugar (initially 
acetobromoglucose), limited success was experienced thus far.  
 
6.2. Future Work  
 
The logical starting point would be to attempt to conjugate quinic acid 
derivatives to the cytidine derivatives synthesised, through suitable linkages. 
Biological evaluation would follow. Firstly, activity in a cell-free enzyme-based 
assay to assess inhibition and then secondly functional assays to assess the 
activity of compounds with regards migration of cells.   
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Another key area for research is optimisation of the Mukaiyama 
reaction, as applied to quinic acid. Success here would allow the 
functionalization of the C1 position in the quinic acid molecule (see schemes 
5.1.25, 5.1.26 and 5.1.27), and be highly publishable. It may be necessary to 
consider alternatives to this approach to achieve the same outcome.  
Regarding other manipulations of the CMP-Neu5Ac structure 
described in scheme 3.1, synthesis of CMP-Neu5Ac with different acyl 
groups would be sensible, particularly given the reported selectivity for STX 
inhibiton by Man5But and Man5Pent, in order to create a library of these 
compounds ready for testing their inhibitory activity towards STX and PST.   
 Further possibilities include alteration of the monophosphate linkage, 
for higher stability by C-, S- (sulfides, disulfides) or N-sialosides. 
Replacement or modification of the cytidine nucleoside is also planned for the 
future. Compounds that are transition state mimetics, with delocalized 
positive charge, are also of interest to future studies. 
The synthesis of sialic acid disulfides is a very interesting area of 
research. Following identification of the novel compound, its utility for 
synthesis of disulfide compounds became clear. Further optimisation of 
alkylation conditions would uncover a completely new and easy way to 
synthesise disulfides. Experiments are already underway in the group. 
The ultimate goal would be to arrive at an inhibitor with good activity in 
the in vitro biological assays, to be able to investigate the effects of 
polysialyltransferase inhibition in vivo. 
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7. EXPERIMENTAL 
 
7.1. QUINIC ACID-BASED SYNTHESIZED COMPOUNDS 
 
 
 
7.1.1. 3, 4-O-isopropylidene-1,5-quinic lactone (1)  
 
Quinic acid (D(-)-quinic acid 98%, sigma Aldrich, lot 523568-025 MW 
192.174 g,20.8 mmol) and of Na2SO4 (17.8 g, 6 eq, 62.4 mmol) were 
suspended in acetone (160 mL). Then concentrated H2SO4 (~10 drops) was 
added as a catalyst. The suspension was stirred at reflux for 24 hrs. After 
that time TLC (EtOAc /petroleum ether 1:1) showed that no starting material 
was present. After cooling, the reaction was quenched, , by neutralization to 
pH 6-7 via the addition of solid NaHCO3. The mixture was filtered and the 
acetone was evaporated under vacuum. The residue was partitioned 
between water (50 mL) and DCM (50 mL), the combined organic extracts 
were dried with Na2SO4 and concentrated in vacuum, giving compound 1 as 
a white solid (4.29 g, 20.03 mmol,  96 %). The analytical data correspond to 
the reported values.95, 96, 97 
Rf (EtOAc): 0.80; Rf (EtOAc/pet.ether 1:1): 0.5; [α]20D – 34.8 (c 0.175, 
CH2Cl2); 
1H NMR (CDCl3): δ 1.33 (s, 3H, CH3), 1.52 (s, 3H, CH3), 2.18 (dd, 
1H, J = 14.7, 2.9 Hz, H2eqt), 2.29 - 2.41 (m, 2H, H6eqt and H2ax), 2.65 (d, 1H, 
J = 11.8 Hz, H6ax), 4.30 (ddd, 1H, J = 6.5, 2.4, 1.4 Hz H4), 4.5 (app. td, 1H, J 
= 7.1, 2.8 Hz, H3) and 4.73 (app. dd, 1H, J = 6.1, 2.4 Hz, H5) ppm; 13C NMR 
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(CDCl3): δ 24.29 (CH3), 26.97 (CH3), 34.29 (CH2, C6), 38.30 (CH2, C2), 
71.53 (CH, C4), 72.12 (CH, C3), 75.87 (CH, C5), 78.77 (C1)109.81 
(Cisopropylidene), and 178.71 (C=O) ppm; MS (AP
+) C10H14O5 (214.22) m/z (%): 
215.0 [M+H)+ (100). 
 
7.1.2. Methyl quinate (2) 
 
 Quinic acid (D(-)-quinic acid 98%, sigma Aldrich, lot 523568-025 MW 
192.17, 2 g, 10.4 mmol) was suspended in MeOH (100 mL). Amberlite ion 
exchange resin IR120H+ (2.5 g, previously washed with MeOH) was then 
added to the solution (). The suspension was stirred at reflux for 24 hrs. The 
reaction was filtered (to remove the resin) and the solvent was evaporated, 
giving compound 2 as a colourless powder (2.10 g, 10.2 mmol, 98%). The 
analytical data correspond to the reported values. 36, 98 
Rf (DCM:MeOH 15%) 0.40; [α]20D – 31.3 (c 0.28, MeOH);  
1H NMR 
(CDCl3): 1.75-2.13 (m, 4 H, H2ax, H2eqt, H6ax and H6eqt), 2.3 (s, OH5), 2.54 
(d, J = 9.2 Hz, OH4), 3.33 (td, 1H, J = 9.2, 3.4 Hz, H4), 3.44 (d, J = 8.6 Hz, 
OH3), 3.70 (s, 3H, COOCH3), 3.94 - 4.02 (m, 1 H, H3) and 4.07 (app. dd, 1H, 
J = 8.6, 3.2 Hz, H5) ppm; 13C NMR (CDCl3): 38.35 (CH2, C2), 41.97 (CH2, 
C6), 52.93 (COOCH3), 68.21 (CH, C5), 71.47 (CH, C3), 76.54 (C4), 76.82 
(CH, C1) and 175.96 (C=O) ppm; MS (AP+) C8H14O6 (206.20) m/z (%): 207.3 
[M+H]+ (100). 
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7.1.3. Methyl 3,4,5-tri-O-acetylquinate (3)  
 
 Methyl quinate (2) (1.17 g, 5.67 mmol) was dissolved in  pyridine (3 
mL) and the mixture cooled to 0ºC (ice bath). Then acetic anhydride (1.9 mL, 
3.5 eq, 19.8 mmol) was added very slowly dropwise during 30 min with the 
reaction temperature maintained at 0 ºC. The mixture was allowed to warm 
up to RT and stir for 3.45 hrs, after which analysis using TLC (DCM/MeOH 
15%) showed the total consumption of starting material. The reaction mixture 
was cooled to 0 ºC and anhydrous MeOH (10 mL) was added and stirred for 
1 hr. The mixture was concentrated, extracted with saturated aqueous 
solution of NaHCO3 and EtOAc, dried (Na2SO4), filtered and evaporated. 
Flash column chromatography (EtOAc/pet.ether gradient 1:5 to 1:1) and 
NMR (CDCl3) enable to identify compound 3 as an amorphous solid (930 mg, 
2.8 mmol,  49%). The analytical data correspond to the reported values. 36, 100 
Rf (EtOAc/PE 1:2) 0.53; [α]20D – 41.6 (c 0.25, CH2Cl2);  
1H NMR 
(CDCl3): δ 1.98 (s, 3H, Ac), 1.99 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.08 - 2.24 (m, 
4H, H2ax, H2eqt, H6ax and H6eqt), 3.21 (s, 1H, OH), 3.74 (s, 3 H, COOCH3), 
4.98 (dd,1 H, J = 9.5, 3.4 Hz, H4), 5.35 - 5.44 (m, 2 H, H3 and H5) ppm; 13C 
NMR (CDCl3): δ 20.78 (Ac, CH3), 20.93 (Ac, CH3), 21.11 (Ac, CH3), 35.45 
(CH2, C2), 38.67 (CH2, C6), 53.25 (COOCH3), 67.04 (CH, C3), 68.71 (CH, 
C5), 71.63 (CH, C4), 73.66 (C1), 168.88 (Ac, C=O), 170.20 (Ac, C=O), 
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170.32 (Ac, C=O), 174.51 (COOCH3) ppm; MS (AP
+) C14H20O9 (332.30) m/z 
(%): 333.0 [M+H]+ (100). 
 
 
7.1.4. 3,4,5-tri(tert-butyldimethylsilyloxy)-1-hydroxy cyclohexane-
1-carboxylate (4) 
 
Methyl quinate (2) (100 mg, 0.48 mmol) was dissolved in anhydrous 
DMF (5 mL) and imidazole (500 mg, 15 eq, 7.35 mmol) and TBDMSCl (740 
mg, 10 eq, 4.8 mmol) were added. The reaction was then stirred at 80 ºC for 
72 hrs. The solvent was evaporated and the crude mixture washed with 
water (100 mL) and extracted with DCM (100 mL). The organic phase was 
dried (Na2SO4), filtered and evaporated. TLC (DCM/MeOH 5%) showed 
several impurities and therefore column chromatography had to be 
conducted (DCM/MeOH gradient DCM to 5% MeOH). NMR (CDCl3) of the 
one of the obtained pure fractions corresponded to compound 4 as a 
colourless solid (247 mg, 0.45 mmol, 93%). The analytical data correspond to 
the reported values. 101 
Rf (DCM/MeOH 5%) 0.8 ; [α]20D + 4.78  (c 0.23, CH2Cl2); 
1H NMR ( 
CDCl3): δ - 0.01 (2s, 6H, SiCH3), 0.04 (2s, 6H, SiCH3), 0.08 (2s, 6H, SiCH3), 
0.82 (1s, 9H, SiC(CH3)3), 0.86 (1s, 9H, SiC(CH3)3), 0.87 (1s, 9H, SiC(CH3)3), 
1.89 (dd, 1H, J = 12.4, 10.2 Hz, H6ax), 1.97 - 2.10 (m, 3H, H2ax, H2eqt and 
H6eqt), 3.53 (m, 1H, H4), 3.68 (s, 3H, COOCH3), 3.86 (m, 1H, H5) and 4.24 
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(m, 1H, H3) ppm; 13C NMR (CDCl3): δ - 4.98 (C, SiCH3), - 4.86 (C, SiCH3), - 
4.81 (C, SiCH3), - 4.70 (C, SiCH3), - 4.45 (C, SiCH3), - 4.17  (C, SiCH3), 
18.09 (C, SiC(CH3)3), 18.17 (C, SiC(CH3)3), 18.20 (C, SiC(CH3)3), 25.81(3C, 
SiC(CH3)3), 25.96 (3C, SiC(CH3)3), 26.03 (3C, SiC(CH3)3), 36.62 (CH2, C2), 
39.75 (CH2, C6), 52.21 (COOCH3), 68.26 (CH, C3), 70.92 (CH, C5), 74.27 
(CH, C4), 77.21 (C1) and 174.46 (C7) ppm; MS (AP+) C26H56O6Si3 (548.98) 
m/z (%): 549.4 [M+H]+ (100). 
 
 
7.1.5. Methyl 3,4-O-isopropylidene quinate (5) 
 
To a solution of quinide acetal (1) (500 mg, 2.3 mmol) in anhydrous 
MeOH (17 mL) was added molecular sieves  and to this mixture was added 
slowly dropwise NaOMe solution (6 mL 0.5 M in MeOH, 1.3 eq, 3 mmol) at 0 
ºC during 30 min, under a N2 atmosphere. Then the mixture was stirred to 
warm up to RT for 22 hrs. Analysis using TLC (EtOAc) showed the absence 
of starting material (Rf 0.8) and so the reaction was neutralized with 
Amberlite resin IR-120 H+ only until pH 7 (smallest amount possible used). 
The reaction was filtered and evaporated.  NMR (CD3OD) showed the 
desired compound 5 as colourless oil (358 mg, 1.5 mmol, 62%). The 
analytical data correspond to the reported values. 38, 86, 97, 102, 103 
Rf (EtOAc): 0.4; [α]20D – 1.21 (c 0.165, CH2Cl2); 
1H NMR (CD3OD): δ 
1.23 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.70 (dd, 1H, J = 13.4, 11.2 Hz, H6ax), 
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1.84 (app. ddd, 1H, J = 13.4, 4.2, 1.8 Hz, H6eqt), 1.88 - 1.97 (m, 1H, H2ax), 
2.14 (dd, 1H, J = 15.1, 5.4, H2eqt), 3.64 (s, 3H, COOCH3), 3.80 (m, 1H, H4), 
3.96(ddd, 1H, J = 11.3, 7.2, 4.3 Hz, H5) and 4.33 (app. dd, 1H, J = 9.8, 5.4 
Hz, H3) ppm; 13C NMR (CD3OD): δ 24.19 (CH3), 26.76 (CH3), 35.23 (CH2, 
C2), 38.06 (CH2, C6), 53.30 (COOCH3), 67.42 (CH, C3), 73.19 (CH, C5), 
73.66 (C1), 78.94 (CH, C4),109.67 (Cisopropylidene), and 175.67 (C=O) ppm; MS 
(AP-) C11H18O6 (246.26) m/z (%): 269 [M+Na]
+ (100) and 247 [M+H]+ (45). 
 
 
7.1.6. 5-(tert-butyldimethylsilyloxy)-3,4-O-isopropylidene quinate 
(6) 
 
Methyl 3,4-O-isopropylidene quinate (5) (47 mg, 0.19 mmol) was 
dissolved in DMF (1 mL) and then imidazole (38.6 mg, 3 eq, 0.57 mmol) and 
TBDMSCl (57 mg, 2 eq, 0.38 mmol) were added.  
The resulting mixture was then stirred at 60 ºC for 3.5 hrs. The 
reaction was then quenchedthrough DMF evaporation under vacuum and the 
residue was washed with water (100 mL) and extracted with DCM (100 mL). 
The organic layers were dried (Na2SO4), filtered and evaporated. Column 
chromatography was conducted to remove impurities (EtOAc/petroleum ether 
1:9 to 1:1) and NMR (CDCl3) of the  one of the obtained fractions showed 
compound 6 as a colourless oil (30 mg, 0.083 mmol, 44%). 
Rf (EtOAc/PE 1:2) 0.52; [α]20D – 54.12 (c 0.09,CH2Cl2); 
1H NMR 
(CDCl3): δ -0.01 (1, 3H, SiCH3), 0.02 (1s, 3H, SiCH3), 0.81 (s, 9H, 
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SiC(CH3)3),1.28 (s, 3H, CH3),1.45 (s, 3H, CH3), 1.77 (dd, 1H, J = 13.7, 10.5 
Hz, H6ax), 1.90 (ddd, 1H, J = 13.7, 4.6, 2.0 Hz, H6eqt), 2.10 - 2.17 (m, 1H, 
H2ax), 2.20 (dd, 1H, J = 15.7, 4.3 Hz, H2eqt),  3.35 (s, 1H, OH), 3.71 (s, 3H, 
COOCH3), 3.86 (t, 1H, J = 6.1 Hz, H4), 4.03 (ddd, 1H, J = 10.8, 6.5, 4.7 Hz, 
H5) and 4.37 – 4.41 (m, 1H, H3) ppm; 13C NMR (CDCl3): δ - 4.81(C, SiCH3), 
- 4.53 (C, SiCH3), 18.01 (SiC(CH3)3), 25.58 (3C, SiC(CH3)3), 25.81 (CH3), 
28.24 (CH3), 34.29 (CH2, C2), 40.58 (CH2, C6), 52.84 (COOCH3), 69.18 (CH, 
C5), 73.84 (CH, C3), 74.14 (C1), 80.29 (CH, C4),108.86 (C isopropylidene), and 
174.96 (C=O) ppm; MS (AP+) C17H32O6Si (360.52) m/z (%): 361.2 [M+H]
+ 
(100). 
 
 
7.1.7. 1-O-(thiocarbonyldiimidazolyl)-3,4-O-isopropylidene-1,5-
quinic lactone (7) 
 
Quinide acetal (1) (1 g, 4.7 mmol) was dissolved in anhydrous DCE 
(25 mL) and DMAP (230 mg, 0.4 eq, 1.88 mmol) was added. Then 
thiocarbonyldiimidazole (1.7 g, 2 eq, 9.4 mmol) was added and the mixture 
stirred at reflux  under N2 atmosphere for 24 hrs. The solvent was evaporated 
and the residue washed with a saturated aqueous solution of NH4Cl and 
extracted with DCM. The organic phase was dried (Na2SO4), filtered and 
evaporated. Column chromatography (EtOAc/pet.ether gradient 1:1 top 2:1) 
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and NMR (CDCl3) allow isolation of compound 7 as a colourless sugar-like 
(1.3 g, 4 mmol, 86%). 
Rf (EtOAc) 0.65; [α]20D – 2.3 (c 0.13, CH2Cl2); 
1H NMR (CDCl3): δ 1.38 
(s, 3H, CH3), 1.57 (s, 3H, CH3), 2.66 (ddd, 1H, J = 14.3, 7.6, 2.4 Hz, H6eqt), 
2.76 (d, 1H, J = 14.3, 3.0 Hz, H6ax), 2.92 (d, 1H, J = 11.6 Hz, H2ax), 3.59 
(dddd, 1H, J = 11.5, 6.5, 2.2, 1.3 Hz, H2eqt), 4.41 (ddd, 1H, J = 6.5, 2.3, 1.1 
Hz, H4), 4.63 (td, 1H, J = 7.2, 3.0 Hz, H3), 4.92 (dd, 1H, J = 6.5, 2.4 Hz, H5), 
7.06 (d, 1H, J = 0.8 Hz, H2’imidazole), 7.63 (app. t, 1H, J = 1.4 Hz, H3’imidazole) 
and 8.32 (s, 1H, H1’imidazole) ppm; 
13C NMR (CDCl3): δ 24.27 (CH3), 26.91 
(CH3), 29.79 (CH2, C6), 35.63 (CH2, C2), 71.03 (CH, C5), 72.35 (CH, C4), 
75.73 (CH, C3), 82.30 (C1), 110.15 (C isopropylidene), 117.99 (C2’imidazole), 131.09 
(C3’imidazole), 136.74 (C1’imidazole), 171.3 (C=O) and 179.22 (C=S) ppm; MS 
(AP+) C14H16N2O5S (324.35) m/z (%): 325.1 [M+H]
+ (100). 
 
 
7.1.8. 1-O-(thiocarbonyldiimidazolyl)-3,4,5-tri-O-acetylquinate (8) 
 
Methyl 3,4,5-tri-O-acetylquinate (3) (87 mg, 0.26 mmol) was dissolved 
in anhydrous DCE (5 mL), and then DMAP (46 mg, 1.5 eq, 0.39 mmol) and 
thiocarbonyldiimidazole (133 mg, 3 eq, 0.78 mmol), batch two lot 
BCBF5117V Sigma-Aldrich) were added. The mixture stirred at reflux for 48 
hrs. The reaction was evaporated, washed with saturated aqueous solution 
of NH4Cl (50 mL) and extracted with DCM (50 mL). The organic phase was 
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dried (Na2SO4), filtered and evaporated. Column chromatography 
(EtOAc/pet.ether gradient 1:5 to 2:1) and NMR (CDCl3) gave compound 8 as 
a yellow oil (16 mg, 0.036 mmol, 14% yield, the low yield was expected due 
to the large amount of unreacted starting material showed by TLC analysis 
during the monitoring of the reaction).  
Rf (EtOAc/PE 2:1) 0.41; [α]20D – 24 (c 0.075,CH2Cl2); 
1H NMR (CDCl3): 
δ 1.62 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.14 (m, 1H, H2eqt), 
2.50 (dd, 1H, J = 16.6, 3.3 Hz, H6ax), 2.88 (m, 1H, H2ax), 3.38 (dt, 1H, J = 
16.6, 3.3 Hz , H6eqt),  3.75 (s, 3H, COOCH3), 5.07 (dd, 1H, J = 10.4, 3.6 Hz 
H4), 5.42 (tt, 1H, J = 11.3, 5.6 Hz, H3), 5.61 (q, 1H, J = 3.4 Hz, H5), 7.06 (d, 
1H, J = 0.8 Hz, H2’imidazole), 7.72 (app. t , 1H, J = 1.4 Hz, H3’imidazole) and 8.45 
(s, 1H, H1’imidazole) ppm; MS (AP
+) C18H22N2O9S (442.44) m/z (%): 443.1 
[M+H]+ (100). 
 
 
 
7.1.9. 1-O-(thiocarbonyldiimidazolyl)-3,4,5-tri-O-(tert-
butyldimethylsilyloxy)cyclohexane-1-carboxylate (9)  
 
3,4,5-tri(tert-butyldimethylsilyloxy)-1-hydroxy cyclohexane-1-
carboxylate (4) (80 mg, 0.146 mmol) was dissolved in DCE (4 mL), and then 
DMAP (13.5 mg, 0.8 eq, 0.11 mmol) and thiocarbonyldiimidazole (102 mg, 4 
eq, 0.57 mmol) were added. The mixture stirred at reflux for 48 hrs. The 
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reaction was quenched with saturated aqueous solution of NH4Cl (50 mL) 
and extracted with DCM (50 mL). The organic phase was dried (Na2SO4), 
filtered and evaporated. Column chromatography (EtOAc/pet.ether gradient 
pet.ether only to 1:4) and NMR (CDCl3) gave one fraction that corresponded 
to the unreacted starting material (4) (white solid, 34.5 mg, 0.063 mmol, 36% 
recovered, Rf 0.6 in 80% PE in EtOAc solvent) and an UV-reactive fraction 
as compound 9  a colourless oil (30 mg, 0.046 mmol, 31% yield). 
Rf (80% PE in EtOAc) 0.5; [α]20D + 16.25 (c 0.16,CH2Cl2); 
1H NMR 
(CDCl3): δ 0.04 (1s, 3H, SiCH3), 0.05 (1s, 3H, SiCH3), 0.08 (1s, 3H, SiCH3), 
0.11 (1s, 3H, SiCH3), 0.12 (1s, 3H, SiCH3), 0.13 (1s, 3H, SiCH3), 0.87 (1s, 
9H, SiC(CH3)3), 0.90 (1s, 9H, SiC(CH3)3), 0.92 (1s, 9H, SiC(CH3)3), 1.94 - 
2.07 (ddd, 3H, J = 39.8, 14.8, 5.1 Hz, H2ax, H6eqt and H6ax), 2.74 (dd, 1H, J = 
13.4, 3.0 Hz, H2eqt),  3.66 (m, 1H, H4), 3.76 (s, 3H, COOCH3), 4.12 - 4.18 (m, 
1H, H5), 4.40 - 4.47 (m, 1H, H3), 7.06 (d, 1H, J = 0.8 Hz, H2’imidazole), 7.36 
(app. t , 1H, J = 1.4 Hz, H3’imidazole) and 8.08 (s, 1H, H1’imidazole); MS (AP
+) 
C30H58N2O6SSi3 (659.11) m/z (%): 660.3 [M+H]
+ (100). 
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7.1.10. 1-O-benzyl-3,4-O-isopropylidene-1,5-quinic lactone 
(10) 
 
Sodium hydride (22.4 mg, 2 eq,  0.934 mmol, 60% suspension in oil) 
was suspended in DMF (2 mL) at 0 ºC under N2 atmosphere. Then a solution 
of quinide acetal (1) (100 mg, 0.47 mmol) in  DMF (1mL) and benzyl bromide 
(66 µL, 1.2 eq, 0.56 mmol) was added dropwise during 30 min to the NaH 
solution in DMF at 0 ºC with stirring. The mixture was left stirring to warm up 
to RT for 19 hrs, after which TLC analysis (EtOAc/petroleum ether 1:1) 
showed only a small portion of unreacted starting material and an UV 
reactive compound. The reaction was then quenched slowly throught the use 
of a saturated aqueous solution of NH4Cl (2 mL) at 0 ºC. The mixture was 
thenextracted with DCM (5 mL), and the organic phases were dried 
(Na2SO4), filtered and evaporated to give a white crude. Column 
chromatography (EtOAc/petroleum ether 1:2 to EtOAc only) and NMR 
(CDCl3) gave compound 10 as a colourless solid (73mg, 0.24 mmol, 51%). 
The analytical data correspond to reported values. 118 
Rf (EtOAc/pet.ether 1:1) 0.8; [α]20D + 8 (c 0.05, CH2Cl2); 
1H NMR 
(CDCl3): δ 1.34 (s, 3H, CH3), 1.52 (s, 3H, CH3), 2.26 (dd, 1H, J = 8.0, 3.4 Hz, 
H2eqt), 2.46 – 2.56 (m, 3H, H2ax and H6), 4.32 (m, 1H, H4), 4.55 (dd, 1H, J = 
7.0, 2.7 Hz, H3), 4.58 - 4.67 (A, B of AB, 2H, J = 10.8 Hz, CH2Ph), 4.70 (dd, 
1H, J = 6.0, 2.4 Hz, H5), 7.29 – 7.40 (m, 5H, C6H5) ppm; 
13C NMR (CDCl3): δ 
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24.3, 27.0 (CH3), 30.7 (C6), 36.1 (C2), 67.0 (CH2Ph), 71.4 (C3), 72.4 (C4), 
75.0 (C5), 76.9 (C1), 109.6 (Cisopropylidene), 127.8, 127.9, 128.4, 137.4 (6C, 
C6H5), 175.8 (C=O) ppm; MS (ES
+) C17H20O5 (304.34) m/z (%): 305.1 [M+H]
+ 
(100). 
 
7.1.11. 1-(tert-butyldimethylsilyloxy)-3,4-O-isopropylidene-
1,5-quinic lactone (11)  
 
Quinide acetal (1) (100 mg, 0.47 mmol) was dissolved in anhydrous 
DCM (2 mL) and pyridine (75 µL, 2 eq, 0.94 mmol). Then TBDMSCl (212 mg, 
3 eq, 1.41 mmol) was added at 0 ºC. The mixture stirred for 30 min at 0 ºC 
and then for 20 hrs at RT. After that time TLC analysis (EtOAc) showed total 
consumption of starting material and so the reaction was quenched with 
DCM (50 mL) and water (50 mL). The aqueous layer was separated and 
acidified with an aqueous solution of HCl 10% and then extracted twice with 
DCM (50 mL). The organic phase was then dried (Na2SO4), filtered and 
evaporated. NMR (CDCl3) gave compound 11 as colourless crystals (88 mg, 
0.27 mmol, 57%). The analytical data of the crude correspond to reported 
values. 119 
Rf (EtOAc/pet. ether 1:2) 0.8; [α]20D + 1.9 (c 1.1, CHCl3); 
1H NMR 
(CDCl3): δ 0.01(s, 3H, SiCH3), 0.03 (s, 3H, SiCH3), 0.82 (s, 9H, SiC(CH3)3), 
1.23 (s, 3H, CH3), 1.42 (s, 3H, CH3), 2.08 (dd, 1H, J = 11.6, 3.1 Hz, H6eqt), 
2.23 – 2.30 (m, 2H, H2eqt and H6ax), 2.55 (d, 1H, J = 11.7 Hz, H2ax), 4.19 
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(ddd, 1H, J = 6.5, 3.5, 1.4 Hz, H4), 4.37 – 4.42 (m, 1H, H3), 4.62 (dd, 1H, J = 
6.1, 2.5 Hz, H5) ppm; 13C NMR (CDCl3): δ - 3.1 (C, SiCH3), - 3.2 (C, SiCH3), 
17.82 (SiC(CH3)3), 24.42 (C, SiC(CH3)3), 25.59 (C, SiC(CH3)3), 27.24 (C, 
SiC(CH3)3), 35.57 (C6), 39.36 (C2), 71.67 (C3), 72.20 (C4), 73.1 (C1), 75.1 
(C5), 109.64 (Cisopropylidene), 176.9 (C=O) ppm; MS(ES
+) C16H28O5Si (328.48) 
m/z (%): 329.8 [M+H]+ (100). 
 
 
7.1.12. 3,4-O-isopropylidene-1,5-lactone cyclohexane (12) 
 
1-O-(thiocarbonyldiimidazolyl)-3,4-O-isopropylidene-1,5-quinic lactone 
(7) (80 mg, 0.25 mmol) was dissolved in anhydrous toluene (5 mL) and AIBN 
was added as a catalyst (8 mg, 0.2 eq, 0.05 mmol). The mixture was purged 
under a N2 atmosphere for 5 min. Then TTMSS was added (150 µL, 2 eq, 0.5 
mmol) and the mixture was stirred at 90 ºC under N2 atmosphere for 20 hrs. 
After that time, TLC analysis (EtOAc/pet.ether 1:3) showed total consumption 
of the starting material. The reaction mixture was then quenched with 
saturated aqueous solution of NH4Cl (50 mL) and extracted with DCM (50 
mL). The organic phase was dried (Na2SO4), filtered and evaporated. 
Column chromatography (EtOAc/pet.ether gradient 1:4 to 2:3) and NMR 
(CDCl3) gave compound 12 as colourless crystals (47 mg, 0.24 mmol, 96%). 
Nonetheless the reaction presented very inconsistent yields varying from 56 
to 96%. 
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Rf (EtOAc/pet.ether 1:3) 0.45; [α]20D – 42.9 (c 0.07, CH2Cl2);
 1H NMR 
(CDCl3): δ 1.19 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.95 (ddd, 1H, J = 15.1, 6.4, 
3.2 Hz, H2eqt), 2.05 - 2.12 (m, 1H, H2ax), 2.18 (ddt, 1H, J = 15.1, 7.6, 1.8 Hz, 
H6eqt), 2.28 (d, 1H, J = 12.2 Hz, H6ax), 2.48 (dd, 1H, J = 8.3, 3.5 Hz, H1), 
4.12 - 4.16 (m, 1H, H4), 4.25 - 4.30 (m, 1H, H3) and 4.57 (dd, 1H, J = 5.7, 
2.5 Hz, H5) ppm; 13C NMR (CDCl3): δ 24.41 (CH3), 27.13 (CH3), 27.97 (CH2, 
C6), 29.96 (CH2, C2), 35.37 (CH, C1), 70.48 (CH, C3), 72.76 (CH, C4), 77.41 
(CH, C5), 109.35 (Cisopropylidene), 178.90 (C=O) ppm; MS(AP
+) C10H14O4 
(198.22) m/z (%): 199.7 [M+H]+ (100). 
 
 
7.1.13. 3,4-O-isopropylidene-cyclohexane-1-carboxylate (13) 
 
3,4-O-isopropylidene-1,5-lactone cyclohexane (12) (126 mg, 0.64 
mmol) in anhydrous MeOH (2mL) was added slowly dropwise to a NaOMe 
solution (1.7 mL, 0.5 M in MeOH, 1.3 eq, 0.83 mmol) at 0 ºC during 30 min, 
under a N2 atmosphere. Then the reaction mixture was left stirring to warm 
up to RT for 3 hrs. TLC analysis (EtOAc/PE 2:1) gave a compound with Rf 
0.5 and total consumption of starting material (Rf 0.8) and for that reason the 
reaction mixture was neutralized with Amberlite resin IR until pH 3-4, filtered 
and evaporated.  Column chromatography (EtOAc/pet.ether gradient PE only 
to 2:1) andNMR (CDCl3) gave compound 13 as a colourless solid (25 mg, 
0.109 mmol, 17% yield). 
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Rf (EtOAc/PE 2:1) 0.5; [α]20D – 116.3 (c 0.08, CH2Cl2);
 1H NMR 
(CDCl3): δ 1.30 (s, 3H, CH3), 1.47 (s, 3H, CH3), 1.83 (dd, 1H, J = 13.7, 10.6 
Hz, H6ax), 2.00 (dd, 1H, J = 13.6, 4.1 Hz, H6eqt), 2.19 (d, H, J = 3.7 Hz, H2), 
2.68 (tt, 1H, H1), 3.76 (s, 3H, COOCH3), 3.90 - 3.94 (m, 1H, H4), 4.07 (ddd, 
1H, J = 10.6, 7.5, 4.0 Hz, H5) and 4.41 (dt, 1H, J = 5.7, 3.7 Hz, H3) ppm; 13C 
NMR (CDCl3): δ 25.65 (CH3), 28.17 (CH3), 34.69 (CH2, C2), 38.88 (CH2, 
jC6), 53.23 (COOCH3), 68.27 (CH, C1), 73.47 (CH, C3), 73.84 (CH, C5), 
79.84 (CH, C4), 109.36 (Cisopropylidene), and 175.7 (C=O) ppm; MS (AP
+) 
C11H18O5 (230.26) m/z (%): 231.2 [M+H]
+ (100). 
 
 
7.1.14. 3,4,5-tri-O-hydroxy-cyclohexane-1-carboxylate (14)  
 
3,4-O-isopropylidene-1,5-lactone cyclohexane (12) (100 mg, 0.51 
mmol) in anhydrous MeOH (2mL) was added slowly dropwise to a NaOMe 
solution (1.4 mL, 0.5 M in MeOH, 1.3 eq, 0.66 mmol) at 0 ºC during 30 min, 
under a N2 atmosphere. The mixture was then left stirring to warm up to RT 
for 3 hrs. TLC analysis (EtOAc/PE 2:1) showed a the presence of a 
compound with Rf 0.49 and total consumption of the starting material. 
Therefore the reaction mixture was neutralized with an excess amount of 
Amberlite resin IR until acidic pH. After neutralization TLC analysis showed 
that the compound had now a lower Rf  of 0.11, as it was expected if the 
formation of the desired compound was achieved. The reaction was then 
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filtered and evaporated. Column chromatography (EtOAc/PE gradient 1:1 to 
EtOAc only) and NMR (CD3OD) gave compound 14 as a colourless solid (66 
mg, 0.35 mmol,  68%).  
Rf (EtOAc/MeOH 5%) 0.37; [α]20D – 52 (c 0.05, MeOH);
 1H NMR 
(CDCl3): δ 1.35 (dd, 1H, J = 24.1, 12.5 Hz, H6ax), 1.48 - 1.57 (m, 1H, H2eqt), 
1.92 - 1.96 (m, 1H, H2ax), 2.02 - 2.09 (m, 1H, H6eq), 2.75 (tt, 1H, J = 12.5, 3.6 
Hz, H1), 3.19 (dd, 1H, J = 9.2, 3.0 Hz, H4), 3.59 (s, 3H, COOCH3), 3.63 - 
3.71 (m, 1H, H5) and 3.97 (dd, 1H, J = 6.0, 3.0 Hz, H3) ppm; 13C NMR 
(CDCl3): δ 33.35 (CH2, C6), 34.78 (CH2, C2), 35.8 (CH, C1), 50.8 (COOCH3), 
68.6 (CH, C3), 68.9 (CH, C5), 75.79 (CH, C4) and 175.6 (C=O) ppm; MS 
(AP+) C8H14O5 (190.19) m/z (%): 191.2 [M+H]
+ (100). 
 
 
 
7.1.15. 3,4,5-tri-O-(tert-butyldimethylsilyloxy) cyclohexane-1-
carboxylate (15) 
 
3,4,5-tri-O-hydroxy-cyclohexane-1-carboxylate (14) (172 mg, 0.91 
mmol) was dissolved in pyridine (4 mL) and then imidazole (558 mg, 9 eq, 
8.2 mmol) and TBDMSCl (823 mg, 6 eq, 5.5 mmol) were added. The reaction 
mixture stirred at 80 ºC for 24 hrs, and after that  time  was quenched 
throughtpyridine evaporation under vacuum and then the residue was 
washed with a saturated aqueous solution of NH4Cl (100 mL) and extracted 
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with DCM (100 mL). The organic layers were then dried (Na2SO4), filtered 
and evaporated. Column chromatography (EtOAc/PE gradient PE only to 5% 
EtOAc) and NMR (CDCl3) gave compound 15 as a colourless syrup (380 mg, 
0.71 mmol, 78%). 
Rf (EtOAc 5% in PE) 0.7; 1H NMR (CDCl3): δ - 0.01(2s, 6H, SiCH3), 
0.03 (2s, 6H, SiCH3), 0.07 (2s, 6H, SiCH3), 0.84 (s, 9H, SiC(CH3)3), 0.86 (s, 
9H, SiC(CH3)3), 0.88  (s, 9H, SiC(CH3)3), 1.78 - 2.02 (m, 4H, H6 and H2), 
2.61 (tt, 1H, J = 12.5, 3.6 Hz, H1), 3.51 - 3.55 (m, 1H, H4), 3.68 (s, 
3H,COOCH3), 3.77 - 3.80 (m, 1H, H3) and 4.15 - 4.17 (m, 1H, H5) ppm; 
13C 
NMR (CDCl3): δ - 4.96 (C, SiCH3), - 4.87 (C, SiCH3), - 4.81 (C, SiCH3), - 4.59 
(C, SiCH3), - 4.51(C, SiCH3), - 4.32 (C, SiCH3), 18.08 (C, SiC(CH3)3), 18.18 
(C, SiC(CH3)3),   18.22 (C, SiC(CH3)3), 25.85 (3C, SiC(CH3)3), 25.94 (3C, 
SiC(CH3)3), 26.07 (3C, SiC(CH3)3), 28.28 (CH2, C2), 29.63 (CH2, C6), 51.38 
(COOCH3), 67.99 (CH, C3), 71. 83 (CH, C1), 71.92 (CH, C5), 75.10 (CH, C4) 
and 175.54 (C=O) ppm; MS (AP+) C26H56O5Si3 (532.98) m/z (%): 533.2 
[M+H]+ (100). 
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7.2. CYTIDINE SYNTHESIZED COMPOUNDS 
 
 
7.2.1. 2’,3’-O-isopropylidene cytidine (16)  
 
To a suspension of cytidine (alfa aesar lot 10132023, MW 243.22) 
(2.09 g, 8.6 mmol) in dry acetone (300 mL) was added p-toluene sulfonic 
acid monohydrate (15.17 g, 79.7 mmol, 9.3 eq) and the mixture was stirred at 
reflux for 2 hrs. Then solid NaHCO3 was added until the yellow solution was 
white in colour (pH7, deprotonation of NH3
+). The solid was then filtered 
under vacuum, giving a yellow oil crude residue. Column chromatography 
(DCM/MeOH 10%) and  NMR (CDCl3) gave compound 16 as a colourless 
solid compound (2.2 g, 7.8 mmol, 95 %). The analytical data correspond to 
reported values.  
Rf  (DCM/MeOH 10%) 0.24. 1H NMR (CDCl3): δ 1.32 (s, 3H, CH3), 
1.53 (s, 3H, CH3), 3.77 (dd, 1H, J = 11.9, 4.7 Hz, H5’), 3.87 (dd, 1H, J = 11.9, 
3.6 Hz, H5’), 4.26 (m, 1H, H4’), 4.73 (dd, 1H, J = 6.4, 3.6 Hz, H3’), 5.05 (d, 
1H, J = 2.5 Hz, H2’), 5.55 (d, 1H, J = 7.4 Hz, H1’), 5.88 (d, 1H, J = 7.4 Hz, 
H5), 7.45 (d, 1H, J = 7.4 Hz, H6) ppm. 13C NMR (CDCl3): δ 25.23 (CH3), 
27.17 (CH3), 61.97 (C5’), 80.50 (C3’), 84.28 (C2’), 87.32 (C4’), 95.58 (C1’), 
96.45 (C5, C=C), 113.75 (Cisopropylidene), 143.77 (C6, C=C), 156.36 (C2, C=O), 
166.33 (C4) ppm; MS (AP+) C12H17N3O5  (283.28) m/z (%) 284.2 
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[M+H]+ (100); HRMS (ESI) (m/z) [M+H]+ calculated for 
C12H18N3O5 found 284.1241. 
 
 
7.2.2. 2´, 3´-O-isopropylidene-5´-tert-butyldimethylsilyloxy 
cytidine (17) 
 
 
Propargyl cytidine (16) (2.13 g, 7.5 mmol) was dissolved in anhydrous 
DMF (8 mL). Imidazole (2.55 g, 5 eq, 37.5 mmol) and TBDMSCl (2.48 g, 2.2 
eq, 16.5 mmol) were added to the reaction mixture and stirred for 1 hr at RT 
under a N2 atmosphere. TLC analysis (DCM/MeOH 10%) showed total 
consumption of the starting material. DMF solvent was then removed under 
vacuum and the crude residue was dissolved in DCM (100 mL) and extracted 
with water (100 mL) to separate the excess of imidazole and TBDMSCl. The 
organic extracts were then dried (Na2SO4), then filtered and evaporated. 
NMR (CDCl3) gave compound 17 as a yellow oil (2.9 g, 7.3 mmol, 97%). The 
analytical data correspond to reported values. 
Rf (DCM/MeOH 10%) 0.37; 1H NMR (CDCl3): δ 0.00 (s, 6H, SiCH3), 
0.82 (s, 9H, SiC(CH3)3), 1.27 (s, 3H, CH3), 1.49 (s, 3H, CH3), 3.72 (dd, 1H, J 
= 11.4, 3.9 Hz, H5'), 3.84 (dd, H, J = 11.4, 3.9 Hz, H5'), 4.20 (dd, 1H, J = 6.5 
Hz, 3.3 H4'), 4.65 – 4.71 (m, 2H, H2’ and H3’), 5.66 (d, 1H, J = 7.4 Hz, H5), 
5.82 (d, 1H, J = 1.5 Hz, H1'), 7.57 (d, 1H, J = 7.4 Hz, H6) ppm; 13C NMR 
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(CDCl3): δ - 5.45 (2C, SiCH3), 18.12 (SiC(CH3)3), 25.38 (CH3), 25.87 (3C, 
SiC(CH3)3), 27.23 (CH3), 63.28 (C5’), 80.19 (C2’), 85.87 (C3’), 87.27 (C4’), 
93.33 (C1’), 94.42 (C5, C=C), 113.25 (C isopropylidene), 141.57 (C6, C=C), 
155.00 (C2, C=O), 165.75 (C4) ppm; MS (AP+) C18H31N3O5Si (397.54) m/z 
(%) 398.2 [M+H]+ (100). HRMS (ESI) (m/z) [M+H]+ calcd for C18H32N3O5Si 
found 398.2103.  
 
 
 
7.2.3. N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (18a) 
 
Silylated cytidine (17) (394 mg, 0.99 mmol) was dissolved in  
anhydrous THF (5 mL) and DMAP (115 mg, 0.95 eq, 0.94 mmol) and di-tert-
butyl dicarbonate (Boc2O, 373 mg, 1.7 eq, 1.7 mmol) were added. The 
reaction mixture was stirred at RT overnight. TLC analysis (EtOAc/pet.ether 
1:1) showed total consumption of starting material and so the reaction was 
quenched with  MeOH (5 mL) and stirred for 1 hr. The solvents were then 
evaporated and flash column chromatography was preformed 
(EtOAc/pet.ether gradient 1:2 to 1:1). NMR (CDCl3) gave compound 18a as a 
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colourless sugar-like (207 mg, 0.42 mmol, 35%). The analytical data 
correspond to reported values. 
Rf (EtOAc/pet.ether 1:1) 0.4; 1H NMR (CDCl3): δ 0.00 (d, 6H, J 1.6 Hz, 
Si(CH3)2), 0.80 (s, 9H, SiC(CH3)3), 1.27 (s, 3H, CH3), 1.49 (s, 3H, CH3), 1.43 
(s, 9H, NCOOC(CH3)3), 3.73 (dd, 1H, J = 11.5, 3.5 Hz, H5’), 3.88 (dd, 1H, J = 
11.5, 2.6 Hz, H5’), 4.30 (dd, 1H, J = 5.8, 2.8 Hz, H4’), 4.68 (dd, 1H, J = 6.2, 
2.3 Hz, H3’), 4.68 - 4.71 (m, 1H, H2’), 5.88 (d, 1H, J = 1.5 Hz, H1’), 7.07 (d, 
1H, J = 7.5 Hz, H5), 7.98 (d, 1H, J = 7.5 Hz, H6) ppm; 13C NMR (CDCl3): δ -
5.50 (2C, Si(CH3)2), 25.27 (CH3), 25.81 (SiC(CH3)3), 25.92 (3C, SiC(CH3)3), 
27.17 (CH3), 27.97 (3C, NCOOC(CH3)3), 63.25 (C5'), 82.50 (C3'), 84.87 (3C, 
NCOOC(CH3)3), 86.05 (C2'), 87.91 (C4'), 94.02 (C1'), 94.32 (C5, C=C), 
113.61 (Cisopropylidene), 144.67 (C6, C=C), 151.21 (NCOOC(CH3)3), 154.83 
(C2, C=O), 162.76 (C4) ppm. MS (ES+) C23H39N3O7Si (497.66) m/z (%) 498.1 
[M+H]+ (100); HRMS (ESI) (m/z) [M+H]+  calculated for C23H40O7N3Si 
498.2630, found 498.2625. 
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7.2.4. N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (18b) 
 
Silylated cytidine (17) (394 mg, 0.99 mmol) was dissolved in  
anhydrous THF (5 mL) and DMAP (115 mg, 0.95 eq, 0.94 mmol) and di-tert-
butyl dicarbonate (Boc2O, 373 mg, 1.7 eq, 1.7 mmol) were added. The 
reaction mixture stirred at RT overnight. TLC analysis (EtOAc/pet.ether 1:1) 
showed total consumption of the starting material and so the reaction was 
quenched with MeOH (5 mL) and stirred for 1 hr. The solvents were then 
evaporated and flash column chromatography was preformed 
(EtOAc/pet.ether gradient 1:2 to 1:1). NMR (CDCl3) gave compound 18b as a 
colourless sugar-like (261 mg, 0.44 mmol, 44%). The analytical data 
correspond to reported values. 
Rf (EtOAc/pet.ether 1:1) 0.70; 1H NMR (CDCl3): δ 0.00 (d, 6H, J = 1.0 
Hz, SiCH3), 0.81 (3s, 9H, SiC(CH3)3), 1.27 (s, 3H, CH3), 1.48 (s, 18H, 
NCOOC(CH3)3), 1.50 (s, 3H, CH3), 3.73 (dd, 1H, J = 11.5, 3.8 Hz, H5’), 3.86 
(dd, 1H, J = 11.5, 2.7 Hz, H5’), 4.28 (dd, 1H, J = 6.4, 3.3 Hz, H4’), 4.66 (dd, 
1H, J = 6.1, 3.3 Hz, H3’), 4.71 (dd, 1H, J = 6.1, 1.9 Hz, H2’), 5.84 (d, 1H, J = 
1.8 Hz, H1’), 6.93 (d, 1H, J = 7.6 Hz, H5), 7.92 (d, 1H, J = 7.6 Hz, H6) ppm; 
13C NMR (CDCl3): δ  - 5.43 (2C, SiCH3), 18.34 (SiC(CH3)3), 25.32 (CH3), 
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25.92 (3C, SiC(CH3)3), 27.24 (CH3), 27.97 (6C, NCOOC(CH3)3), 63.33 (C5’), 
80.19 (C3’), 84.87 (2C, NCOOC(CH3)3), 86.04 (C2’), 88.04 (C4’), 94.23 (C1’), 
95.67 (C5, C=C), 113.71 (Cisopropylidene), 144.30 (C6, C=C), 149.54 (2C, 
NCOOC(CH3)3), 154.09 (C2, C=O), 162.51 (C4) ppm.  MS (ES
+) 
C28H47N3O9Si (597.77) m/z (%) 598.2 [M+H]
+ (100).  
 
 
7.2.5. N-tert-butyldicarbonate 2´,3´-O-isopropylidene cytidine 
(19a) 
 
 N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (18a) and N,N-Di-tert-butyldicarbonate 2´,3´-O-
isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (18b) mixture (468 mg, 
0.78 mmol) were dissolved in anhydrous THF (3 mL) and then TBAF (0.94 
mL, 1.2 eq, 1.0 M in THF) was added dropwise. The reaction mixture was 
then stirred at RT for 2 hrs, after which the solvents were removed under 
vacuum. TLC analysis (EtOAc/pet.ether 1:1) showed several impurities, 2 of 
them  UV-reactive. Flash column chromatography was preformed 
(EtOAc/pet.ether gradient 1:2 to EtOAc only) andNMR (CDCl3) gave 
compound 19a as a white solid (368 mg, 0.96 mmol, 54%). The analytical 
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data correspond to reported values. The pure compounds were given to 
Bradley Springett for his experiments. 
Rf (EtOAc) 0.4; 1H NMR (CD3OD): δ 1.27 (s, 3H, CH3), 1.44 (s, 9H, 
NCOOC(CH3)3), 1.48 (s, 3H, CH3), 3.65 (d, 1H, J = 4.6, 12.0 Hz, H5'), 3.74 
(dd, 1H, J = 3.5, 12.0 Hz, H5'), 4.23 (dd, 1H, J = 5.6, 3.1 Hz, H4'), 4.75 (dd, 
1H, J = 6.5, 3.4 Hz, H3'), 4.82 (dd, 1H, J =  6.5, 2.7 Hz, H2'), 5.80 (d, 1H, J = 
2.7 Hz, H1'), 7.19 (d, 1H, J = 7.5 Hz, H5), 8.13 (d, 1H, J = 7.5 Hz, H6) ppm; 
13C NMR (CD3OD): δ 25.49 (CH3),  27.50 (CH3), 28.33 (3C, NCOOC(CH3)3), 
63.08 (C5’), 82.29 (C3’), 83.15 (NCOOC(CH3)3), 86.84 (C2’), 89.50 (C4’), 
96.21 (C1’), 96.50 (C5, C=C), 114.85 (C isopropylidene), 147.16 (C6, C=C), 
153.43 (NCOOC(CH3)3), 157.72 (C2, C=O), 165.44 (C4) ppm; MS (AP
+) 
C17H25N3O7 (383.40) m/z (%) 384.1 [M+H]
+ (100); HRMS (ESI) (m/z) [M+H]+  
calculated for C17H25N3O7 384.1765, found 384.1769. 
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7.2.6. N,N-Di-tert-butyldicarbonate 2´,3´-O-isopropylidene cytidine 
(19b) 
 
 N-tert-butyldicarbonate 2´,3´-O-isopropylidene-5´-tert-
butyldimethylsilyloxy cytidine (18a) and N,N-Di-tert-butyldicarbonate 2´,3´-O-
isopropylidene-5´-tert-butyldimethylsilyloxy cytidine (18b)  mixture (468 mg, 
0.78 mmol) were dissolved in anhydrous THF (3 mL) and then TBAF (0.94 
mL, 1.2 eq, 1.0 M in THF) was added dropwise. The reaction mixture stirred 
at RT for 2 hrs, after which the solvents were removed under vacuum. TLC 
analysis (EtOAc/pet.ether 1:1) showed several impurities, 2 of them UV-
reactive, reason by which flash column chromatography was preformed 
(EtOAc/pet.ether gradient 1:2 to EtOAc only). NMR (CDCl3) gave compound 
19b as a white solid (756 mg, 1.87 mmol, 43%).The analytical data 
correspond to reported values. The pure compounds were given to Bradley 
Springett for his experiments 
Rf (EtOAc) 0.6; 1H NMR (CD3OD): δ 1.27 (s, 3H, CH3), 1.44 (s, 18H, 
NCOOC(CH3)3), 1.48 (s, 3H, CH3), 3.65 (d, 1H, J = 4.6, 12.0 Hz, H5'), 3.74 
(dd, 1H, J = 3.5, 12.0 Hz, H5'), 4.23 (dd, 1H, J = 5.6, 3.1 Hz, H4'), 4.75 (dd, 
1H, J = 6.5, 3.4 Hz, H3'), 4.82 (dd, 1H, J =  6.5, 2.7 Hz, H2'), 5.80 (d, 1H, J = 
2.7 Hz, H1'), 7.19 (d, 1H, J = 7.5 Hz, H5), 8.13 (d, 1H, J = 7.5 Hz, H6) ppm; 
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13C NMR (CD3OD): δ 25.49 (CH3),  27.50 (CH3), 28.33 (6C, NCOOC(CH3)3), 
63.08 (C5’), 82.29 (C3’), 83.15 (2C, NCOOC(CH3)3), 86.84 (C2’), 89.50 (C4’), 
96.21 (C1’), 96.50 (C5), 114.85 (C isopropylidene), 147.16 (C6), 153.43 (2C, 
NCOOC(CH3)3), 157.72 (C2), 165.44 (C4) ppm; MS (AP
+) C22H33N3O9 
(483.51) m/z (%) 484.1 [M+H]+ (100). 
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7.3. SIALIC ACID SYNTHESIZED COMPOUNDS 
 
 
7.3.1. Methyl 5-acetamido-3,5-dideoxy-β-D-glycero-D-galacto-2-
nonulopyranosonate (N-Acetylneuraminic methyl ester) (20)  
 
Starting material N-Acetylneuraminic acid (5 g, 16.18 mmol, MW 309 
g/mol, lot CCDx42-71 Dextra Lab.) was dispersed in anhydrous MeOH (180 
mL), then Amberlyte resin IR-120 H+ (8.5 g) was added. The reaction mixture 
stirred at RT for 48 hrs. Then it was filtered and evaporated. NMR (CD3OD) 
gave compound 20 as a yellow sugar (4.98 g, 15.4 mmol, 95% yield). The 
analytical data correspond to reported values. 
[α]20D – 24 (c 0.15,MeOH); 
1H NMR (CD3OD): δ 1.86 (s, 3H, NAc), 
1.92 (dd, 1H, J = - 12 Hz, H3ax), 2.28 (dd, 1H, J = 4.5 Hz, H3eq), 3.53 (dd, 1H, 
J = 10 Hz, H5), 3.65 (dd, 1H, J = 5, - 11.5 Hz, H9a), 3.74 (m, 1H, J = 2, 5 Hz, 
H8), 3.82 (s, 3H, COOCH3),3.84 (m, 2H, J = 1 Hz, H7 and J = 2, - 11.5 Hz, 
H9b), 3.96 (dd, 1H, J = 1, 10 Hz, H6), 4.1 (m,1H, J = 10 Hz, H4); 13C NMR 
(CD3OD): δ 21.04 (NHCOCH3), 39.14 (CH2, C3), 51.59 (COOCH3), 52.81 
(CH, C7), 63.19 (CH2, C9), 66.30 (CH, C4), 68.61 (CH, C5), 70.08 (CH, C8), 
70.48 (CH, C6), 94.97 (C2), 170.19 (NHCOCH3) and 173.65 (COOCH3) ppm; 
MS (AP-) C12H21NO9  (323.30) m/z (%) 324 [M+H]
+ (100).  
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7.3.2. Methyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-
glycero-D-galacto-2-nonulopyranosonate (21) 
 
N-Acetylneuraminic methyl ester (20) (4.36 g, 13.5 mmol) was 
suspended in anhydrous pyridine (45 mL) and acetic anhydride (45 mL) 
under a N2 atmosphere at 0 ºC. The reaction mixture was stirred and allowed 
to warm up to RT and then stirred for 24 hrs more. TLC analysis 
(EtOAc/MeOH 20:1) showed total consumption of the starting material and 
therefore the reaction was slowly quenched with cold MeOH (100 mL) (0ºC, 
since it’s very exotermic reaction) and stirred for 1 hr. Afterwards the solvents 
were evaporated and the residue was dissolved in DCM (100 mL) and 
extracted with saturated aqueous solution of NaHCO3 (100 mL, very fizzy 
reaction). Then the organic phases were washed with water (100 mL), dried 
(MgSO4), filtered and evaporated. Flash column chromatography 
(EtOAc/MeOH gradient EtOAc only to EtOAc/MeOH 20:1) and NMR (CDCl3) 
gave compound 21 as a white solid (5.95 g, 11.2 mmol, 83%).  
Rf (EtOAc/MeOH 20:1) 0.53 and 0.47; 1H NMR (CDCl3): δ 1.86 (s, 3H, 
NAc), 2.00 (2s, 6H, 2OAc), 2.03 (s, 3H, OAc), 2.11 (2s, 6H, 2OAc), 2.03 - 
2.10 (m, 1H, H3ax), 2.52 (dd,1H, J = 13.4, 4.9 Hz, H3eq), 3.76 (s, 3H, 
COOCH3) plus mixture of peaks from both anomers but with predominance 
of the β anomer; 13C NMR (CDCl3): δ 20.75 (CH3, AcO), 20.78 (CH3, AcO), 
20.81 (CH3, AcO), 20.87 (CH3, AcO), 20.93 (CH3, AcO), 23.20 (NHCOCH3), 
35.90 (CH2, C3), 49.28 (CH, C7), 53.23 (COOCH3), 62.19 (CH2, C9), 67.78 
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(CH, C4), 68.30 (CH, C5), 71.35 (CH, C8), 72.95 (CH, C6), 97.40 (C2), 
166.34 (NHCOCH3), 168.25 (C=O, AcO), 170.08 (C=O, AcO), 170.28 (C=O, 
AcO), 170.64 (C=O, AcO), 170.83 (C=O, AcO) and 171.03 (COOCH3) ppm; 
MS (ES+) C22H31NO14  (533.48) m/z (%) 534 [M+H]
+ (100). 
 
 
7.3.3. Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-
dideoxy-β-D-glycero-D-galacto-2-nonulopyranosonate (22) 
 
Methyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-
D-galacto-2-nonulopyranosonate (21) (5.95 g, 11.2 mmol) was dissolved in 
acetyl chloride (110 mL). Dry hydrogen chloride was then bubbled through 
the solution for 15 min at 0 ºC. The solution was tightly closed and the 
mixture stirred and left to warm up to RT for 48 hrs. The excess of HCl in the 
mixture was removed with the use of a stream of N2 gas for some minutes, 
and the excess of acetyl chloride was removed with the use of the vacuum. 
The crude residue was then co-evaporated with ether to give compound 22 
as a colourless sugar-like (5.6 g, 10.98 mmol,  99%, β anomer) as confirmed 
by NMR (CDCl3).  
Rf (EtOAc/MeOH 20:1) 0.59; 1H NMR (CDCl3): δ 1.90 (s, 3H, NAc), 
2.04 (2s, 6H, 2OAc), 2.06 (s, 3H, OAc),  2.09 (s, 3H,OAc), 2.27 (dd, 1H, J = 
13.9, 9.2 Hz, H3ax), 2.77 (dd, 1H, J = 13.9, 4.8 Hz, H3eq), 3.86 (s, 3H, 
COOCH3), 4.04 (dd, 1H, J = 10.8, 5.4 Hz, H9a), 4.20 (dd, 1H, J = 10.8, 2.4 
Hz, H9b), 4.33 (m, 1H, H5), 4.40 (m, 1H, H6), 5.17 - 5.18 (m, 1H, H4), 5.39 
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(dd, 1H, J = 6.9, 2.4 Hz, H8), 5.46 (dd, 1H, J = 6.7, 2.4 Hz, H7); 13C NMR 
(CDCl3): δ 20.76 (CH3, AcO), 20.81 (CH3, AcO), 20.85 (CH3, AcO), 20.95 
(CH3, AcO), 23.13 (NHCOCH3), 40.62 (CH2, C3), 48.69 (CH, C5), 53.82 
(COOCH3), 62.07 (CH2, C9), 66.84 (CH, C4), 68.77 (CH, C7), 69.97 (CH, 
C8), 73.87 (CH, C6), 96.59 (C2), 165.64 (NHCOCH3), 169.73 (C=O, AcO), 
169.98 (C=O, AcO), 170.53 (C=O, AcO), 170.70 (C=O, AcO) and 171.02 
(COOCH3) ppm; MS (ES
+) C20H28ClNO12 (509.89) m/z (%) 510 [M+H]
+ (100). 
 
 
 
7.3.4. Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-S-acetyl-2,3,5-
trideoxy-2-thio-α-D-glycero-D-galacto-2-nonulopyranosonate 
(Neu5Ac-2SAc, 23) 
 
Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-β-D-
glycero-D-galacto-2-nonulopyranosonate (22) (5.6 g,  9.92 mmol) was 
dissolved in EtOAc (50 mL), then potassium thioacetate (7.6 g, 6 eq, 66.2 
mmol, batch two BCBF7702 Sigma-Aldrich) and iodine (4.2 g, 1.5 eq, 16.6 
mmol) were added. The reaction mixture was stirred at RT overnight. The 
insoluble salts were then filtered and the reaction mixture was washed with 
saturated aqueous solution of sodium thiosulphate (50 mL). The organic 
phases were then dried (Na2SO4), filtered and evaporated. Flash column 
chromatography (EtOAc/PE gradient 1:1 to EtOAc only) and NMR (CDCl3) 
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gave a mixture of compound 23 and compound 24 as a orange sugar-like 
crude, in a SAc:SSAc ratio of 60% to 40%.  
To improve the SAc:SSAc ratio of the mixture  (23 and 24), 500 mg 
(0.98 mmol) were dissolved in  EtOAc (5 mL), then potassium thioacetate 
(672 mg, 6 eq, 5.88 mmol, batch two BCBF7702 Sigma-Aldrich) and iodine 
(373 mg, 1.5 eq, 1.47 mmol) were added. The reaction mixture stirred at RT 
overnight. Then the insoluble salts were filtered and the mixture was washed 
with saturated aqueous solution of sodium thiosulphate (50 mL). The organic 
phases were then dried (Na2SO4), filtered and evaporated. Flash column 
chromatography (EtOAc/PE 2:1 to EtOAc only) and NMR (CDCl3) gave an 
improved ratio of SAc 30% and SSAc 70%. 
Characterization of compound 23: 
Rf (EtOAc/PE 9:1) 0.41; 1H NMR (CDCl3): δ 1.88 (s, 3H, NHAc), 2.00 
(s, 3H, OAc), 2.07 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.13 (s, 3H, OAc), 2.09 
(dd, 1H, J = 12.9, 9.2 Hz, H3ax), 2.27 (s, 3H, SAc), 2.60 (dd,1H, J = 12.9, 4.6 
Hz, H3eqt), 3.78 (s, 3H, COOCH3), 4.02 (dd,1H, J = 12.4, 5.8 Hz, H9a), 4.08 
(m, 1H, H5), 4.37 (dd, 1H, J = 12.4, 2.4 Hz, H9b), 4.65 (dd, 1H, J = 10.8, 2.2 
Hz, H6), 4.87 - 4.91 (m, 1H, H4), 5.16 (d, 1H, J = 5.1 Hz, NH), 5.20 - 5.22 (m, 
1H, H8), 5.34 (dd, 1H, J = 6.7, 2.2 Hz, H7) ppm; 13C NMR (CDCl3): δ 20.05 
(CH3, AcO), 20.56 (CH3, AcO), 20.86 (CH3, AcO), 20.90 (CH3, AcO), 23.25 ( 
NHCOCH3), 30.26 (SAc, CH3), 37.45 (CH2, C3), 49.28 (CH, C7), 53.60 
(COOCH3), 62.41 (CH2, C9), 67.75 (CH, C4), 68.91 (CH, C5), 70.25 (CH, 
C8), 75.18 (CH, C6), 84.54 (C2), 167.37 (NHCOCH3), 170.19 (C=O, AcO), 
170.23 (C=O, AcO), 170.55 (C=O, AcO), 170.88 (C=O, AcO), 171.97 
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(COOCH3) and 191.54 (SCOCH3) ppm; MS (AP
-) C22H31NO13S  (549.55) m/z 
(%) 572.1 [M+Na]+ (100). 
 
 
 
7.3.5. Methyl 2-(acetylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-acetyl-
2,3,5-trideoxy-2-thio-α-D-glycero-D-galacto-2-
nonulopyranosonate (Neu5Ac-2SSAc, 24) 
 
Data according to previous work from the group. 
Rf (EtOAc/PE 9:1) 0.41; [α]20D + 155 ± 1.0 (c 0.85, CH2Cl2); 
1H NMR 
(CDCl3): δ 1.88 (s, 3H, NHAc), 2.02 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.10 (s, 
3H, OAc), 2.12 (s, 3H, OAc), 2.07 (dd, 1H, J = 12.2, 9.4 Hz, H3ax), 2.46 (s, 
3H, SSAc), 2.81 (dd,1H, J = 12.2, 4.4 Hz, H3eqt), 3.77 (s, 3H, COOCH3), 3.86 
(d,1H, J = 9.4 Hz, H6), 4.00 - 4.05 (m, 1H, H5), 4.12 (dd, 1H, J = 12.1, 4.7 
Hz, H9a), 4.34 (d, 1H, J = 12.1 Hz, H9b), 4.83 - 4.88 (m, 1H, H4), 5.21 (d, 
1H, J = 10.8 Hz, NH), 5.29 - 5.33 (m, 2H, H7 and H8) ppm; 13C NMR 
(CDCl3): δ 20.87 (2CH3, AcO), 20.90 (CH3, AcO), 21.24 (CH3, AcO), 23.20 
(NHCOCH3), 28.81 (SSAc, CH3), 37.07 (CH2, C3), 49.45 (CH, C7), 53.50 
(COOCH3),  62.01 (CH2, C9), 67.23 (CH, C4), 69.04 (CH, C5), 69.57 (CH, 
C8), 74.44 (CH, C6), 84.72 (C2), 166.85 (NHCOCH3), 170.00 (C=O, AcO), 
170.18 (C=O, AcO), 170.80 (C=O, AcO), 170.89 (C=O, AcO), 171.68 
(COOCH3) and 192.51 (SSCOCH3) ppm; MS (AP
-) C22H31NO13S2  (581.61) 
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m/z (%) 582.2 [M+H]+ (30), 604.2 [M+Na]+ (100); HRMS (ES+) found 
599.1575, calculated for C22H31NO13S2  [M+NH4]
+. 
 
 
 
7.3.6. Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-
dideoxy-D-glycero-D-talo-non-2-enonate (Neu5Ac2en, 25) 
 
Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-β-D-
glycero-D-galacto-2-nonulopyranosonate (22) (5 g, 9.92 mmol) was dissolved 
in of solvent (50 mL), then potassium thioacetate (6.8 g, 6 eq, 59.5 mmol, 
batch one LF005421, Alfa Aesar) and iodine (3.8 g, 1.5 eq, 14.9 mmol) were 
added. Using as conditions: EtOAc RT overnight or EtOAc reflux  overnight 
or DMF heating 80ºC overnight. The insoluble salts were then filtered and the 
mixture was washed with saturated aqueous solution of sodium thiosulphate 
(50 mL). The organic phases were dried (Na2SO4), filtered and evaporated. 
Flash column chromatography (EtOAc/MeOH gradient EtOAc only to 5% 
MeOH) and NMR (CDCl3) gave compound 25 as a yellow sugar-like. Using 
the same method but batch two of potassium thioacetate under EtOAc reflux  
overnight, the obtained compound was also 25 as a red sugar-like. 
1H NMR (CDCl3): δ 1.90 (s, 3H, NHAc), 2.01 (s, 3H, OAc), 2.02 (s, 3H, 
OAc), 2.05 (s, 3H, OAc), 2.09 (s, 3H, OAc), 3.77 (s, 3H, COOCH3), 4.17 (dd, 
1H, J = 12.3, 6.9 Hz, H9a), 4.35 - 4.38 (m, 2H, H4 and H6), 4.57 (dd, 1H, J = 
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12.3, 3.4 Hz, H9b), 5.33 - 5.34 (m, 1H, NH), 5.34 - 5.42 (m, 2H, H5 and H7), 
5.58 (m, 1H, H8) and 5.98 (d, 1H, J = 2.7 Hz, H3) ppm; MS (AP+) 
C20H27NO12  (473.43) m/z 474 [M+H]
+ , 496 [M+Na]+. 
 
 
7.3.7. Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-S-benzyl-2,3,5-
trideoxy-2-thio-β-D-glycero-D-galacto-2-nonulopyranosonate 
(Neu5Ac-2SBn, 26) 
 
Mixture of compounds 23 and 24, 100 mg  was dissolved in  DMF (2 
mL). Then Et3N (72 µL, 3 eq, 0.516 mmol) was added dropwise, afterwards 
benzylbromide (40 µL, 2 eq, 0.344 mmol) was added, and then finally 
hydrazine acetate (17,4 mg, 1.1 eq, 0.189 mmol). The reaction mixture was 
then stirred at 50 ºC for 20 min. Then DMF was evaporated under vacuum, 
and the crude residue washed with saturated aqueous solution of NH4Cl (50 
mL) and extracted with DCM (50 mL). The organic phase was dried (MgSO4), 
filtered and evaporated. Flash column chromatography (EtOAc/PE 9:1) and 
NMR (CDCl3) gave a mixture of compounds 26 and 27 as a yellow sugar-like, 
which was confirmed by mass spectrometry. Data according to previous work 
from the group not yet published. 
When purified compound 24 was used as starting material, for the 
same reaction conditions stated above, NMR (CDCl3) gave compound 26, 
which was confirmed by mass spectometry. MS (ES+) C27H35NO12S (597.7) 
m/z (%) 620.1 [M+Na]+(100). 
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Characterization of compound 26: 
Rf (EtOAc/PE 9:1) 0.52;1H NMR (CDCl3): δ 1.93 (s, 3H, NHAc), 1.98 
(dd, 1H, J = 11.8, 12.7 Hz, H3ax), 2.02 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.14 
(s, 3H, OAc), 2.18 (s, 3H, OAc), 2.70 (dd,1H, J = 12.6, 4.7 Hz, H3eqt), 3.54 (s, 
3H, COOCH3), 3.80 (d, 1H, J = 13.6 Hz, SCH2Bn), 3.89 (dd, 1H, J = 9.6, 2.4 
Hz, H6), 3.91 (d, 1H, J = 13.6 Hz, SCH2Bn),  4.04 (m, 1H, H5), 4.11 (dd, 1H, 
J = 12.5, 5.1 Hz, H9a), 4.31 (dd, 1H, J = 12.5, 2.5 Hz, H9b), 4.85 (m, 1H, 
H4), 5.28 (d, 1H, J = 2.4 Hz, NH), 5.32 – 5.37 (m, 1H, H7), 5.43 - 5.46 (m, 
1H, H8), 6.95 - 7.28 (m, 5H, Bn) ppm; 13C NMR (CDCl3): δ 20.79 (CH3, AcO), 
20.91 (CH3, AcO), 20.96 (CH3, AcO), 21.25 (CH3, AcO), 23.32 (NHCOCH3), 
37.43 (CH2, C3), 42.91 (SCH2Bn), 49.44 (CH, C5), 53.31 (COOCH3), 61.29 
(CH2, C9), 68.71 (CH, C4), 69.42 (CH, C7), 70.92 (CH, C8), 75.19 (CH, C6), 
89.43 (C2), 127.75 (1C, Bn), 128.76 (2C, Bn), 129.89 (2C, Bn), 134.18 (1C, 
Bn), 168.10 (NHCOCH3), 170.05 (C=O, AcO), 170.21 (C=O, AcO), 170.32 
(C=O, AcO), 170.73 (C=O, AcO) and 170.07 (COOCH3) ppm; MS (AP
+) 
C27H35NO12S  (597.63) m/z (%) 598.3 [M+H]
+ (100). 
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7.3.8. Methyl 2-(benzylsulfanyl)-5-acetamido-4,7,8,9-tetra-O-
acetyl-2,3,5-trideoxy-2-thio-β-D-glycero-D-galacto-2-
nonulopyranosonate (Neu5Ac-2SSBn, 27) 
 
Data according to previous work from the group. 
Rf (EtOAc/PE 9:1) 0.52; [α]20D - 29 ± 1.0 (c 0.53, CHCl3); 
1H NMR 
(CDCl3): δ 1.88 (s, 3H, NHAc), 1.94 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.09 (s, 
3H, OAc), 2.17 (s, 3H, OAc), 2.23 (dd, 1H, J = 12.6, 12.5 Hz, H3ax), 2.69 (dd, 
1H, J = 12.6, 4.7 Hz, H3eqt), 3.81 (s, 3H, COOCH3), 4.00 - 4.14 (m, 5H, H9b, 
H5, NH and SCH2), 4.36 (dd, 1H, J = 12.5, 2.7 Hz, H9a), 4.89 (app. td, 1H, J 
= 11.7, 4.7 Hz, H4), 5.26 (d, 1H, J = 10.1 Hz, H6), 5.34 (dd, 1H, J = 10.1, 2.2 
Hz, H7), 5.34 - 5.39 (m, 1H, H8), 7.24 - 7.33 (m, 5H, Bn) ppm; 13C NMR 
(CDCl3): δ 20.79 (CH3, AcO), 20.91 (CH3, AcO), 20.96 (CH3, AcO), 21.25 
(CH3, AcO), 23.32 (NHCOCH3), 37.54 (CH2, C3), 44.71 (SSCH2Bn), 49.44 
(CH, C5), 53.25 (COOCH3), 62.23 (CH2, C9), 67.47 (CH, C4), 69.43 (CH, 
C7), 69.79 (CH, C8), 75.01 (CH, C6), 89.47 (C2), 127.77 (1C, Bn), 128.66 
(2C, Bn), 129.69 (2C, Bn), 136.41 (1C, Bn), 168.00 (NHCOCH3), 170.05 
(C=O, AcO), 170.21 (C=O, AcO), 170.32 (C=O, AcO), 170.73 (C=O, AcO) 
and 171.09 (COOCH3) ppm; MS (ES
+) C27H35NO12S2  (629.70) m/z (%) 630.3 
[M+H]+ (100); HRMS (ES+) found 630.16, calculated for 
C27H35NO12S2  [M+H]
+. 
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7.4. ACETOBROMO-GLUCOSE SULFIDE AND DISSULFIDE 
SYNTHESIZED COMPOUNDS 
 
 
7.4.1. 1-(Acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosate (AcGluc-1SAc, 28) 
 
Starting material acetobromo-α-D-glucose (AcBrGlu, lot 077k5304, 10 
g, Sigma-Aldrich) (100 mg, 0.24 mmol) was dissolved in anhydrous acetone 
(5 mL). Then KSAc (165 mg, 6 eq, 1.44 mmol, BCBF7702 Sigma-Aldrich) 
was added and the mixture stirred at reflux  for 3 hrs. TLC analysis 
(EtOAc/PE 1:2) showed that there was still unreacted starting material but 
nonetheless the reaction was filtered (to remove the insoluble KSAc salts) 
and  then concentrated under vacuum. Flash column chromatography 
(EtOAc/PE gradient 1:5 to 2:5) NMR (CDCl3) gave compound 28, α isomer, 
as a yellow oil (81 mg, 0.2 mmol, 82%).  
Rf (EtOAc/PE 1:2) 0.3; [α]20D + 13.33 (c 0.24,CH2Cl2); 
1H NMR 
(CDCl3): δ 2.00 (s, 3H, AcO), 2.02 (2s, 6H, 2AcO) 2.07 (s, 3H, AcO), 2.38 (s, 
3H, SAc), 3.83 (ddd, 1H, J = 10.1, 4.4, 2.1 Hz, H5), 4.09 (dd, 1H, J = 12.6, 
2.6 Hz, H6a), 4.26 (dd,1H, J = 12.6, 4.4 Hz, H6b), 5.09 - 5.14 (m, 2H, H3 and 
H4) and 5.23 - 5.29 (m, 2H, H2 and H1) ppm; 13C NMR (CDCl3): δ 20.60 
(CH3, AcO), 20.61 (CH3, AcO), 20.63 (CH3, AcO), 20.75 (CH3, AcO), 30.88 
(SAc, CH3), 61.65 (CH2, C6), 67.82 (CH, C4), 69.93 (CH, C3), 73.94 (CH, 
C2), 76.35 (CH, C5), 80.18 (CH, C1), 169.38 (C=O, AcO), 169.42 (C=O, 
 169 
 
AcO), 170.08 (C=O, AcO), 170.68 (C=O, AcO) and 192.08 (SCOCH3); MS 
(AP+) C16H22O10S  (406.4) m/z (%) 407 [M+H]
+ (100). 
 
 
7.4.2. 1-(Acetylsulfanyl)-2,3,4,6-tetra-O-acetyl-1-thio-α-D-
glucopyranosate (AcGluc-1SSAc, 29) 
 
 Starting material acetobromo-α-D-glucose (AcBrGlu, lot 077k5304, 10 
g, Sigma-Aldrich) (100 mg, 0.24 mmol) was dissolved in anhydrous acetone 
(5 mL). Then KSAc (165 mg, 6 eq, 1.44 mmol, BCBF7702 Sigma-Aldrich) 
and iodine (91 mg, 1.5 eq, 0.36 mmol) were added and the mixture stirred at 
reflux for 2 hrs. TLC analysis (EtOAc/PE 1:2) showed unreacted starting 
material but nontheless the reaction was filtered and evaporated. The crude 
residue was then washed with saturated aqueous solution of sodium 
thiosulphate (50 mL) and extracted with EtOAc (50 mL). The organic phase 
was dried (Na2SO4), filtered and evaporated. Flash column chromatography 
(EtOAc/PE gradient 1:5 to 1:1) and NMR (CDCl3) gave a mixture of 
compounds 28 and 29 as yellow oil.  
When starting material acetobromo-α-D-glucose, (100 mg, 0.24 mmol) 
were dissolved in anhydrous acetonitrile (5 mL) and then KSAc (165 mg, 6 
eq, 1.44 mmol, BCBF7702 Sigma-Aldrich) was added and the mixture stirred 
at reflux for 2 hrs (after 2 hrs there wasn’t unreacted starting material). Then 
the reaction mixture was cooled down to RT and iodine (91 mg, 1.5 eq, 0.36 
mmol) was added and the reaction stirred at RT overnight. The reaction was 
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filtrated, concentrated under vacuum and the residue was washed with 
saturated aqueous solution sodium thiosulphate (50 mL) and extracted with 
DCM (50 mL). The organic phase was dried (Na2SO4), filtered and 
evaporated. Flash column chromatography (EtOAc/PE gradient 90% PE only 
to 1:1) and NMR (CDCl3) gave again a mixture of compounds 28 and 29, in a 
ratio of 39% SSAc: 61% SAc.  
Characterization of compound 29: 
Rf (EtOAc/PE 1:2) 0.3; 1H NMR (CDCl3): δ 2.00 (s, 3H, AcO), 2.02 (2s, 
6H, 2AcO) 2.07 (s, 3H, AcO), 2.44 (s, 3H, SSAc), 3.98 (ddd, 1H, J = 10.1, 
4.1, 2.3 Hz, H5), 4.07 (dd, 1H, J = 7.1, 2.3 Hz, H6a), 4.31 (dd,1H, J = 7.1, 4.0 
Hz, H6b), 5.09 - 5.14 (m, 2H, H3 and H4), 5.21 – 5.25 (m, 1H, H2) and 6.24 
(d, 1H, J = 5.2 Hz, H1) ppm; 13C NMR (CDCl3): δ 20.60 (CH3, AcO), 20.61 
(CH3, AcO), 20.63 (CH3, AcO), 20.75 (CH3, AcO), 30.92 (SSAc, CH3), 61.65 
(CH2, C6), 67.82 (CH, C4), 69.93 (CH, C3), 73.94 (CH, C2), 76.35 (CH, C5), 
81.23 (CH, C1), 169.38 (C=O, AcO), 169.42 (C=O, AcO), 170.08 (C=O, 
AcO), 170.68 (C=O, AcO) and 192.13 (SSCOCH3); MS (AP
+) 
C16H22O10S2  (438.4) m/z (%) 439 [M+H]
+ (10), 407.1 [M-S]- (40). 
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